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Abstract
Jamaican males are a high-risk population for aggressive prostate cancer (PrCa) due to
genetic influences, and identifying empirical data on treatments, which provide survival
benefits is a prime challenge for clinicians who manage Jamaican PrCa patients. Thus,
the purpose of this investigation was to elucidate treatment effects of brachytherapy and
ERBT in the survival of a Jamaican PrCa cohort. Differences in survival outcomes of
brachytherapy and ERBT treated Jamaican, and White U.S.-born PrCa patients with
localized PrCa were compared. The mechanism of radiation programmed cell death in
PrCa carcinogenesis explained in the oxidative stress theory, was the theoretical base for
interpreting the research questions. A retrospective cohort design was used, and included
survival analysis of secondary data from the Surveillance Epidemiology and End Results
database. The sample size was 10,752 Jamaican and White U.S.-born prostate cancer
patients diagnosed between 1992 and 2011. Kaplan-Meier and Cox proportional hazard
regression models confirmed that brachytherapy resulted in enhanced survival benefits to
the Jamaicans, HR 0.63, 95% CI [0.55, 0.73], p < .001, but ERBT did not, HR 1.6, 95%
CI [1.38, 1.84] p < .001. Hence, brachytherapy may be an appropriate treatment option
for Jamaican PrCa patients. Clinicians and health care planners can utilize the results for
policy decisions aimed at increasing access to brachytherapy treatments to Jamaicans.
Improving access to efficient PrCa treatments could reduce the morbidity and mortality
rates of PrCa among Jamaicans, decrease years of potential life lost from PrCa, and
enhance the life expectancy of the Jamaican male population.
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1
Chapter 1: Introduction to the Study
The survival outcome of brachytherapy and external beam radiation treatment
(ERBT) for the management of localized PrCa, is understudied among Jamaicans in their
native country (Morrison, Aiken, & Mayhew, 2014). The effects of brachytherapy and
ERBT are well documented among Europeans (Goldner et al., 2012; Zuber et al., 2015),
Canadians (Smith et al., 2015), and in U.S. populations (Alumini et al., 2015; Cendales et
al., 2015). However, the findings of current studies may not apply to Jamaican PrCa
patients. Jamaican PrCa patients are typically diagnosed with higher prostate-specific
antigen (PSA) levels, Gleason scores, and tumor stages when compared with the White
and African American PrCa patients (Fedewa & Jemal, 2013; Rich et al., 2013).
Jamaicans also have the recessive and dominant genes, which increase their risk for PrCa
(Kidd et al., 2012). Kidd et al. (2012) compared the influence of Chemokine-associated
single nucleotide polymorphisms (SNPs) in PrCa susceptibility of African Americans and
Jamaicans. The findings of Kidd et al. demonstrated that the Jamaican cohort had 1.52 to
1.73 increased for PrCa (p < .001), due to the genes CCR5 rs1799987 AA, CCR5
rs1799988 GG, and CCR7 rs 3136685 AG+GG. Hence, conclusions of current literature
suggested that Jamaican PrCa patients may have other biological factors which, could
support the type of PrCa noted in this cohort. Consequently, ERBT and brachytherapy
treatment outcomes of PrCa patients of other populations may not generalize to
Jamaicans.
Recent studies have also indicated that higher numbers of Jamaican PrCa patients
residing in the United States and Jamaica are diagnosed with Gleason scores 6 and 7
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PrCa; when compared with men who are diagnosed with Gleason scores 8 to 10 PrCa
(Anderson-Jackson, McGrowder, & Alexander-Lindo, 2012; Kampel, Tse, & Joseph,
2011). In a cohort of 127 Jamaican PrCa patients who were treated at the Memorial
Sloan-Kettering Cancer Center in New York, Kampel et al. (2011) recognized that 51
(40%) were diagnosed with Gleason score 6 PrCa, while 57 (45%) had Gleason score 7
PrCa. Fewer PrCa patients (15%) were diagnosed with Gleason scores 8 to 10 (Kampel et
al., 2011). In Jamaica West Indies, Anderson et al. (2012), documented similar patterns
of PrCa diagnosis among 191 PrCa patients treated at a private diagnostic center in the
country. Anderson et al. reported that the highest proportion of PrCa patients (69.7%)
who were treated at a radiology center in Jamaica had Gleason scores 6 and 7 PrCa. The
findings of Anderson et al. and Kampel et al. suggested that currently Jamaican males are
detected at the earlier stages of PrCa. Therefore, it was important to determine the
treatment methods, which are most appropriate for Jamaicans with the earlier stages of
the disease.
Currently, urologists in Jamaica are challenged with identifying publications,
which support evidenced-based decisions for treating Jamaican PrCa patients with
localized PrCa (Morrison et al., 2014). Besides, advocates for PrCa treatment in Jamaica
are promoting greater use of brachytherapy, ERBT, and active surveillance for managing
localized PrCa (Morrison et al., 2014). At present, brachytherapy, ERBT, and active
surveillance are underutilized in Jamaica owing to infrastructural and economic
constraints (Morrison et al., 2014). Due to the factors which limit the uptake of PrCa
treatments among Jamaicans in their homeland, data are needed to base decisions on the
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most clinically efficient and cost-effective treatment methods for these PrCa patients with
localized disease (Morrison et al., 2014).
It was necessary to determine the efficacy of brachytherapy and ERBT treatment
for the management of early stage PrCa among Jamaicans males. Researchers reported
increase utilization of brachytherapy treatment in the United States since the 1990s
(Alumini et al., 2015; Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014;
Nepple et al., 2013). Investigators have also described the survival benefits and
limitations of brachytherapy and ERBT for patients with localized PrCa. Schreiber et al.
(2013), cited that brachytherapy provided improved survival outcomes and fewer side
effects when compared with other PrCa treatments. On the other hand, Schreiber et al.
reported that brachytherapy is associated with socioeconomic constraints resulting in
disparities in its use among African American and White PrCa patients. Williams et al.
(2011) noted that younger PrCa patients were also more likely to access brachytherapy.
Furthermore, when compared with the traditional ERBT, brachytherapy treatment did not
demonstrate superior survival benefits for men with the earlier stages of PrCa (Goldner et
al., 2012; Nepple et al., 2013; Smith et al., 2015). However, the reports of recent
investigations demonstrated no treatment effects of brachytherapy and ERBT in a
Jamaican cohort. Hence, additional studies are necessary to elucidate the survival benefits
of brachytherapy and ERBT in the management of localized PrCa among Jamaicans.
In existing publications, investigators documented mixed results for PrCa patients
who did not receive directive treatment for the disease (Bul et al., 2013; Odom et al.,
2014; Selvadurai et al., 2013; Wilt et al., 2012). Current studies showed disparities in
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survival outcomes of White and African American PrCa patients who were managed with
active surveillance (Bul et al., 2013; Odom et al., 2014; Selvadurai et al., 2013; Wilt et
al., 2012). Researchers also indicated that African American PrCa patients who were
managed without directive PrCa treatment were more likely to progress to the advanced
forms of the disease (Odom et al., 2014). Nevertheless, the survival outcomes of active
surveillance as a treatment protocol in White and African American cohorts documented
in other studies may not apply to Jamaicans. Investigators documented that small samples
of the Black populations in studies on PrCa survival limit extrapolation of the findings to
similar groups (Bul et al., 2013; Odom et al., 2014; Selvadurai et al., 2013; Wilt et al.,
2012).
Additionally, investigators alluded to the impact of the sociodemographic
characteristics of the PrCa patient and smoking in their survival (Crawford, 2013; Fufaa,
2011; Huncharek et al., 2010; Lin, Porter, & Montgomery., 2009; Parris, 2013). Data on
the influence of the sociodemographic characteristics in the treatment outcomes of
Jamaican PrCa patients were not reported in current publications.
Jamaicans in the 18 participating Surveillance Epidemiology and End Results
(SEER) database were chosen for this study to infer findings to their populations.
Jamaicans in the SEER database were selected for data analysis because they comprised
the largest subgroups of non-U.S.-born Black males of the SEER cancer registries
(Fedewa & Jemal, 2013). Besides, Fedewa and Jemal (2013) documented that Jamaicans
in the SEER database had Gleason scores, which were comparable with Jamaicans
residing in their native country. Moreover, I identified a higher proportion of Jamaican-
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born PrCa patients (87.64%) in the SEER database with localized PrCa when compared
with PrCa patients who were diagnosed with the distant stage of the disease 21 (7.87 %).
Thus, the findings of the SEER database suggested that the cohort of Jamaican-born PrCa
patients in that dataset was appropriate for this research.
This study was necessary because current findings on PrCa treatment effects may
not generalize to the Jamaican communities owing to differences in the disease
characteristic of Jamaicans and other groups of PrCa patients (Fedewa & Jemal, 2013;
Kid et al., 2012; Rich et al., 2013). Jamaicans are usually diagnosed with higher stages
and grades of PrCa when compared with other populations (Fedewa & Jemal, 2013; Rich
et al., 2013), and researchers recommended other studies on the treatment of localized
disease among men with this type of PrCa (Klotz et al., 2010). Researchers also endorsed
future studies on the relationship between disparities of brachytherapy treatment, race,
socioeconomic status and PrCa survival (Schreiber et al., 2013). Furthermore, it was
important to understand the role of socioeconomic status in treatment outcomes among
the Jamaican cohort because, brachytherapy treatment is not adequately utilized among
native Jamaicans without health insurance (Morrison et al., 2014). The reason for this
disparity among Jamaicans is not well documented in the literature. Consequently, this
dissertation which investigated the effectiveness of treatments for localized PrCa among
Jamaicans was relevant.
I anticipate that this dissertation will contribute to public health practice and
policies aimed at improving the years of potential life lost (YPLL) of a Jamaican PrCa
patient. I also project that this research may provide information to the medical fraternity
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of urologists in Jamaica who currently seek data on appropriate treatment choices for
Jamaicans with localized PrCa. Additionally, I assume that this study will offer evidence
to influence the decision-making of PrCa patients with localized disease about
appropriate treatment choices and assist health care planners in increasing access to these
PrCa treatments. The efficacy of brachytherapy and ERBT in the management of early
and intermediate stages PrCa among Jamaicans, may improve the survival rates of
affected males and enhance their survival outcomes (Fufaa, 2011).
In Chapter 1, I presented the background of this dissertation; the research problem
statement, questions, and purpose; as well as the theoretical framework, nature of the
study, and the definitions of the primary variables. The background summarizes the
current literature on the survival outcomes of PrCa patients who were treated with
brachytherapy and ERBT. The problem statement discusses the focus of the investigation
and the need for new data to guide treatment decisions for the management of low and
intermediate stages PrCa among Jamaicans. In Chapter 1, 1 also included the five
research questions and hypotheses, which were intended to measure the relationship
between brachytherapy treatment and ERBT with PrCa survival. The research questions
and hypotheses allowed me to compare differences in PrCa survival with Jamaicans and
the White U.S.-born cohort of the SEER 18 research databases. The research questions
further assisted me to determine the influence of the sociodemographic characteristics in
treatment effects.
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Background
Since the 1990s, brachytherapy, and active surveillance are accepted treatment
choices among men with low-grade PrCa (Cooperberg & Carroll, 2015; Mahmood et al.,
2014; Safdieh, Wong, Weiner, Schwartz, & Schreiber, 2016; Valdivieso et al., 2015;
Weiner, Patel, Etzioni, & Eggener, 2015). However, in studies on the management of
localized PrCa with brachytherapy, ERBT, and active surveillance, researchers provided
mixed results on treatment efficacy (Alumini et al., 2015; Cendales et al., 2015; Marshall
et al. 2014; Nepple et al., 2013; Rodrigues et al., 2014; Smith et al., 2015; Zuber et al.,
2015).
Investigators have also documented underutilization of brachytherapy in specific
populations (Schreiber et al., 2013; Smith et al., 2015; Williams et al., 2011; Zuber et al.,
2015). Schreiber et al. (2013) confirmed that brachytherapy is more widely utilized
among White males when compared with males of African American descent. Williams
et al. (2011) revealed that brachytherapy is better accepted among young PrCa patients
Alumini et al. (2015), Williams et al., and Zuber et al. (2015) reported that brachytherapy
is a safe and efficient treatment for PrCa patients with Gleason scores 6 and 7. On the
other hand, Williams et al. indicated that brachytherapy is an expensive treatment option.
Moreover, Rodrigues et al. (2014) noted that brachytherapy enhances biochemical free
survival for PrCa patients with low and intermediate stage disease, but it does not
improve overall survival of PrCa. Additionally, Goldner et al. (2012), Nepple et al.
(2013), and Smith et al. (2015) reported similarities in the effectiveness of brachytherapy
treatment and ERBT for the management of localized PrCa. Thus, the results of current
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studies on the survival advantage of brachytherapy and ERBT provided wide-ranging
outcomes in the populations studied (Goldner et al., 2012; Nepple et al., 2013; Smith et
al., 2015).
There is a dearth of current publications on the effects of brachytherapy and
ERBT in the survival of Jamaican PrCa patients, and current data on treatment effects
among Jamaicans are needed (Morrison et al., 2014). In addition, investigators
recommended additional research on the effects of ERBT and brachytherapy treatment on
PrCa survival (Bannuru et al., 2011; Klotz et al., 2010; Nepple et al., 2013; Schreiber et
al., 2013). Klotz et al. (2010) also suggested that further studies on the effects of ERBT
and brachytherapy treatment on PrCa survival should include men who are diagnosed
with the aggressive forms of PrCa. Besides, Nepple et al. (2013) recommended that
further observations on treatment effects should include active surveillance and AfricanAmerican men with low-risk disease. Moreover, Rand et al. (2014), and Schreiber et al.
(2013) endorsed additional inquiries in the disparities of race and socioeconomic status in
the relationship between brachytherapy and PrCa survival. Hence, this dissertation was
designed to explore the effectiveness of brachytherapy and ERBT PrCa treatments and
determine the influence of socioeconomic indicators in treatment effects.
This study is relevant to provide new insights on the effectiveness of PrCa
treatments among Jamaicans with localized disease. Jamaicans are diagnosed with
localized PrCa, and empirical data on the most effective treatment options for that cohort
are lacking. An understanding of the roles of brachytherapy and ERBT, in the prognosis
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of Jamaican PrCa patients, could support appropriate treatment decisions, aimed at
improving their overall survival.
Problem Statement
Recent publications established that higher numbers of Jamaican males are
currently diagnosed with Gleason scores 6, and 7 PrCa, when compared with Gleason
scores 8 to 10 PrCa (Anderson-Jackson et al., 2012; Kampel et al., 2011). However,
identifying empirical data on appropriate treatments, which will provide greater survival
benefits for PrCa patients with early and intermediate stage disease, is a prime challenge
for the management of PrCa in Jamaica (Morrison et al., 2014). There is also a need for
data on the outcomes of brachytherapy treatment in the Jamaican population (Morrison et
al., 2014).
The effect of PrCa treatment on early and intermediate stage disease in the
survival of affected males is well studied in many populations (Alumini et al., 2015;
Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014; Nepple et al., 2013;
Rodrigues et al., 2014; Smith et al., 2015; Williams et al., 2011; Zuber et al., 2015).
However, findings on the treatment methods which offer the best survival benefits for
PrCa patients with localized disease require further examination (Alumini et al., 2015;
Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014; Nepple et al., 2013;
Rodrigues et al., 2014; Schreiber et al., 2013; Smith et al., 2015; Williams et al., 2011;
Zuber et al., 2015). Several researchers reported favorable treatment outcomes for
brachytherapy (Alumini et al., 2015; Cendales et al., 2015; Williams et al., 2011; Zuber et
al., 2015). Other investigators suggested that the traditional ERBT may be a better option

10
for the overall survival of PrCa patients (Goldner et al., 2012; Nepple et al., 2013; Smith
et al., 2015). None of the studies which explained the effects of brachytherapy and ERBT
was conducted in the Jamaican population.
Recent publications cited the survival benefits of brachytherapy in White
populations (Alumini et al., 2015; Cendales et al., 2015; Marshall et al. 2014; Nepple et
al., 2013; Rodrigues et al., 2014; Williams et al., 2011). Results on the survival effects of
brachytherapy and ERBT in PrCa survival were identified among German (Zuber et al.,
2015), Dutch (Goldner et al., 2012), Canadian (Smith et al., 2015), and the U.S. White
populations (Alumini et al., 2015; Cendales et al., 2015; Marshall et al. 2014; Nepple et
al., 2013; Rodrigues et al., 2014; Williams et al., 2011). The conclusions of studies in
other populations may not be relevant to the Jamaican cohort. Jamaicans PrCa patients
are diagnosed with higher PSA levels, Gleason scores, and tumor stages when compared
with the White and African American PrCa patients (Fedewa & Jemal, 2013; Rich et al.,
2013). Jamaican PrCa patients also have the recessive and dominant genes which are
associated with a two-fold increased risk of PrCa in that cohort (Kidd et al., 2012).
Therefore, it was important to elucidate the effects of treatments for early and
intermediate stages of PrCa in the Jamaican communities with a similar cohort.
Purpose of the Study
In this quantitative dissertation, I utilized a retrospective cohort study design, and
analyses of secondary data with survival models, to examine the survival patterns of
Jamaican PrCa patients who were treated with brachytherapy and ERBT for the period
1992 to 2011. The purpose of this dissertation was to determine the survival outcomes of
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Jamaican PrCa patients who were diagnosed with early and intermediate stage disease,
and ascertain whether there were survival differences among Jamaican PrCa patients and
White U.S.-born PrCa patients who were treated with brachytherapy and ERBT. In this
investigation, I also aimed to examine the influences of sociodemographic indicators of
age, marital status, and health insurance status in the survival outcomes of the PrCa
patients. The key independent variables of this research were a history of brachytherapy
treatment, history of ERBT, and the stage and grade of PrCa. The dependent variable was
the length of time a prostate cancer patient lived with the disease after treatment. The
covariates for this study were the sociodemographic indicators of age, marital status, and
health insurance status of the PrCa patients.
Research Questions and Hypotheses
In this study, I utilized five research questions with their related hypotheses to
compare the treatments effects in the survival of the Jamaican and White U.S.-born
cohorts. The smoking variable was not examined because data were not available. The
hypothesis of this study speculated a difference in the survival time of the Jamaicans
versus the White U.S.-born PrCa patients. The five research questions and hypotheses
follow.
Research Question 1. Are there differences in the length of time Jamaican-born
PrCa patients compared with U.S.-born White PrCa patients who were treated with
brachytherapy for low and intermediate stages PrCa, live with the disease?
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H01: There are no differences in the length of time Jamaican-born and U.S.-born
White PrCa patients treated with brachytherapy for low and intermediate stages PrCa;
live with the disease.
Ha1: There are differences in the length of time Jamaican-born PrCa patients
versus U.S.-born White PrCa patients who were treated with brachytherapy for low and
intermediate stages PrCa, live with the disease.
Research Question 2. Are there differences in the length of time Jamaican-born
PrCa patients compared with U.S.-born White PrCa patients who were treated with
ERBT for low and intermediate stages PrCa, live with the disease?
H02: There are no differences in the length of time Jamaican-born PrCa patients
and U.S.-born White PrCa patients treated with ERBT for low and intermediate stages
PrCa, live with the disease.
Ha2: There are differences in the length of time Jamaican-born PrCa patients
compared with U.S.-born White PrCa patients who were treated with ERBT for low and
intermediate stages PrCa, live with the disease.
Research Question 3. Are there differences in 5-year survival intervals of
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients, according to
treatment received for the period 1992 to 2011?
H03: There are no differences in 5-year survival intervals of Jamaican-born and
U.S.-born White PrCa patients according to treatment received for the period 1992 to
2011.
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Ha3: There are differences in 5-year survival intervals of Jamaican-born PrCa
patients compared with U.S.-born White PrCa patients according to treatment received
for the period 1992 to 2011.
Research Question 4. Are there differences in the length of time brachytherapy
treated Jamaican-born PrCa patients, and U.S.-born White PrCa patients with low and
intermediate stages PrCa live with the disease, after controlling for sociodemographic
characteristics?
H04: There are no differences in the length of time brachytherapy treated
Jamaican PrCa patients and U.S.-born White PrCa patients with low and intermediate
stages PrCa, live with the disease, after controlling for sociodemographic characteristics.
Ha4: There are differences in the length of time brachytherapy treated Jamaican
PrCa patients, and U.S.-born White PrCa patients with low and intermediate stages PrCa
live with the disease, after controlling for sociodemographic characteristics.
Research Question 5. Are there differences in the length of time ERBT treated
Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and
intermediate stages PrCa live with the disease, after controlling for sociodemographic
characteristics?
H05: There are no differences in the length of time ERBT treated Jamaican PrCa
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live
with the disease, after controlling for sociodemographic characteristics.
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Ha5: There are differences in the length of time ERBT treated Jamaican PrCa
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live
with the disease, after controlling for sociodemographic characteristics.
Introduction of the Theory
The oxidative stress theory was utilized to explain the relationship between the
variables of this dissertation. Denham Harman conceptualized the oxidative stress theory
in 1956 as the free radical theory of aging (Preedy, 2014; Sowell, Aluise, & Butterfield,
2010). The oxidative stress theory postulates that accumulation of the production of free
radicals and or reactive oxygen species (ROS) affects cellular functioning by impairing
the deoxyribonucleic acid (DNA), lipid, and protein biomolecules of the cells of the body
(Preedy, 2014; Sowell et al., 2010). Khandrika, Kumar, Koul, and. Maroni. (2009) linked
the oxidative stress theory with programmed cell death which occurs because of
intracellular and extracellular environmental conditions of the prostate gland. According
to Khandrika et al. (2009), radiation is one of the environmental conditions which
induces oxidative stress in the prostate gland, increases ROS production and
consequently inhibits carcinogenesis. I anticipated that the oxidative stress theory would
support the mechanism of radiation in the cellular transformations of the prostate gland in
reducing carcinogenesis and consequently influencing the survival of PrCa patients. The
major premise of the oxidative stress theory was confirmed where the research
hypotheses were accepted. The mechanism of oxidative stress in PrCa survival is further
explained in Chapter 2.
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Kumar, Koul, Khandrika, and Meacham (2008) established that the cancerous
cells of the prostate gland produced high levels oxidative stress which are toxic to these
cells. Fang, DeMarco, and Nicholl (2012), and You et al. (2015) also supported the roles
of the oxidative stress pathway in inhibiting PrCa carcinogenesis through radiation.
Based on the mechanism of oxidative stress and its link with radiation-induced cell death
in the prostate gland, this theory was considered appropriate to create the framework for
providing a better understanding of the relationship between brachytherapy, ERBT, and
survival of the PrCa patients in this study.
Nature of the Study
I utilized a retrospective cohort study design, survival analyses, and secondary
data sources to answer the research questions. I selected a retrospective study design for
this study to examine survival patterns of PrCa patients that occurred at different intervals
between 1992 and 2011. The retrospective design was appropriate to examine both
exposures and outcomes historically (Aschengrau & Seage 111, 2008, p. 207) and
promote analyses of time to event data because of its historical nature (FrankfortNachmias & Nachmias, 2008, p. 277).
The independent variables were PrCa patients diagnosed with localized disease,
and PrCa treatments which, included brachytherapy treatment, ERBT, and other radiation
treatment (radiation sequenced with surgery). The dependent variable was the length of
time that a prostate cancer patient lived with the disease after treatment. The covariates
for this study were sociodemographic indicators of age, marital, and health insurance
status.

16
The source of secondary data for analysis was the 18 participating Surveillance
Epidemiology and End Results (SEER) registries of the United States, November 2013
submission. I chose this database because the SEER program of the National Cancer
Institute (NCI) is a reputable source of data on the incidence and survival of cancer in the
United States (NCI, 2017c). The SEER program gathers and publishes cancer rates and
survival information from 18 participating population-based registries and covers
approximately 28% of the U.S. population (NCI, 2017c). The SEER program is
recognized as the only comprehensive population-based registry in the United States,
which provides data on the tumor stage at the time of diagnosis as well as survival
information (NCI, 2017c). The SEER registries data include the demographics of the
PrCa patients and morphology and stage of the tumor at diagnosis (NCI, 2017c). The
SEER program information also includes the cancer patients’ first course of treatment
and the follow-up for their vital status (NCI, 2017c). The National Center for Health
Statistics provide the mortality data to the SEER program, and the U.S. Census Bureau
the population data. Thus, the SEER database was appropriate for this dissertation.
The analysis of data for this dissertation included preliminary descriptive
estimates for each of the variables of the study (Mills, 2011a). In addition, Kaplan-Meier
analyses were used to estimate the survival distributions and hazard rates of the PrCa
patients for varying intervals during the observation period. Furthermore, the Coxproportional hazards regression model was utilized to measure differences in the
relationship between the independent and dependent variables and to evaluate
confounding effects of the covariates in the outcomes of the study. I interpreted the
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results of these statistical analyses with alpha level (p < .05), and 95% confidence
intervals (Rich, 2010). I analyzed the data with the International Business Machines
(IBM) Statistical Package for the Social Sciences (SPSS) software version 23.
Definitions of Research Variables Relating to the Research Questions
Dependent Variable
The dependent variable of this dissertation is PrCa survival. PrCa survival was
defined as the duration that an affected person lived with PrCa from the date of initial
diagnosis to the time of the first outcome (death or censoring) (Hu et al., 2014; Lin et al.,
2009; Redaniel et al., 2013; Thompson et al., 2013). The time of diagnosis was the month
and year of diagnosis which were documented in the SEER registry database (SEER,
2013). The time of death was the period the death of a case was recorded in the registry
database (SEER, 2013). The vital status included the SEER cause-specific mortality
definition and confirmation of death using death certificate or autopsy information
(SEER, 2013). Censored cases were PrCa patients who died of causes other than PrCa
(NCI, 2017a). The definition of PrCa survival also included active follow-up of each
PrCa patient (SEER, 2013).
Independent Variables
In this study, I classified a prostate cancer patient according to the International
Classification of Diseases for Oncology version 10 (ICD-O) code C60, and used the
SEER cause-specific death (sequence numbers 01) definition of the 1973 to 2011
submission (National Institutes of Health [NIH], 2017). Additionally, a prostate cancer
patient in this research was a confirmed case by histology, or cytology according to the
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SEER Research Data Record Description 1973 to 2011 (SEER, 2013). Jamaican PrCa
patients were males with Jamaican birthplace who were recorded in 15 of the 18 SEER
registries, November 2013 submission (SEER, 2014). The 15 participating SEER cancer
registries included in the study were Connecticut, Detroit Metropolitan, San FranciscoOakland, Seattle (Puget Sound), Atlanta Metropolitan, Los Angeles, New Jersey, Greater
California, Rural and Greater Georgia, Kentucky, Louisiana, New Mexico, San JoseMonterey, and Utah (SEER, 2014). A White PrCa patient was defined as a U.S.-born
White PrCa patient of the 15 SEER participating cancer registries which, had Jamaican
PrCa patients (SEER, 2014).
The definition for the localized stage PrCa included the tumors which, were
confined to the prostate (Young et al., 2000). PrCa patients with localized disease were
classified according to Gleason grades G1, G2, and G3 (SEER, 2015, p. 96; Young et al.,
2000, p. 224). PrCa patients were also classified according to the TNM stages T1 and T2
of the AJCC 6th Edition tumor node metastases (TNM classification), and the SEER
Historic Stage A classification (SEER, 2013; SEER, 2014). According to the AJCC 6th
Edition TNM classification, the localized stages T1a, T1b, and T1c, are clinically inapparent tumors (SEER, 2013; Young et al., 2000). PrCa was defined as stage T2a with
the involvement of one lobe; and T2b for involvement of more than one lobe (Young et
al., 2000). Stage T2NOS was assigned to each PrCa patient who had no specified TNM
stage (SEER, 2013).
Prostate cancer treatments were ERBT, brachytherapy, and other radiation
treatments. Brachytherapy was defined as PrCa patients who received radioactive
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implants, radioisotopes, and a combination of radioactive implants and radioisotopes
(SEER, 2013). ERBT was PrCa patients who received beam radiation as monotherapy
(SEER, 2013). Other radiation treatment was PrCa patients who received radiation
sequenced with surgery (SEER, 2013). The radiation sequenced with surgery variable
included other types of radiation treatments, which were not accounted for in the
brachytherapy and ERBT definitions.
Covariates
Covariates for this study were the sociodemographic characteristics of the patient.
The sociodemographic characteristics included the marital status, age, and health
insurance status of the PrCa patient as recorded in the SEER registries data and reported
at diagnosis (SEER, 2013). Marital status was the marital union reported by the patient
at the time of PrCa diagnosis (SEER, 2013). Health insurance status was the PrCa
patient’s primary means of payment for health care, and the health insurance coverage
plan at the time of diagnosis as recorded in the SEER data (SEER, 2013). Age was the
actual age in years at diagnosis as recorded in the SEER registry database (SEER, 2013).
Age also included all PrCa patients who were older than 35 years for the 1973 to 2011
SEER reporting period (SEER, 2013).
Assumptions
One of the assumptions that guided the execution of this dissertation was the
secondary data of the SEER registries were appropriate for the exploratory design of this
study. The SEER registry data on PrCa patients were collected by federal agencies, which
employed trained personnel for data collection processes, and applied quality assurance
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measures (Boslaugh, 2010). In addition, the data were deidentified and recoded where
appropriate to protect the research participants (SEER, 2013). I also assumed that the
SEER registry dataset would provide the cancer-specific information, which was related
to the independent and dependent variables of this dissertation because the SEER registry
database is a national database (Su & Jang, 2011). Multicenter and national databases are
better suited to capture data on specific details about the characteristics of the tumor for
comparisons of the outcomes of different treatments a PrCa patient receives (Su & Jang,
2011). Hence, I presumed that the SEER registry database was an appropriate data source
for this study.
My supposition that the choice of secondary data for this investigation was
appropriate was grounded in the likelihood that it could determine the probable
relationships between the dependent and independent variables. The assumption was also
based on the concept that secondary data sources are advantageous to examine the
variables of an investigation in a socioeconomic, geographic, and historical context
(Flowerdew, & Martin, 2013, p. 59). Besides, secondary data are helpful for comparison
of a specified cohort with the larger population from which it was taken and facilitate the
evaluation of differences and trends (Flowerdew, & Martin, 2013, p. 59).
Additionally, I assumed that the theoretical framework was ideal to explain the
relationships between the independent and dependent variables. The oxidative stress
theory, which hypothesized that oxidative stress is linked to age-related cancers including
PrCa, and radiation-induced programmed cell death in the prostate gland is a biological
concept. A biological conceptual framework generates data for defining, evaluating, and
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managing clinical problems (Wenzel, 2017, p. 492). Hence, I presumed that the oxidative
stress theory was suitable to determine the role of radiation in the oxidative stress
pathway and PrCa carcinogenesis.
Scope and Delimitations
The primary focus of this dissertation was to determine survival outcomes of
brachytherapy and ERBT treated Jamaican PrCa patients who were diagnosed with
localized disease and resided in the United States. The study was important because there
were limited publications on PrCa treatment outcomes among Jamaicans and studies on
PrCa treatments were primarily conducted in the White populations and with small
samples of African Americans. Hence, results of current publications were not applicable
to Jamaicans. Subsequently, an enquiry using a Jamaican cohort was necessary to
extrapolate the findings to that cohort.
In this study, I included all Jamaicans from the SEER database who met the
selection criteria. The Jamaicans in the SEER registries database were the largest nonU.S.-born Black population (87.6%) (Fedewa & Jemal, 2013) and had the similar stage
and grade PrCa as the patients residing in Jamaica West Indies (Anderson et al., 2012;
Kampel et al., 2011). I balanced the selection of a White U.S.-born comparison group
with the Jamaican cohort by excluding three of 18 SEER reporting sites (Hawaii, Iowa
and Alaska Native) which had no Jamaican PrCa patients.
The study included all the PrCa patients who satisfied the selection criteria in the
SEER registry data set to maximize group differences on the dependent and independent
variables and improve generalization of the research findings (Polit & Beck, 2013, p.
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246). The inclusion of a White U.S.-born referent group improved the sensitivity of the
study to detect the effects observed (Polit & Beck, 2013, p. 246) among the Jamaican and
White U.S.-born cohorts. I included the variable, radiation sequenced with surgery, to
determine whether the treatment outcomes would differ significantly from brachytherapy
and ERBT. The radiation sequenced with surgery variable included other types of
radiation treatments that were not accounted for in the brachytherapy and ERBT
definitions, hence it was important to determine whether it contributed significantly to the
outcomes of the study. Additionally, I chose a biological theoretical framework to
conceptualize the findings of the study because the research problem and questions were
focused on PrCa treatment effects.
Limitations
One of the primary limitations anticipated in this study was the inability to make
causal inferences about the variables from secondary data sources (Smith et al., 2011).
Secondary data limits the options to choose appropriate populations for the study and
influences the generalizability of the research results (Smith et al., 2011). Nonetheless,
the questions of this research were developed to address the limitations on the study’s
findings (Smith et al., 2011). The research questions were structured based on logical
reasoning from the conclusions of the literature reviewed and the recommendations of
other researchers. The questions were developed on the premise that although they may
not facilitate causal inferences from the data, they can generate findings on the clinical
significance of the research (Smith et al., 2011). The SEER registry (a national database)
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which collects data from 18 participating cancer registries in the USA was used for the
data analysis to enhance generalizations of the research findings.
I utilized survival models for data analysis, and there are limitations of these
statistical techniques. The Kaplan-Meier survival method is not effective to quantify the
actual effect size of the study and is limited in addressing confounding effects (Flynn,
2012). However, in this study the Cox-proportional hazards model complemented the
Kaplan-Meier survival model. The Cox-proportional hazards regression model is robust,
flexible, and uses data efficiently (Harrell, 2015). The Cox-proportional hazards
regression model also replaced the proposed Ederer 11 and Pohar Perme methods, which
were limited in analyzing PrCa patients in the older age group (Lambert, Dickman, &
Rutherford, 2015; Roche et al., 2013; SEER*Stat, 2015; Seppa, Hakulinen, & Pokhrel,
2015).
Possible Biases
A potential bias in this study was the threat of maturation of the research
participants (Polit & Beck, 2013, p. 247). Some PrCa patients may change their vital
status with time, irrespective of the treatment they receive, because of other conditions
such as comorbidities, which could not be measured in this study owing to the limitations
of the dataset.
Another possible source of bias for this dissertation was sampling bias (Leighton,
2010a, p. 83). In addressing the likelihood of possible selection bias in this dissertation, I
used an evidenced based approach to create the selection criteria. I developed the
selection criteria for the research participants using their characteristics in the SEER
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Research Data Description for PrCa cases who were diagnosed between 1973 to 2011
(SEER, 2013). I also utilized a random selection method to choose the comparison group
for the study.
Significance
This dissertation may add new epidemiological data to the current body of
knowledge on PrCa in the Jamaican community. While PrCa is a public health problem
among Jamaicans, there is limited information on the treatment of localized PrCa in the
Jamaican communities (Aiken & Eldemire-Shearer, 2012; Fedewa & Jemal, 2013;
Gibson, Hanchard, Waugh, & McNaughton, 2013; Morrison et al., 2014; Rich et al.,
2012).
I also expect that this dissertation will contribute to public health practice and
policies aimed at improving the years of potential life lost (YPLL) of a Jamaican PrCa
patient, by informing clinical interventions and policies that address access to treatments
for localized PrCa. If these interventions are effective in managing the early and
intermediate stages of this disease, the survival rates of affected males may be improved
because earlier stages of PrCa demonstrate better survival outcomes (Fufaa, 2011).
This study has important social change implications for the Jamaican population.
The Jamaican population has a high rate of PrCa, and affected males experience
disparities in access to PrCa treatment (Aiken & Eldemire-Shearer, 2012; Gibson et al.,
2013; Rich et al., 2012). This inequality is primarily due to a combination of social
factors such as lack of health insurance and affordable preventive care (Aiken & Shearer,
2012; Morrison et al., 2014). Therefore, this research may provide data, which can be
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used to make appropriate decisions for improving the clinical management of PrCa
patients, enhance access to health care, improve the health outcomes of PrCa patients,
and subsequently reduce the disparities in PrCa survival. Currently, the Jamaican
government is seeking to advance the services offered to cancer patients in Jamaica by
utilizing assistance from the international organization International Atomic Energy
Agency (IAEA) to address the existing epidemiological status of cancers in the country
(Ministry of Health Jamaica, 2013). The Jamaican urological society is also seeking
information on PrCa treatment effectiveness among Jamaicans, which will support
appropriate treatment choices for localized PrCa (Morrison et al., 2014). This research
would improve access to empirical data that focused on addressing the PrCa cancer
epidemiology among Jamaicans.
Summary and Transition
The treatment of PrCa patients with low and intermediate stage disease using
Brachytherapy and ERBT are well documented among the White population of the
United States as well as other European cohorts. However, findings of recent publications
may not generalize to Jamaicans because of small samples of African Americans, which
were included in those investigations. There is also a dearth of information on the
relationship between brachytherapy treatment, ERBT, and PrCa survival among
Jamaicans. Besides, it was important to study the effects of brachytherapy and ERBT in
localized PrCa among Jamaicans because of currently reported trends in the detection of
the disease. Additionally, it was relevant to examine for intervening effects of the
sociodemographic characteristics in the survival of PrCa patients because of their

26
relationship with the key variables of the study. Hence, the sociodemographic indicators
of the research subjects were studied for their covariate effects in the results of the
research. The research utilized a retrospective design and survival models to examine the
effects of brachytherapy and ERBT on the survival of Jamaican PrCa patients with low
and intermediate stage PrCa. These survival models included the Kaplan-Meier and Coxproportional hazard models. The oxidative stress theory was chosen to explain the
relationship between the main variables of the study. In Chapter 2, I provided a deeper
analysis of the literature that clarifies the theoretical framework of the study. Chapter 2
also has the literature synthesis which describes the variables of the study, their roles in
the study; and the gaps in the literature.
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Chapter 2: Literature Review
Introduction
The outcomes of brachytherapy and ERBT in treating low and intermediate stage
PrCa are well reported in retrospective, prospective, and observational studies (Alumini
et al., 2015; Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014;
Nepple et al., 2013; Rodrigues et al., 2014; Smith et al., 2015; Williams et al., 2011;
Zuber et al., 2015). However, researchers documented diverse conclusions on the
effectiveness of brachytherapy, ERBT, and active surveillance for treating localized PrCa
(Alumini et al., 2015; Cendales et al., 2015; Goldner et al., 2012; Marshall et al. 2014;
Nepple et al., 2013; Rodrigues et al., 2014; Smith et al., 2015; Williams et al., 2011;
Zuber et al., 2015). Findings of current publications were noted primarily in the White
populations (Alumini et al., 2015; Cendales et al., 2015; Marshall et al. 2014; Nepple et
al., 2013; Rodrigues et al., 2014; Williams et al., 2011). Additionally, investigators who
examined treatment effects of brachytherapy and ERBT in PrCa survival, documented
limitations of small sample sizes of the Black population (Cendales et al., 2015; Goldner
et al., 2012; Nepple et al., 2013; Smith et al., 2015; Zuber et al., 2015). Hence, data from
current literature may not extrapolate to the Jamaican cohort. Consequently, the intent of
this dissertation was to explore the effects of ERBT, and brachytherapy treatment on the
survival of Jamaican PrCa with low and intermediate stage disease. This dissertation was
also designed to examine the covariate effects of the sociodemographic indicators of age,
marital status, and health insurance status in the survival rates of Jamaican and White
U.S. PrCa patients. This research investigated the association of PrCa treatment for low
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and intermediate stage disease with the survival rates of Jamaican and U.S.-born White
PrCa patients, using a retrospective cohort study design, secondary data, and survival
models.
A vast number of current retrospective and prospective studies documented
disparities in PrCa survival in the African American, and Caribbean Black populations
(Antwi, Tucker, Coker, & Fleming, 2013; Mutetwa et al., 2012; Ragin, Mutetwa, AttongRogers, Roach, & Taioli, 2011; Tyson & Castle, 2014). Meliker, Goovaerts, Jacquez,
AvRuskin, and Copeland (2009), and Tyson and Castle (2014) reported that the White
PrCa patients in the United States experienced better survival overall when compared
with Black males. Mutetwa et al. (2012) and Ragin et al. (2011) established that men who
were born in the Caribbean and lived in the United States had similar five-year survival
patterns from PrCa as other African Americans. However, the reasons for the survival
disparities in PrCa among racial groups were not well explained in current literature.
Recently, researchers also documented that brachytherapy (with or without
ERBT), and active surveillance, were popular treatment choices among PrCa patients
who are living in the United States (Hamilton et al., 2010; Weiner, 2015). However,
retrospective, prospective and observational studies on brachytherapy treatment and PrCa
survival demonstrated mixed results (Alumini et al., 2015; Cendales et al., 2015;
Marshall et al. 2014; Rodrigues et al., 2014; Williams et al., 2011; Zuber et al., 2015).
Alumini et al. (2015), Cendales et al. (2015), Smith et al. (2015), Rodrigues et al. (2014),
Skowronek (2013), and Zuber et al. (2015) reported survival benefits among
brachytherapy treated PrCa patients. On the other hand, Goldner et al. (2012), Nepple et
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al. (2013), and Smith et al. (2015) cited no statistically significant differences among
PrCa patients who were treated with ERBT as a monotherapy, versus PrCa patients who
received brachytherapy with and without ERBT. Moreover, Schreiber et al. (2013)
documented disparities in brachytherapy treatment among Whites and African
Americans. Furthermore, Williams et al. (2011) established that brachytherapy was a
costlier treatment option for localized disease when compared with other PrCa
treatments. Hence, current literature provided mixed findings on the survival advantage
of brachytherapy treatment and ERBT among PrCa patients with low and intermediate
stage disease. Additionally, the outcomes reported in the literature suggested that the
effect of brachytherapy treatment for localized PrCa required further exploration
particularly among African American males.
In current publications, researchers documented favorable survival outcomes
among PrCa patients who were diagnosed with low and intermediate risk disease and
were managed without directive treatment (Bul et al., 2013; Odom et al., 2014;
Selvadurai et al., 2013; Wilt et al., 2012). In three prospective studies, Bul et al. (2013),
Klotz et al. (2010), and Selvadurai et al. (2013) reported low death rates among PrCa
patients on active surveillance and observation. However, Klotz et al. recommended
additional research, which include PrCa patients with the aggressive forms of the disease
to verify their findings. Nepple et al. (2013) also suggested that observation should be
added as a treatment option in studies, which examine the effects of ERBT and
brachytherapy treatment in PrCa survival.
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Additionally, findings of the review of the literature revealed that the
sociodemographic characteristics of age, grade, and stage of the disease influenced the
survival of PrCa patients, particularly the African American population (Antwi et al.,
2013; Fufaa, 2011; Lin et al., 2009). Scholars have also identified differences in survival
of PrCa according to the sociodemographic characteristics and treatment status of men
from varying geographic backgrounds, and indicated that these variables might be
responsible for PrCa survival (Parris, 2013; Shafique et al., 2013; Xiao, Warrick, &
Wang, 2009). Therefore, the sociodemographic indicators of age, marital, and health
insurance status of a PrCa patient were examined in this study for their covariate effects.
Finally, recent studies documented that smoking impacts the survival of PrCa
patients (Kenfield et al., 2011; Warren et al., 2012; Watters et al., 2009). Smoking may
be related to high death rates among PrCa patients, and the African American population
is more likely to be affected (Kenfield et al., 2011; Warren et al., 2012; Watters et al.,
2009). Furthermore, data from the Jamaican Lifestyle Survey (453304) indicated that
smoking was a common lifestyle factor among Jamaican males and a contributing factor
to chronic diseases in that cohort (Wilks, Younger, Tulloch-Reid, Mcfarlane, & Francis,
2008). Hence, smoking was a covariate in this study; but, data were not available for this
research to examine its effects on PrCa survival.
Chapter 2 includes the origins of the oxidative stress theoretical framework, its
main propositions, and its role in the relationship between the independent and dependent
variables. Chapter 2 also comprises the literature search strategy, the synthesized
literature of the variables of the study, and the research questions. The main areas of the
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literature review were prostate cancer survival, current trends in PrCa survival,
differences in survival among ethnic groups, treatment for low and intermediate stage
PrCa and survival, and the sociodemographic characteristics and PrCa survival.
Literature Search Strategy
I conducted the literature search using publications from the major databases of
the Walden University Library. The primary library resources were ProQuest
Dissertations and Theses at Walden University, Google Scholar, EBSCO Host, Academic
Search Complete, Thoreau, and Science Direct. The Boolean search engines and phrases
were the major search modes used to identify appropriate literature for this dissertation.
The key search terms were prostate cancer, prostate cancer mortality and
survival, prostate cancer and Jamaican males, prostate cancer in the White population of
the United States, prostate cancer, and radiation treatment, prostate cancer in the
Caribbean, and prostate cancer in the United States. Search terms also included, prostate
cancer treatment for localized disease, active surveillance and prostate cancer, external
beam radiation therapy (ERBT) and localized prostate cancer, and brachytherapy and
localized prostate cancer, treatment of prostate cancer and 1973 to 2011. In addition,
search terms included radiation and the oxidative stress theory, oxidative stress theory
and prostate cancer, the mechanism of the oxidative stress theory, and radiation-induced
apoptosis. Other terms used for the literature search were sociodemographic
characteristics and prostate cancer treatment, smoking and prostate cancer survival,
smoking among Jamaicans, and the SEER cancer registry.
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I also used the reference listings of current primary research articles to identify
other relevant sources of the literature. Publications were sorted by relevance and
currency, for those written in English, and included peer-reviewed primary sources.
However, both peer-reviewed and non-peer-reviewed articles on the Jamaican population
were included because of limited literature. I utilized the studies on the African American
population to make deductions about Jamaicans where the data on the variables of
interest and the research questions were inadequate. Articles older than five years were
included where data were lacking on important variables, and for their relevance to the
study.
Theoretical Foundation
The free radical theory of ageing, currently known as the oxidative stress theory
(Sowell et al., 2010) was utilized to conceptualize the relationship between treatment for
localized PrCa, clinical characteristics of PrCa, and PrCa survival. Denham Harman
developed this theory in 1956 (Sowell et al., 2010).
Major Theoretical Propositions
The oxidative stress theory proposed that oxidative stress is an outcome of
increased and sustained metabolic processes of the body, which contributes to major agerelated chronic diseases, including cancers (Sowell et al., 2010, p. 341). The oxidative
stress theory posits that accumulation of the production of free radicals and ROS, affects
cellular functioning by impairing the DNA, lipid, and protein biomolecules of the cells of
the body (Preedy, 2014; Sowell et al., 2010). Khandrika et al. (2009) linked the oxidative
stress theory with programmed cell death, which occurs because of intracellular and
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extracellular environmental conditions of the prostate gland. These intracellular and
extracellular environmental conditions generate ROS during the metabolic activities of
the cell, and ROS subsequently activate signaling pathways to react to the cellular states
(Khandrika et al., 2009). According to Khandrika et al. radiation is one of the
environmental conditions which induces oxidative stress in the prostate gland and
consequently increases ROS production. Radiation also inhibits carcinogenesis by
increasing ROS production (Khandrika et al., 2009). Increasing ROS production results
in damage to the DNA of the cell and inhibits cell duplication and division (Khandrika et
al., 2009). Subsequently, radiation-induced cell death occurs, and the damaged cells are
removed from the body through apoptosis (Khandrika et al., 2009; Nakajima, 2008). The
process of radiation-induced apoptosis impedes the progression of PrCa carcinogenesis
(Nakajima, 2008). Thus, the assumptions of the oxidative stress theory are linked with the
mechanism of radiation-induced programmed cell death in halting PrCa carcinogenesis.
Literature and Research-Based Analysis of Theory Application
Findings from studies, which clarified the roles of the oxidative stress pathway in
PrCa development, supported a relationship between oxidative stress and PrCa
carcinogenesis (Barocas et al 2011, Freitas et al., 2012; Kumar et al., 2008). In the
Nashville’s Men’s Health study Barocas et al. (2011) confirmed that oxidative stress
played a role in PrCa development. Barocas et al. identified that F2-Isoprostane level,
which is associated with oxidative stress in PrCa, was elevated in men with the disease.
In another experimental study, which used the oxidative stress theory as its conceptual
framework, Kumar et al. (2008) described the functions of oxidative stress in healthy

34
cells of the prostate gland and three different types of PrCa cells with varying degrees of
aggressiveness. Kumar et al. confirmed that PrCa cells produced higher levels of ROS
when compared with normal cells, and subsequently created functional abnormalities of
the prostate cells. Freitas et al. (2012) also established that ROS was toxic to PrCa cells in
the localized stage of PrCa. However, Freitas et al. indicated that the influence of ROS in
low-grade PrCa was less marked when compared with metastatic disease. The finding of
Freitas et al. suggested that small increments of ROS also create changes in the cells of
the prostate gland.
Experimental studies also supported the roles of the oxidative stress pathway in
inhibiting PrCa carcinogenesis (Fang et al., 2012; You et al., 2015). Fang et al. (2012)
and You et al. (2015) indicated that the oxidative stress pathway plays a key role in
explaining the functions of ROS in stimulating signaling pathways in response to the
cellular environment of the prostate gland. Fang et al. and You et al. demonstrated that
radiation promotes apoptosis, and decreases cell proliferation in localized PrCa. The
findings of these studies suggested that radiation promotes programmed cell death and
subsequently inhibits carcinogenesis (Fang et al., 2012; You et al., 2015). The effects of
radiation-induced programmed cell death in decreasing PrCa carcinogenesis may
determine the length of time individuals who are treated with radiation live with the
disease. Therefore, the oxidative stress theory was appropriate to explain the relationship
between the primary variables of this dissertation because it clarified the mechanism of
radiation- induced PrCa cell death in halting carcinogenesis (Fang et al., 2012; You et al.,
2015).
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Relationship of the Theory to the Study and the Research Questions to the Theory
The aim of this study and the research questions were to determine the survival
intervals of ERBT and brachytherapy treated Jamaican PrCa patients with low and
intermediate stages PrCa, and compare survival outcomes with White U.S.-born ERBT
and brachytherapy treated PrCa patients. Experimental studies documented the role of the
oxidative stress pathway in the development of PrCa, and paradoxically in halting PrCa
carcinogenesis (Fang et al., 2012; Khandrika et al., 2009; You et al., 2015). According to
the findings of these studies, radiation is an extracellular environmental factor which
induces oxidative stress in the prostate gland and damages the cell’s DNA structure (Fang
et al., 2012; Khandrika et al., 2009; You et al., 2015). Thus, the cell cycle is arrested,
radiation-induced apoptosis occurs, and consequently, carcinogenesis of the prostate is
halted (Fang et al., 2012; Khandrika et al., 2009; You et al., 2015). The outcome of this
process may explain the length of time a PrCa patient lives with the disease. Therefore,
this theory was appropriate to test the hypotheses of a relationship between the prime
variables of this dissertation.
Literature Review Related to Key Variables and Concepts
In the literature review, I discussed the significant variables and covariates in the
context of the study. I also highlighted how the key variables were measured in this
dissertation, and the gaps addressed with the research questions.
Prostate Cancer Survival
Prostate cancer survival is the dependent variable in this dissertation and was
investigated among Jamaican and White PrCa patients residing in the United States. In
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defining PrCa survival, it was necessary to clarify the dates of initial diagnosis and the
time of death from PrCa. Researchers who conducted investigations in PrCa survival
defined survival as the date of initial diagnosis to the time of the first outcome (death or
censoring) (Hu et al., 2014; Lin et al., 2009; Redaniel et al., 2013; Thompson et al.,
2013). According to Mills, (2011a) knowledge of the time of the event helps in
determining whether continuous or discrete time methods should be used to complete
survival analyses. Redaniel et al. (2013) examined PrCa survival with secondary data and
used the definitions of the cancer registry that provided the data. Redaniel et al. defined
the date of initial diagnosis of PrCa as the date of initial histological or cytological
confirmation of the primary tumor. Mills and Redaniel et al. supported the relevance of
establishing the parameters, which defined the survival intervals of the PrCa patients in
this research.
Another vital element of the definition of prostate cancer survival in this study
was specifying the time of death. In survival data, the precise survival times for a variable
may be difficult to determine, or data may not be available in the data set (Mills, 2011a).
The survival time that is not known is usually accounted for as censoring in survival
studies (Mills, 2011a). Hence, censoring was a critical component of the definition of
survival in this research. An important consideration for the definition of censoring was
variation in its meaning according to the source of data used for an investigation. In
examining survival time, Lin et al. (2009) and Thompson et al. (2013) defined censoring
of PrCa patients as the date that they were last reported as being alive in the study, based

37
on available follow-up data. In this dissertation, I used the definition for censored data
that was available in the database.
Additionally, an appropriate endpoint was a key aspect of the definition of
prostate cancer survival. Prostate cancer-specific and cause-of-death mortality are two
important endpoints which are used to estimate PrCa survival (NCI, 2011). However, the
NCI (2011) reported that it is usually challenging to choose appropriate sources of
information from which to confirm these endpoints for PrCa. Cause of death data is one
source of information used for this purpose, but it is limited in providing the correct
endpoint for verifying PrCa survival (NCI, 2011). Nonetheless, information from the NCI
suggested that despite its limitations, cause-of-death data is useful to establish endpoints
to estimate PrCa survival. The cause-of-death data represents the survival from PrCa in
the absence of other causes of death and allows for censoring of individuals who die of
causes that were not studied (NCI, 2011).
Lin et al. (2009) and Thompson et al. (2013) used cause-specific and all-cause
mortality data to measure PrCa survival and described the benefits and limitations of
using both data sources. Thompson et al. indicated that there were limitations in using
cause-specific data to determine PrCa survival; conversely, Lin et al. highlighted the
advantage of using both cause-specific and all-cause mortality data to examine survival.
In estimating survival in a treatment versus a placebo group using PrCa specific mortality
data, Thompson et al. did not detect an effect in a placebo group because of inadequate
information on cancer-specific deaths. On the other hand, Lin et al. identified a difference
in overall survival (survival rate 2.1%, 95% [CI 1.38, 3.19]) and PrCa specific survival
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(survival rate 0.71%, 95% [CI, 0.54, 0.92]), using cause-specific and all-cause mortality
data from the SEER registry. Lin et al. examined PrCa survival in a 55 to 64 age group
cohort diagnosed with all stages of PrCa. Although 38% of the data were reported
missing in the study, this did not affect the study’s outcome (Lin et al., 2009). The
studies’ results of Lin et al. and Thompson et al. implied that using both cause-specific
and all-cause mortality data may be a better choice to estimate PrCa survival when
compared with utilizing cause-specific data exclusively.
Lin et al. (2009) relied on the information from death certificates to obtain cause
of death data to base endpoints for PrCa survival; however, the NCI (2011) reported
limitations in using death certificates for this purpose. According to the NCI, one of the
drawbacks of using death certificates to determine death from PrCa is ensuring that the
data accurately classify the cases. The precision of the endpoints from death certificates
might vary according to the accuracy of the information of the death certificates; this
could be problematic when classifying metastatic cases if the death certificates
incorrectly list the cause of death (NCI, 2011). Although the NCI reported limitations in
the use of death certificates, the organization advocates for its use to ascertain causes of
death in population-based survival data obtained from cancer registries. In this
dissertation, the definition of prostate cancer survival was developed based on the
recommendations of the NCI, the findings of the literature, and the definitions of the
cancer registries data description (SEER, 2014).
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Differences in Prostate Cancer Survival Among the White U.S.-Born and Ethnic
Groups
Investigators who conducted studies on PrCa survival in the United States
documented greater survival disadvantage of the U.S.-born ethnic groups when compared
with the White population (Antwi et al., 2013; Meliker et al., 2009; Mutetwa et al., 2012;
Ragin et al., 2011; Tyson & Castle, 2014). Antwi et al. (2013) explored differences in
PrCa survival in a cohort of 18,200 (91.3% Whites, 8.7% African-American) men from
the State of Kentucky cancer registry. The results of the enquiry demonstrated that the
African American PrCa patients experienced higher mortality (10.9%) from the disease
when compared with the Whites (7%), (p < .001) (Antwi et al., 2013). The African
American men were also more likely to be diagnosed with distant stage PrCa (6.5%)
when compared with the White population (4.3%) (Antwi et al., 2013). Additionally, a
higher proportion of African American versus White PrCa patients received surgery as
the primary treatment (29.6% versus 25.2%, p < .001) (Antwi et al., 2013). Additionally,
the survival disparities of the White and African American cohorts remained at ten years
of follow-up (Antwi et al., 2013). Antwi et al. recommended further exploration of
survival differences of African Americans including socioeconomic status, treatment
guidelines, underlying biological influences among the races, and comorbidities.
Meliker et al. (2009) examined survival disparities in a sample of 120,615 PrCa
patients from the State of Michigan cancer surveillance program and demonstrated mixed
results. Using the Space-Time Intelligence System, Meliker et al. estimated racial
disparities across Federal and State House Legislative Districts and community-defined
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localities. The findings of the study revealed racial differences in PrCa survival in 47% of
the Federal State House Legislative Districts (Meliker et al., 2009). However, the survival
experience for the State House Legislative Districts and urban communities were mixed
(Meliker et al., 2009). One of the high points of this study was the utilization of
geographic information systems to quantify the survival outcomes of the PrCa patients
(Meliker et al., 2009). On the other hand, Meliker et al. asserted that their study could not
determine variations in PrCa survival according to the country of origins of
subpopulations of Blacks and Whites.
Tyson and Castle (2014) also documented disparities in PrCa survival among
Blacks when compared with Hispanics, Asians, and Whites. Tyson and Castle utilized a
cohort of 294,160 PrCa patients from the SEER cancer data registries who were
diagnosed between January 1995 and December 2003. The findings of the study
conducted by Tyson and Castle revealed that the Black PrCa patients had poorer survival
when compared with the White U.S. cohort, HR 1.37, 95% [CI 1.33, 1.41], p < .001.
Tyson and Castle alluded to the problems encountered in determining racial peculiarities
due to the broad ethnic classification of the population-based data, and recommended
future studies to explain the factors favoring differences in survival.
Additionally, investigators demonstrated survival disparities among Caribbeanborn PrCa patients living in the United States and their country of birth (Mutetwa et al.,
2012; Ragin, 2011). Mutetwa et al. (2012) investigated the disparities of PrCa among
Caribbean ethnic groups who resided in the United States and compared survival patterns
with Caribbean men who lived in their native country. Mutetwa et al. utilized three
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cancer registries databases in the United States, as well as Caribbean cancer registries
data to estimate survival differences among the Afro-Caribbean males, and compare
survival patterns with men living in the Caribbean. Mutetwa et al. recognized that males
who were born in the Caribbean and resided in the United States had similar five-year
survival patterns from PrCa as African Americans. The survival rate for Caribbean men
living in their native countries was 78.1%, 95% [CI 70.9, 83.7] and 81.4% for African
Americans males, 95% CI [69.5, 89.1] (p = 0.792) (Mutetwa et al., 2012).
On the other hand, Mutetwa et al. (2012) reported that the survival rate for the
Caribbean-born PrCa patients residing in the Caribbean was 41% when compared with
81% for the men who resided in the United States. According to Mutetwa et al., the
disparities in the survival rates of Caribbean-born PrCa patients who lived in their
country of birth and the United States may be attributed to the methods of detection of the
disease and genetic factors. One of the limitations reported by Mutetwa et al. was missing
and incomplete data that defined the ethnic groups. On the other hand, a strong point of
the researchers’ methodology was data triangulation with the Caribbean cancer registries
and three United States cancer databases.
Ragin et al. (2011) conducted further studies on the disparities in PrCa survival in
a Brooklyn cohort of Caribbean-born males and PrCa patients living in the Caribbean to
determine the underlying factors for their survival differences. Ragin et al. studied the
survival differences among men who were currently diagnosed with stages 1 to 111 PrCa.
The results of the study confirmed that the Caribbean-born PrCa patients who resided in
their home country were three times more likely to die of PrCa, adjusted HR 3.6, 95%
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[CI 2.8, 5.0] when compared with their Caribbean counterparts residing in the United
States (Ragin et al., 2011). Ragin et al. also confirmed that there were significant
differences in the treatments that the two cohorts received. The Caribbean-born males in
the United States were managed surgically (35%); while, men residing in the Caribbean
received hormone treatment (33%) (Ragin et al., 2011). Hence, the survival differences
among PrCa patients in the Caribbean and the United States may be explained by
treatment differences (Ragin et al., 2011). Ragin et al. recommended additional studies
among Caribbean men to validate the results of their study.
The findings of the current literature confirmed that the White U.S. PrCa patients
had better survival probability from PrCa when compared with the Black population.
Therefore, the White U.S. PrCa patients were suitable for the referent group for this
research. The conclusions of studies on disparities in PrCa survival support the need for
other research, which examine PrCa treatment outcomes in subpopulations of the African
American and other ethnic communities in the United States. Additionally, researchers
advocated for the inclusion of the socioeconomic status of PrCa patients in studies, which
examine treatment effects in PrCa outcomes. Thus, it was necessary to study PrCa
treatment outcomes in a minority population and include their socioeconomic
characteristics.
Trends in the Treatment of PrCa 1992 to 2011
The treatment of PrCa evolved since the 1990s, and brachytherapy, ERBT, and
active surveillance are widely used to treat localized disease (Cooperberg & Carroll,
2015; Hager et al., 2014; Hamilton et al., 2010; Mahmood et al., 2014; Safdieh et al.,

43
2016; Valdivieso et al., 2015, Weiner et al., 2015). Hamilton et al. (2010) examined
trends in PrCa treatments for localized PrCa for the 1998 to 2002 interval using data from
ten cancer registries in the United States. Hamilton et al. identified no significant changes
in the number of PrCa patients who utilized radical prostatectomy or ERBT as
monotherapy. Nevertheless, the proportion of patients who received brachytherapy
treatment as monotherapy or combined with ERBT increased from 14.9% to 17.7%
(Hamilton et al., 2010). Hamilton et al. also reported a decline in the number of PrCa
patients who chose watchful waiting as an option for managing localized PrCa. Hamilton
et al. recommended additional studies on recent trends in PrCa treatments for localized
disease, and endorsed further studies which will delineate the subgroup of PrCa patients
who would benefit from brachytherapy and ERBT.
Hager et al. (2014) also reported a shift in treatment trends for localized PrCa for
the period 2004 to 2011. Hager et al. compared current trends in PrCa treatments among
cohorts of United States and German PrCa patients. The sample of U.S. PrCa patients
was 132,506 PrCa patients whose data were abstracted from the SEER cancer registry.
Hager et al. reported a decline in radical prostatectomy treatment (37.1% to 34.2%,
p = .004), and radiotherapy (42.8% to 31.8%, p < .001) for the period 2004 to 2011.
Hager et al. also identified that deferred and defensive treatments were the preferred
choices for treating localized PrCa in the United States and there was a steady increase in
the utilization of these treatment methods. However, Hager et al. alluded to the influence
of physician’s preferences and the health care systems in the choice of treatment for men
with localized PrCa. On the other hand, the PrCa patient’s preferences in treatment
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options were not well documented (Hager et al., 2014). Additionally, Valdivieso et al.
(2015) reported that brachytherapy was widely used among PrCa patients in the SEER
Medicare-linked database for the 1992 to 2009 period. Forty percent of PrCa patients in
the SEER Medicare-linked database used brachytherapy as monotherapy, 19% as a
combination with ERBT, and 27% as a combination with Androgen Deprivation Therapy
(ADT) (Valdivieso et al.,2015). Valdivieso et al. suggested that current investigations
which extend beyond 2009 were needed to determine further shifts in PrCa treatment in
the United States.
On the other hand, Mahmood et al. (2014) and Safdieh et al. (2016) provided
differing data on recent developments in PrCa treatments in the United States. Mahmood
et al. investigated current trends in brachytherapy and ERBT utilization for treating
localized PrCa for the period 2004 to 2009 using the SEER registry data. Mahmood et al.
recognized a decline in brachytherapy treatment of 6.2% for the periods 2004 to 2009 and
a similar increase of in ERBT uptake for that period. Brachytherapy utilization decreased
according to the SEER geographic sites, race, age, marital status, health insurance status,
and income, of the PrCa patients (Mahmood et al., 2014). Safdieh et al. studied a sample
89,413 PrCa patients using the National Cancer Database for the period 2004 and 2012
and reported a reduction in brachytherapy treatment from 62.9% in 2004 to 51.3%
in 2012 (p < .001). Safdieh et al. indicated that the decrease in brachytherapy use was
more evident among PrCa patients who lived furthest from treatment sites and purported
that it could be attributed to physician’s preferences. Nonetheless, the study was limited
by selection bias, coding errors, and incomplete data (Safdieh et al., 2016). Safdieh et al.
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recommended further studies on the barriers to brachytherapy treatments. Based on the
recommendations from researchers who investigated the current trends in PrCa
treatments, this dissertation was necessary.
Treatments for Low and Intermediate Stage PrCa and Survival
In retrospective, observational, experimental, and prospective studies, researchers
documented the survival benefits and limitations of ERBT and brachytherapy for treating
PrCa patients in different settings (Alumini et al., 2015; Cendales et al., 2015; Goldner et
al., 2012; Marshall et al. 2014; Nepple et al., 2013; Rodrigues et al., 2014; Smith et al.,
2015; Williams et al., 2011; Zuber et al., 2015). Among the benefits described in the
literature, brachytherapy treatment provided fewer unpleasant side effects, and better
biochemical control for PrCa patients with the localized disease when compared with
other PrCa treatments (Alumini et al., 2015; Williams et al., 2011; Zuber et al., 2015).
Alumini et al. (2015), Zuber et al. (2015), and Williams et al. (2011) established that
brachytherapy is one of the safer methods to treat PrCa patients with early stage disease,
and PrCa patients experienced fewer side effects with this treatment. The literature also
highlighted that at higher doses, brachytherapy treatment was an equally effective
treatment method for localized PrCa (Cendales et al., 2015; Rodrigues et al., 2014;
Skowronek, 2013). Cendales et al. (2015), Rodrigues et al. (2014), and Skowronek
(2013) confirmed that at high doses, brachytherapy treatment remained a safe and
effective treatment for localized PrCa and toxicity among PrCa patients with localized
disease was small. Additionally, the literature demonstrated that treatment outcomes for
both low-dose and high-dose brachytherapy treatment were comparable (Rodrigues et al.,
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2014; Skowronek, 2013). Skowronek documented that at both Low-dose and high doses,
brachytherapy treatment was equally cost effective for controlling localized PrCa.
Similarly, Rodrigues et al. confirmed that brachytherapy at high and low doses was
effective in reducing biochemical failure in both intermediate and low-risk PrCa patient.
However, Rodrigues et al. reported that their study was limited by small sample size due
to attrition of the study’s participants.
On the other hand, researchers highlighted disadvantages with brachytherapy
treatment in PrCa survival (Schreiber et al., 2013; Williams et al., 2011). The limitations
of brachytherapy treatment included racial, socioeconomic, and age disparities; treatment
side effects, and cost (Schreiber et al., 2013; Williams et al., 2011). Schreiber et al.
(2013) reported racial and socioeconomic disparities in the use of brachytherapy among
African Americans and Whites. Schreiber et al. documented that African American males
of lower socioeconomic status were less likely to include brachytherapy in their PrCa
treatment when compared with White males. Williams et al. (2011) asserted that
brachytherapy is expensive, better accepted among men in the younger age group
(p < .001), and resulted in bowel complications in PrCa treated patients.
Nonetheless, Schreiber et al. (2013), and Williams et al. (2011) cited limitations
of their studies. Schreiber et al. acknowledged that misclassification, which occurred by
arbitrarily assigning PrCa patients to socioeconomic groups was an important limitation
of their study. Consequently, Schreiber et al. recommended further studies which
examine racial and socioeconomic disparities in brachytherapy treatment. Schreiber et al.
also indicated that lack of comorbidity data in the SEER cancer registry data was another
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limitation, which influenced the results of the study. In addition, Williams et al. asserted
that the quality of the clinical information used for their study was a prime limitation.
Williams et al. noted that the data used for the study were lacking relevant clinical
information about the PrCa patient because they were billing information. On the other
hand, Aluwini et al. (2015), and Zuber et al. (2011) utilized prospective designs, reliable
SEER coding, and documented that the high-quality Medicare data was one of the
strengths of their study.
Researchers have also compared the effectiveness of brachytherapy treatment
with ERBT for the management of localized PrCa, and identified no statistically
significant differences in overall survival of PrCa patients (Goldner et al., 2012; Nepple
et al., 2013; Smith et al., 2015). In a Canadian cohort with low and intermediate stages
PrCa, Smith et al. (2015) identified no significant differences in overall survival among
men who were treated with brachytherapy versus ERBT. The hazard of death among low
risk PrCa patients was, HR 1.41, (p = 0.500) and HR 1.27, (p = 0.687) for the
intermediate risk cohort (Smith et al., 2015). Nepple et al. (2013) also detected no
significant differences in prostate cancer mortality among a cohort of PrCa patients who
were treated with ERBT and brachytherapy at the Cleveland Clinic in the United States,
HR 1.83, 95% CI [0.88, 3.82]. Similarly, in a Dutch cohort, Goldner et al. (2012)
confirmed that brachytherapy treatment might not provide a greater survival advantage to
PrCa patients with intermediate risk PrCa when compared with ERBT. However, the
studies were limited by small sample sizes and did not include an active surveillance
group, as one of the treatment options for low-risk PrCa.
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The findings of the literature on PrCa treatment outcomes may not generalize to
Jamaican PrCa patients because of small samples of African American cohorts, and the
study populations used to examine the relationship of the major variables. Additionally, I
identified no studies on the outcomes of brachytherapy and ERBT in the Jamaican
population.
Survival of PrCa Patients Without Initial Treatment for Low and Intermediate
Stage PrCa
In recent publications investigators reported favorable survival outcomes among
PrCa patients who were diagnosed with low and intermediate stage disease and were
managed without directive treatment (Bul et al., 2013; Odom et al., 2014; Selvadurai et
al., 2013; Wilt et al., 2012). Bul et al. (2013), Klotz et al. (2010) and Selvadurai et al.
(2013) reported low death rates among PrCa patients who were managed with active
surveillance and observation. However, Bul et al., Klotz et al., and Selvadurai et al.
suggested that the findings of these studies might be inadequate to make safe assumptions
about the impact of active surveillance on PrCa survival because they were limited by
short follow-up periods. Klotz et al. recommended further studies on active surveillance
for men with the more aggressive forms of the disease.
Conversely, Wilt et al. (2012) identified favorable survival outcomes for PrCa
patients who were managed with observation in a 12-year prospective study. Wilt et al.
compared survival of PrCa patients managed with observation, versus PrCa patients who
received prostatectomy treatment. The death rate for PrCa patients after prostatectomy
treatment was 5.8% versus 8.4% for observation, HR 0.63, 95% CI [.36, 1.09], p = .09
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(Wilt et al., 2012). One of the high points of the study conducted by Wilt et al. was its
generalizability. Study participants had similar characteristics of age, health status, and
PSA values (Wilt et al., 2012). The tumor risk characteristics were also similar for PrCa
patients who were eligible to participate in the study but declined (Wilt et al., 2012).
Based on the outcomes of this study, Wilt et al. recommended observation for men with
localized PrCa.
The findings of Bul et al. (2013), Klotz et al. (2010), Nepple et al. (2013),
Selvadurai et al. (2013), and Wilt et al. (2012) indicated that the effects of observation or
active surveillance on the survival of PrCa patients with low and intermediate stage
disease should be examined in this dissertation. Bul et al., Klotz et al., Selvadurai et al.,
and Wilt et al. recommended further studies on the effects of observation in PrCa survival
among men with the more aggressive forms of the disease. In addition, Nepple et al.
suggested that observation is a treatment option, which should be explored in studies,
which examine the effects of ERBT and brachytherapy treatment. However, due to data
limitations, active surveillance was not measured in this research.
Sociodemographic Characteristics and Prostate Cancer Survival
The literature reviewed demonstrated that sociodemographic characteristics of
PrCa patients played a key role in the survival of PrCa patients (Parris, 2013; Xiao et al.,
2009). Therefore, it was necessary to determine whether the sociodemographic indicators
of age, marital status, and health insurance status were confounders in the treatment
outcomes of the PrCa patients in this study. Parris (2013) identified that the
sociodemographic indicators of age, racial background, and marital status of PrCa
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patients were predictors of PrCa survival in a United States cohort, with localized
disease. Likewise, Xiao et al. (2011) demonstrated that PrCa patients without health
insurance had the conditions for poorer survival from PrCa because they were more
likely to be diagnosed with the later stages of the disease.
Age of the PrCa patient and survival. Current studies have shown that the age
of a PrCa patient influences the survival time; and that younger PrCa patients with
advanced stage disease are experiencing similar mortality from PrCa as older men (Fufaa,
2011; Lin et al., 2009). Antwi et al. (2013) reported higher mortality from PrCa among
the younger African American PrCa patients in the state of Kentucky when compared
with White males in that State (African American 10.9% and Whites 7%). Antwi et al.
also documented that the African Americans were more likely to be diagnosed with PrCa
at a younger age (63.9 years ± 10 years), when compared with the White PrCa patients
(66.9 years ± 9.8 years, p < .001). This disparity of age in PrCa incidence and mortality
among the racial groups of the State of Kentucky, which has a small proportion of
African-Americans (8%) (Antwi et al., 2013), suggested that age is a key factor in the
survival of PrCa patients. Fufaa (2011) demonstrated that older PrCa (age > 81years) and
PrCa patients aged 31 to 40 years with the aggressive forms of the disease had shorter
survival times when compared with patients in other age groups. Crawford (2013), Fufaa
and Lin et al. (2009) also examined the effects of age and tumor grade in PrCa survival
using cancer registry data and recommended additional research to clarify the outcomes
of their research. Crawford (2013), documented that misclassification of tumor grade was
a limitation of the investigation. Consequently, Crawford was unable to detect a
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statistically significant difference in survival outcomes among U.S. Black and White
PrCa patients. Fufaa and Lin et al. reported that misclassification of tumor grade and
stage, and underreporting of the cancer registry data were limitations of their studies.
Fufaa also reported limitations of using death certificates to obtain information about the
PrCa patients’ characteristics. Antwi et al. documented their inability to measure
comorbidities and generalize the findings to other populations. Based on the
recommendations of Crawford, Fufaa, and Lin et al., it was important to clarify the
influence of age on the treatment outcomes in this study.
Health insurance status and PrCa survival. Current publications highlighted
the effects of health insurance of PrCa patients in their survival (Abdalsattar, Hendren, &
Wong, 2016; Mahal et al., 2014; Parris, 2013). Paris (2013) examined the effects of the
socioeconomic status of a cohort of PrCa patients in the Florida Cancer Data System and
identified that the health insurance status of these patients affected their survival.
According to Paris, men without health insurance had higher odds of being managed with
watchful waiting when compared with surgery, OR 2.04, 95% [CI 1.75, 2.38]. The PrCa
patients who had no health insurance were also more likely to receive hormonal
treatments, OR 1.43, 95% CI [1.22, 1.69] and radiation treatments, OR 2.32, 95%
[CI 1.96, 2.7] when compared with PrCa patients who had privately funded health
insurance (Parris, 2013).
Abdalsattar et al. (2016) also identified that the health insurance status of PrCa
patients affected their survival outcomes. Abdalsattar et al. studied the extent to which
the health insurance status of cancer patients mitigated the social determinants of health
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in cancer management. Abdalsattar et al. utilized the SEER data, a retrospective study
design, and PrCa patients who were younger than 65 years. The PrCa patients were
classified as living in communities that were either least or most disadvantaged
(Abdalsattar et al., 2016). The findings of the study confirmed that having health
insurance was associated with higher numbers of cancer-directed surgeries for low-risk
patients and improved survival for all PrCa patients in both communities (Abdalsattar et
al., 2016).
Similarly, Mahal et al. (2014) documented the benefits of health insurance in
improving access to favorable PrCa treatments. Mahal et al. compared the odds of
survival of U.S. White and African Americans who had localized PrCa and received
definitive PrCa treatments according to their health insurance status. The PrCa cohort
was taken from the SEER data and had Gleason scores 8 to10, or stage T3a PrCa (Mahal
et al., 2014). The study’s result demonstrated that the odds of receiving life-saving
definitive PrCa treatments were lower for the African American cohort when compared
with the White patients, adjusted OR 0.60, 95% CI [0.56, 0.64], p < .001 (Mahal et al.,
2014). Health insurance status and race also interacted significantly (p < .001) indicating
that having health insurance could reduce the differences identified in the treatment
outcomes (Mahal et al., 2014).
Paris (2013) alluded to a large sample size and a culturally diverse population as
strengths of that study. However, Paris documented that the use all-cause mortality data
to base decisions on survival of the PrCa patient was a limitation of the study. One of the
strengths of the study conducted by Mahal et al. (2014) was the utilization of a
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population-based cancer registry database. On the other hand, there were missing data on
the stage and grade of the disease according to the patient’s health insurance status
(Mahal et al., 2014). Abdalsattar et al. (2016) reported that the SEER data were limited in
providing information on the timing of the patients’ enrolment in an insurance plan at
initial diagnosis and treatment. Abdalsattar et al. also documented difficulties in
interpreting the classification of the PrCa patients’ specific insurance because of the
broad classification of the insurance information in the SEER data. Nonetheless,
Abdalsattar et al., Mahal et al., and Parris illuminated the impact of having health
insurance on the survival of PrCa patients. The findings of the studies on the effect of
health insurance status on PrCa survival signified the relevance of including this
covariate in this dissertation.
Marital status and PrCa survival. The literature reviewed revealed a
statistically significant relationship between the marital status of the PrCa patient and
their likelihood of surviving the disease (Paris, 2013; Rand et al., 2014). Paris (2013)
investigated the relationship between the marital status of PrCa patients and survival
among PrCa patients in the Florida Cancer Data System who were diagnosed between
2001 and 2009. The results of this study revealed that unmarried PrCa patients had
increased odds of presenting with late stage disease, OR 1.24, 95% CI [1.18, 1.30] when
compared with married PrCa patients (Parris, 2013). PrCa patients were followed for five
years, and at the final year of observation, survival rates declined from 99% in the first
year to 80% (p < .001) (Parris, 2013). The survival rates were more favorable for married
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men (82%) when compared with the unmarried (74%), and the risk of dying was higher
for the unmarried cohort, HR 1.34, 95% CI [1.27, 1.41] (Parris, 2013).
Rand et al. (2014) also examined the demographic characteristics of a diverse
population of PrCa patients and their tumor stage in PrCa mortality. The outcomes of the
study showed that most of the PrCa patients (61.6%) were married; 24.3% of the men
were single (Rand et al., 2014). The outcomes of the research also revealed that the
probability of dying was significantly higher for PrCa patients who were single when
compared with patients who were married, OR 1.99, 95% CI [1.06, 3.73], p = .032 (Rand
et al., 2014). Rand et al. asserted that the findings of the study might be limited to the
study’s cohort because it was conducted in a single population. Nonetheless, Rand et al.
recommended future studies on patient demographics, treatment choices and health
outcomes. Thus, it was relevant to include marital status as a covariate in this research.
Smoking and PrCa survival. The studies reviewed documented that smoking is
related to higher death rates of PrCa patients (Kenfield et al., 2011; Warren et al., 2013;
Watters, et al., 2009). Studies revealed higher mortality rates with current smokers when
compared with PrCa patients who either were former smokers or had no history of
smoking at the time of diagnosis (Kenfield et al., 2011; Warren et al., 2013; Watters, et
al., 2009). Warren et al. (2013) identified hazards among smokers and PrCa patients with
a history of current tobacco use, and this relationship was consistent in both overall and
cancer-specific mortality. Additionally, Kenfield et al. (2011) confirmed a statistically
significant relationship with smoking and PrCa mortality, and this relationship remained
statistically significant after adjusting for the clinical stages and grades of the disease, HR
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1.38, 95% CI [0.94, 2.03] and HR 1.41, 95% CI [0.80, 2.49]. The significant findings of
the studies on smoking and PrCa indicate that PrCa patients with a history of current
smoking at the time of diagnosis with the disease have a higher risk of dying from PrCa.
In studies, which examine differences in smoking and PrCa survival across ethnic
groups in the United States, researchers recognized disparities among Black and White
PrCa patients (Antwi et al., 2013; Wong, Ettner, Boscardin, & Shapiro, 2009). Antwi et
al. (2013) identified that Black males had poorer survival outcomes. In their study, Antwi
et al. revealed that 44.7% of the PrCa patients who reported tobacco use were African
Americans while 41.4% were White (p < .001). In this cohort, African Americans had
53% higher risk of dying from PrCa when compared the White patients, HR = 1.53, 95%
CI [1.31, 1.79]. Wong et al. (2009) also documented a difference of .05 years in survival
from PrCa among White and African Americans in the United States, 95% CI [0.01,
0.09] and indicated that this difference was attributed to tobacco use. Antwi et al. and
Wong et al. reiterated that the Black population had similar biological characteristics that
could provide reasonable explanations of the differences in survival among the racial
groups due to their smoking exposure, and recommended further studies to clarify this
supposition.
Smoking is also a high-risk behavior among Jamaicans in their native country
(Wilks et al., 2008). Approximately one-fifth of Jamaican males in their country of origin
reported a history of smoking greater than 100 cigarettes over the life course, and 21%
had a current and history of smoking (Wilks et al., 2008). The frequency of smoking is
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also highest among Jamaican males who are in the high-risk age group for PrCa (Wilks et
al., 2008).
The results of these studies suggested that PrCa patients with a history of smoking
may have differences in survival outcomes according to their racial background. Hence, it
was important to control for effects of smoking in the relationship among the variables.
However, the effects of smoking on the survival outcomes of the ERBT and
brachytherapy treated cohorts were not evaluated in this dissertation because the SEER
data does not report patient-level smoking data. Nevertheless, the influence of smoking
on survival of the Jamaican PrCa patients should be measured in future studies on PrCa
treatment outcomes.
Summary and Transition
The literature reviewed revealed that the African American population of the
United States experienced a higher burden of PrCa and poorer survival of the disease in
general when compared with other ethnic groups. Researchers also demonstrated that
brachytherapy (with or without ERBT) was a widely used treatment option in the United
States for PrCa patients with the low-grade disease, but its utilization is declining in
recent years. Additionally, some researchers alluded to the survival advantages of
brachytherapy in treating PrCa patients who were diagnosed with low and intermediate
stage disease. Other investigators indicated that both ERBT and brachytherapy provided
similar survival benefits. On the other hand, authors noted that brachytherapy is
expensive; widely used in the younger cohort, and is less accessible to AfricanAmericans of lower socioeconomic status. Furthermore, the results in the literature
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confirmed that PrCa patients who were diagnosed with low and intermediate stage
disease, and were managed with observation or active surveillance for PrCa,
demonstrated favorable survival prognosis. Finally, the findings of the literature reviewed
demonstrated an association with the sociodemographic indicators age, marital status, and
health insurance status, and PrCa survival.
Among the literature reviewed, I identified no studies, which verified the
relationship between brachytherapy and ERBT for the treatment of low and intermediate
stage PrCa among the Jamaican cohort. Additionally, most studies reviewed were
conducted primarily in the White populations of the United States and included small
samples of African Americans. Likewise, studies on the relationship between treatment
methods for early and intermediate stages PrCa were identified for the Canadian,
German, and Dutch cohorts. However, the findings of these studies may not generalize to
the Jamaican population because of differences in PrCa characteristics among populaces.
Therefore, this study, which used a cohort of Jamaican-born males of the 18 participating
SEER cancer registries, may provide new data, which are specific to the Jamaican PrCa
patients. This research may also provide new insights on PrCa in the Jamaican cohort,
particularly on the relationship between PrCa treatment and survival outcomes.
In Chapter 3, I described the statistical measures used to examine the effects of
brachytherapy and ERBT in the survival of PrCa patients and the covariates
sociodemographic and smoking status of the PrCa patient. In addition, I provided a
description of the study population, the sampling technique for the selecting the sample
for this study, and ethical and validity issues of this dissertation.
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Chapter 3: Research Method
Introduction
In this dissertation, I aimed to observe the effects of ERBT and brachytherapy
treatment on the survival of Jamaican and White PrCa patients with low and intermediate
stage disease. I also intended to examine the effects of sociodemographic characteristics
of age, marital status, and health insurance status, in the survival outcomes of the PrCa
patients. I utilized a retrospective cohort study design, secondary data, and survival
models to examine the relationship between the independent and dependent variables.
In Chapter 3, I explained and justified the retrospective study design for exploring
the relationship between brachytherapy treatment and ERBT and the survival of
Jamaicans and White U.S.-born PrCa patients. I also presented and rationalized the
sampling techniques for selecting the study participants and the method employed to
determine the sample size for this dissertation. A detailed data analysis plan describing
the statistical measures applied to each of the research question was presented in Chapter
3. In addition, I described the method for operationalization of each variable of the study
in Tables 1 to 5. The procedures for data collection and possible validity and ethical
issues of this research were also highlighted in Chapter 3.
Research Design and Rationale
This dissertation had two key independent variables. The primary independent
variables of this study were PrCa treatments (brachytherapy, ERBT, and other radiation
treatments), and PrCa patients (the Jamaican and White U.S.-born PrCa cohorts) of the 18
participating SEER registries database, November 2013 submission. The dependent
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variable was prostate cancer survival, which is the length of time a PrCa patient treated
with ERBT, brachytherapy, and other radiation treatments lived with the disease. The
covariates for this study were sociodemographic indicators age, marital status, and health
insurance status.
I utilized a retrospective cohort design to examine the relationship between past
exposures (treatment for PrCa, and PrCa stage and grade) and the outcome (PrCa
survival) (Ashengrau & Seage, 2008, p. 207). The retrospective cohort design was
appropriate for the historic nature of this study (Ashengrau & Seage, 2008, p.156).
Additionally, I chose the retrospective cohort design because it was cost efficient. The
retrospective cohort study design generated large amounts of longitudinal data in a very
short period with minimal expenses, and the data were already available. Besides, the
retrospective cohort design facilitated the use of existing records on mortality occurrence
linked to cancer registries (Szklo & Nieto, 2014, pp. 22-23). These design qualities were
consistent with the methodology of this dissertation
Methodology
The Study’s Population
I recruited the participants of this research from a population of Jamaican and
White U.S.-born PrCa patients of the 18 participating SEER cancer registries database
1973 to 2011, November 2013 submission (SEER, 2014). The total population of
Jamaicans and White U.S.-born PrCa patients was 274,201 PrCa patients; this included
273,447 White U.S.-born and 754 Jamaicans.
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Sampling and Sampling Procedures
I selected the Jamaican PrCa patients using purposive sampling. Purposive
sampling reduced the possibility of eliminating from the study critical information about
the research subjects and enhanced the representativeness of the sample (Battalgia, 2008).
I chose purposive sampling method because the study required a cohort with specific
characteristics (Battalgia, 2008; Polit & Beck, 2013, p. 312; Trochim, Donnelly, & Arora,
2015, p. 87). I selected the comparison group from the White U.S.-born population of the
18 participating SEER cancer registries using a random sampling approach (Trochim et
al., 2015, p. 100). The random sampling method provided an equal chance to include the
research subjects, and improve generalization of the findings (Trochim et al., 2015,
p.100).
A PrCa patient in this dissertation was selected for this study according to the
ICD-O version 10, and the site-specific code (C60) (SEER, 2013). PrCa patients in each
participating SEER registry with Jamaican birthplace and satisfied the selection criteria
for a research participant, were purposively chosen from the SEER 18 registries data set
using the birthplace variable. I selected the White U.S.-born PrCa patients from the
population of the 18 participating SEER cancer registries using a random sampling
technique.
The study included all PrCa patients diagnosed with Gleason scores 6 and 7, and
categorized according to the TNM stages T1 and T2, and SEER Historic Stage A
classifications at the time of diagnosis. Included in this investigation were PrCa patients
who received ERBT, brachytherapy and radiation sequenced with surgery for the period
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of the observation. I excluded from the study PrCa patients, who were recommended for
surgery only, refused surgery or had contraindications for surgery (SEER, 2013). I
included the radiation sequenced with surgery variable in the study. The radiation
sequenced with surgery variable comprised other types of radiation treatments that were
not accounted for in the brachytherapy and ERBT definitions. Hence, it was important to
determine whether radiation sequenced with surgery contributed significantly to the
outcomes of the study.
In selecting this sample, I excluded from the sampling population three SEER
districts, Hawaii, Iowa, and Alaska Native, which had no Jamaican PrCa patients.
Subsequently, I reorganized in descending order the identification numbers of the
research participants for the remaining 15 reporting SEER locations. I selected from each
of the remaining 15 SEER reporting sites every 50th White U.S.-born PrCa patient who
met the criteria for inclusion in the study. Finally, I purposively chose every Jamaican
PrCa patient who met the selection criteria for inclusion in the study from the population
of Jamaicans. Figure 1, presents the flow chart of the sampling process.
The sample size determination for this study was derived from the criteria for
survival analysis using the Log-Rank test (Stats Direct, 2013). The criteria for survival
analysis using the Log-Rank test stated that there should be adequate power to detect a
real effect, p-value estimates, and a median survival time for both experimental and
comparison groups (Stats Direct, 2013). I chose an effect size of HR 1.6 based on
estimates from previous studies on the association of radiation therapy and PrCa survival
(Nepple et al., 2013; Smith et al., 2015; Rusthoven et al., 2015). Nepple et al. (2013) and
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Rusthoven et al. (2015) demonstrated effect sizes ranging from HR 1. 31, 95% CI [1.22,
1.41], p < .001, to HR 2.02, 95% CI [1.85, 3.15], p < .001 for ERBT treated PrCa patients
with Gleason scores 6 and 7. Nepple et al. and Rusthoven et al. also provided hazard
ratios ranging from HR 1.27 to HR 1.78, 95% CI [1.37, 2.3] p < .001, for overall survival
of PrCa patients treated with brachytherapy. I used the hazard ratio estimates as a
parameter in the sample size calculation because the results of this research were
presented with hazard ratio estimates and accompanying 95% confidence intervals. I
chose a median survival period of 7.2 years for the comparison group based on a priori
findings (Smith et al., 2015).
Sample size was therefore calculated using the Log-Rank test statistic, two-sided
alpha levels p < .05 (Za/2 = 1.96), 95% power (Zβ, = 1.645), and effect size (HR =1.6).
The median survival time was 2.7 years for the PrCa patients with low and intermediate
stages PrCa, and 7.2 years for the comparison group (the White U.S.-born PrCa patients).
The ratio for the exposed and unexposed group was one Jamaican PrCa patient to four
White U.S.-born PrCa patients. The sample size estimation was conducted using the PS:
Power and sample size calculation (3.1.2) (Dupont & Plummer, 2014). Based on the
sample size estimation, a total sample N = 1,335 was needed to reject the null hypothesis
that the survival curves for PrCa patients in the exposure and the comparison groups were
equal (Dupont & Plummer, 2014). The proposed sample included 267 Jamaican PrCa
patients, and 1,068 White U.S.-born PrCa patients (Dupont & Plummer, 2014).
However, due to the due to the sampling procedures used for the selection of the
PrCa patients and the size of the dataset used for this investigation, the sample size of the
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final study was expanded from N = 1,335 to N = 10,752 (8 times larger than the proposed
sample). The dataset had 754 Jamaican PrCa patients; 719 met the criteria for selection
and were chosen using purposive sampling. The sample of White U.S.-born PrCa patients
was extended to 10,033, with the random sampling technique described in the research
protocol. A final sample N = 10,752 Jamaican and White U.S.-born PrCa patients was
used for the data analysis.
Participant Recruitment
I obtained the dataset for this research following an emailed request to the SEER
Cancer Registry Data System for internet access to the November 2013 submission of the
18 participating SEER registries database. I completed the application with the SEER
Cancer Registry signed data use agreement form (see Appendix A). On receipt of the
signed data use agreement, the SEER Cancer Registry granted approval for internet
access to the SEER*Stat client-server system (see Appendix B). Subsequently, I prepared
a smaller dataset of the 18 participating SEER Cancer Registry database for the study
using a case listing of all the variables of the research. I exported the case listing to the
IBM SPSS statistical software version 23 for data analysis.
Operational Definitions of the Research Variables
Dependent Variable
The dependent variable of this dissertation was PrCa survival. PrCa survival was
defined as the date of initial diagnosis to the time of the first outcome, death or censoring
(Hu et al., 2014; Lin et al., 2009; Redaniel et al., 2013; Thompson et al., 2013). The time
of diagnosis was the month and year of diagnosis documented in the SEER registry
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database (SEER, 2013). The time of death was the time that the vital status of a case was
recorded in the SEER cancer data (SEER, 2013). The definition of the vital status also
included the SEER cause-specific mortality definition and confirmation of death using
death certificate or autopsy information (SEER, 2013). Censored cases were PrCa
patients who died of causes other than PrCa (NCI, 2017a). Additionally, the definition of
PrCa survival included the active follow-up of each PrCa patient (SEER, 2013). I recoded
and measured PrCa survival as a continuous variable on a monthly or yearly basis
according to the research questions.
Independent Variables
The independent variables of the dissertation were the PrCa patients (Jamaican
and White U.S.-born) and PrCa treatments (brachytherapy, ERBT, and other radiation
treatments). I defined a PrCa patient according to the International Classification of
Diseases for Oncology version 10 (ICD-O) code C60, and the SEER cause-specific death
for sequence numbers 01 (NIH, 2017). PrCa patients were also classified according to
Gleason grades G1, G2, and G3 (SEER, 2015, p. 96). Additionally, a PrCa patient had
TNM stages T1 and T2 of the AJCC 6th Edition TNM, and the SEER Historic Stage A
classifications (SEER, 2013; SEER, 2014; Young et al., 2000, p. 224). The localized
stages T1a, T1b, and T1c PrCa were clinically in-apparent tumor (SEER, 2013; Young et
al., 2000, p. 224). Stage T2a PrCa involved one lobe; and stage T2b more than one lobes
of the prostate gland (Young et al., 2000, p.224). Stage T2NOS was assigned to each
PrCa patient whose TNM stage was not specified (SEER, 2013). A prostate cancer
patient in this research was also a confirmed case by histology, or cytology (SEER,
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2013). I selected the Jamaican and White U.S.-born PrCa patients from the birthplace
variable of the 18 SEER participating cancer registries (SEER, 2014) and measured as a
categorical variable.
Prostate cancer treatments were ERBT, brachytherapy and other radiation
treatments. I combined radioactive implants, radioisotopes, and radioactive implants and
radioisotopes, and recoded as brachytherapy treatment (SEER, 2013). ERBT was the
recoded beam radiation variable of the SEER Research Data Record Description 1973 to
2011 (SEER, 2013). The radiation sequenced with surgery variable was a combination of
radiation before surgery, radiation after surgery, intraoperative radiation therapy, and
radiation and surgery sequence unknown (SEER, 2013). The treatment variables were
measured as categorical variables.
Covariates
Covariates for this study included the sociodemographic characteristics of the
patient. The sociodemographic characteristics comprised the marital status, age, and
health insurance status of the PrCa patient as reported at diagnosis and recorded in the
SEER Research Data Description 1973 to 2011 (SEER, 2013). Marital status was the
marital union communicated by the patient at the time of PrCa diagnosis (SEER, 2013).
Health insurance status was the PrCa patient’s primary means of payment for health care
and the health insurance coverage plan as recorded in the SEER data (SEER, 2013). Age
was the actual age in years at diagnosis as recorded in the SEER registry database and
covered all PrCa patients who were older than 35 years for the 1992 to 2011 SEER
reporting period (SEER, 2013). I recoded and measured the variables representing the
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sociodemographic characteristics of the PrCa patients in the SEER database as
categorical and continuous variables. Tables 1 to 5 depict the operationalization of the
research variables including the categories of each variable, coding of the variables, and
the statistical analyses applied.
Operationalization of the Variables
Table 1
Categorizing, Coding, and Measuring the Dependent Variable of the Research Subjects
Variables and
Categories

Operational Concepts of the
Variables

Variable Coding

Statistical Analyses

a) Prostate
cancer
survival in
years or
months.

This is the length of time in
months from the time of
diagnosis to the time of the
event (death or censored)
(SEER, 2013). The survival
period includes the complete
dates of diagnosis and last
contact with the PrCa patient
(SEER, 2013). This period
covered 21 years and
indicated that a PrCa patient
will die at any time on a
continuum of zero to 21
years.

a) Coded according to the
survival time in the SEER
data as:
Survmonths = 0 to 239
(SEER, 2013)

Preliminary descriptive
estimations of the hazard
rates and cumulative
survival probability of the
PrCa patients with Kaplan
Meier and Life Table
estimates.

The cut-off date of the SEER
data set was used for the last
contact date if the PrCa
patient’s recorded vital status
was alive (SEER, 2013).
Death was the confirmed
time of death based on
autopsy report or cause of
death as recorded in the
SEER registry (SEER, 2013).

b) Recoded as Alive = 1
Dead = 2
(SEER, 2013)

(measured as a
continuous
variable)

b) Vital Status.
(measured as a
categorical
variable)

Estimation of the median
survival times of the PrCa
cohorts.
Comparison of the
differences in the survival
distributions of the
Jamaican and White USborn cohorts with Kaplan
Meier survival curves,
Log-rank, Tarone-Ware,
and Breslow’s statistics.
Comparison of the risk
ratios of the Jamaican and
White PrCa patients
using the Coxproportional hazards
analysis.
Hypothesis tests of the
Jamaican and White USborn PrCa patients using
interaction analyses.

67
Table 2
Categorizing, Coding, and Measuring the Treatment Types of the Research Subjects
Variables and
Categories

Operational Concepts
for the Variables

Variable Code

Statistical Analyses

a) Prostate
cancer
treatments.

This was the time of
initiation of the
different types of
treatment for each PrCa
patient.
1. No treatment was
commenced.
2. Time ERBT
commenced to the
time of death, or
presumed alive
(SEER, 2013).
3. The time that
brachytherapy
commenced to the
time of death or
presumed alive
(SEER, 2013).
4. The time that
radiation
sequenced with
surgery
commenced to the
time of death or
presumed alive
(SEER, 2013).
5. It is not known if
treatment was
given (SEER,
2013).
6. The time of
initiation of
radiation
sequenced with
surgery to the time
of death (SEER,
2013).

Radioactive implants,
radioisotopes,
combination of
radioactive implants, and
radioisotopes (SEER,
2013) recoded as:
Brachytherapy = 1
No brachytherapy = 0

Preliminary descriptive
estimates of the frequencies
of treatment utilization
among the Jamaican and
White U.S.-born PrCa
patients.

This includes
patients
receiving
ERBT,
brachytherapy
treatment, and
radiation
sequenced
with surgery
during the
period of the
study.
(measured at
the categorical
level of
measurement.

Beam radiation recoded
as:
ERBT = 1
No ERBT = 0
Intraoperative radiation,
radiation after surgery,
radiation prior to surgery,
intraoperative radiation,
radiation sequence
unknown but both were
given (SEER, 2013) was
recoded as:
Radiation sequenced with
surgery = 1
No radiation sequenced
with surgery = 2

Estimation of the median
survival times of the PrCa
cohorts according to the
treatments received.
Comparison of the
differences in the survival
distributions of the Jamaican
and White U.S.-born cohorts
according to the treatments
received using Kaplan Meier
survival curves, Log-rank,
Tarone-Ware, and Breslow’s
statistics.
Comparison of the risk ratios
of the Jamaican and White
PrCa patients according to
treatments received
using the Cox-proportional
hazards analysis.
Comparison of the 5-year
survival outcomes of PrCa
patients according to each
treatment received.
Hypothesis tests of the
association of brachytherapy
and ERBT in PrCa patients
per treatment using
interaction analyses.
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Table 3
Categorizing, Coding, and Measuring Clinical Characteristics of the Research Subjects
Variables and
Categories

Operational Concepts for the
Variables

Variable Code

Statistical
Analyses

Gleason grades 1
and 11 PrCa at the
time of diagnosis as
recorded in the
SEER (2013)
registry.

1.

Coded according to the
SEER research data as:
1 = Moderately
differentiated, Grade 11
2 = Poorly differentiated,
Grade 111
3 = Well differentiated,
Grade 1
(SEER, 2013)

Preliminary
descriptive
estimates of the
frequencies of
stages and grades
of PrCa among
the Jamaican and
White U.S.-born
PrCa cohorts.

(measured at the
categorical and
continuous levels
of measurement)
(Mills, 2011c)
PrCa stage is the
early and
intermediate stages
of PrCa according
to the Derived
AJCC 6th Edition
(2004 +) and the
SEER Historic
Stage A
classifications
(2013)
(measured at the
categorical level of
measurement)
(Mills, 2011c)

SEER Historic
Stage A
(measured at the
categorical level of
measurement)

2.

3.

Gleason grade 1 is welldifferentiated tumor,
differentiated tumor
(SEER, 2013).
Gleason grade 11 is
moderately differentiated
tumor, or intermediately
differentiated tumor
(SEER, 2013).
Grade not specified NOS
(SEER, 2013).

The stage of the disease is
classified using the SEER
AJCC 6th edition (2000)
classification as:
1. T1a, T1b, and T1c is
clinically inapparent
tumor (SEER, 2013).
2. T1 NOS is clinically
inapparent tumor not
specified (SEER, 2013).
3. T2a, T2b and T2c is
tumor confined to the
prostate (SEER, 2013).
4. T2 NOS confinement to
the prostate is not
specified (SEER, 2013).
5. Unknown
The variable description of
the SEER dataset was
Localized or regionalized
prostate cancer (SEER, 2013)
was used.

Coded according to the first
three of the stages of TNM
stages 6th Ed of the SEER
data as:
a) T1a = 12
b) T1b = 15
c) T1c = 18
d) T1NOS = 19
e) T2a = 21
f) T2b = 22
g) T2c= 23
h) T2NOS = 29
(SEER, 2013)

Coded according to the
SEER research data as:
Blanks =1
Distant = 2
Localized/regionalized = 3
Unstaged = 4 (SEER, 2013)
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Table 4
Categorizing, Coding, and Measuring the Exposure and Comparison Groups
Variables and
Categories

Operational Concepts
for the Variables

Variable Code

Statistical Analyses

a) Jamaican born
PrCa patient.

A Jamaican PrCa
patient was one whose
birthplace was
recorded as Jamaica in
the SEER research
record description
(SEER, 2013).

The birthplacecountry variable of
the SEER data
(SEER, 2013)
was recoded as:

Preliminary descriptive
estimates of the frequencies of
PrCa patients according to the
different variables of the
study.

Jamaica = 1
Other = 0

Estimation of the median
survival times of the PrCa
cohorts according to the
treatments received.

A White U.S.-born
PrCa patient is a PrCa
patient whose
birthplace was
recorded as Jamaica in
the SEER research
record description
(SEER, 2013).

The birthplacecountry variable of
the SEER data
(SEER, 2013)
was recoded as:

Comparison of the differences
in the survival distributions of
the Jamaican and White U.S.born cohorts per treatments
received using Kaplan Meier
survival curves, and the Logrank, Tarone-Ware, and
Breslow’s statistics.

(measured at the
categorical and
continuous levels of
measurement)
(Mills, 2011c)

b) The White U.S.born PrCa patient.
(measured at the
categorical and
continuous levels of
measurement)
(Mills, 2011c)

United States = 2
Other = 0

Comparison of the risk ratios
of the Jamaican and White
PrCa patients according to
treatments received
using the Cox-proportional
hazards analysis.
Development of cohorttreatment contingency tables
for each 5-year interval and
estimating the survival rates
for each interval.
Comparison of the 5-year
survival outcomes of PrCa
patients according to each
treatment received.
Hypothesis tests of the
association of treatment
effects and survival of the
PrCa patients, using
interaction analyses.
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Table 5
Categorizing, Coding, and Measuring the Covariates of the Research
Variables and
Categories

Operational Definitions
for the Variables

Variable Code

Statistical Analyses
For all Covariates

a)

Age at the
time of
diagnosis
(measured at the
categorical and
continuous
levels of
measurement)
(Mills, 2011c)

This is the age recode
with < 1-year-old
variable. This variable
was recoded into 4-year
age groups in the SEER
(2013) and included all
age groups.

The original coding of the
SEER (2013) was used.

Preliminary descriptive
estimates of the
frequencies of the age,
marital status, and
health insurance status
of the PrCa patients.

b) Health
insurance
status at the
time of
diagnosis.
(measured at the
categorical level
of
measurement)
(Mills, 2011c)

Health insurance status
as recorded in the
SEER research record
description (SEER
2013). This was the
primary payer for
health care (SEER,
2013) at the time of
entering the study and
included the recoded
uninsured, any
Medicaid, insured, and
unknown health
insurance status.

Ages 30-34 = 07
Ages 35-39 = 08
Ages 40-44 = 09
Ages 45-49 = 10
Ages 50-54 = 11
Ages 55-59 = 12
Ages 60-64 = 13
Ages 65-69 = 14
Ages 70-74 = 15
Ages 75-79 = 16
Ages 80 +
Coded according to the
SEER research data as:
Uninsured = 1
Any Medicaid = 2
Insured = 3
Insured/no specifics = 4
Insurance status unknown = 5
(SEER, 2013)

Crude estimations of
the hazard ratios for age
and health insurance
status with Cox
proportional hazards
regression models.
Stratification of the
birthplace variable
(Jamaica and the United
States), per ERBT and
brachytherapy
treatments with age,
health insurance status,
and estimations of
adjusted hazard ratios.
Estimations of the
percent change of the
crude and adjusted
hazard ratios of the
birthplace main effects.

(Table continues)
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Table 5
Categorizing, Coding, and Measuring the Covariates of the Research
Variables and
Categories

Operational Definitions
for the Variables

Variable Code

Statistical Analyses

c)

d) Marital status at the
time of diagnosis as
recorded in the SEER
research record
description.
- single
(never married)
- unmarried/
domestic partner
- married
(including
common-law)
- separated
- divorced
- widowed
- status unknown
(SEER, 2013)

Coded according to the
SEER research data as:

Preliminary descriptive
estimates of the
frequencies of marital
status of the PrCa
patients.

Marital
status at the
time of
diagnosis.

(measured at the
categorical level
of
measurement)
(Mills, 2011c)

Single/never married = 1
Married including
common-law = 2
Separated = 3
Divorced = 4
Widowed = 5
Unmarried/
domestic partner = 6
Unknown status = 9
(SEER, 2013)

Crude estimations of the
hazard ratios for marital
status with Cox
proportional hazards
regression models.
Stratification of the
birthplace variable
(Jamaica and the United
States), per ERBT and
brachytherapy and
marital status and
estimations of adjusted
hazard ratios.
Estimations of the
percent change of the
crude and adjusted
hazard ratios of the
birthplace main effects

Data Analysis Plan
Data Cleaning
The SPSS software version 23 was the statistical package for the analysis of the
data. It was important to conduct data cleaning because secondary data were used to
answer the research questions. The data cleaning process included an examination of the
data distribution with skewness and kurtosis estimates and visual inspections of the data
distributions to ascertain and address outliers of the population studied (Osbourne,
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2013b). I also checked the data for missing or incomplete information. It was necessary
to identify missing or incomplete data because this may occur for justifiable reasons in
the secondary database that was used (Osbourne, 2013c) and should be accounted for in
the analysis. I analyzed the data with the following five research questions and their
hypotheses.
Research Question 1. Are there differences in the length of time Jamaican-born
PrCa patients compared with U.S.-born White PrCa patients who were treated with
brachytherapy for low and intermediate stages PrCa lived with the disease?
H01: There are no differences in the length of time Jamaican-born and U.S.-born
White PrCa patients treated with brachytherapy for low and intermediate stages PrCa
lived with the disease.
Ha1: There are differences in the length of time Jamaican-born PrCa patients
versus U.S.-born White PrCa patients who were treated with brachytherapy for low and
intermediate stages PrCa, lived with the disease.
Research Question 2. Are there differences in the length of time Jamaican-born
PrCa patients compared with U.S.-born White PrCa patients who were treated with
ERBT for low and intermediate stages PrCa lived with the disease?
H02: There are no differences in the length of time Jamaican-born PrCa patients
and U.S.-born White PrCa patients treated with ERBT for low and intermediate stages
PrCa lived with the disease.
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Ha2: There are differences in the length of time Jamaican-born PrCa patients
compared with U.S.-born White PrCa patients who were treated with ERBT for low and
intermediate stages PrCa lived with the disease.
Research Question 3. Are there differences in 5-year survival intervals of
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients according to
treatment received for the period 1992 to 2011?
H03: There are no differences in the 5-year survival intervals of Jamaican-born
and U.S.-born White PrCa patients according to treatment received for the period 1992 to
2011.
Ha3: There are differences in the 5-year survival intervals of Jamaican-born PrCa
patients compared with U.S.-born White PrCa patients according to treatment received
for the period 1992 to 2011.
Research Question 4. Are there differences in the length of time brachytherapy
treated Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and
intermediate stages PrCa live with the disease, after controlling for sociodemographic
characteristics?
H04: There are no differences in the length of time brachytherapy treated
Jamaican PrCa patients and U.S.-born White PrCa patients with low and intermediate
stages PrCa, live with the disease, after controlling for sociodemographic characteristics.
Ha4: There are differences in the length of time brachytherapy treated Jamaican
PrCa patients, and U.S.-born White PrCa patients with low and intermediate stages PrCa
live with the disease, after controlling for sociodemographic characteristics.
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Research Question 5. Are there differences in the length of time ERBT treated
Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and
intermediate stages PrCa live with the disease, after controlling for sociodemographic
characteristics?
H05: There are no differences in the length of time ERBT treated Jamaican PrCa
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live
with the disease, after controlling for sociodemographic characteristics.
Ha5: There are differences in the length of time ERBT treated Jamaican PrCa
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live
with the disease, after controlling for sociodemographic characteristics.
I conducted preliminary descriptive estimates of the different variables of the
study to determine their frequency distributions in the data set. I calculated the survival
distributions and cumulative survival probability of the PrCa patients with the Life Table
estimators and Kaplan-Meier estimates (Forthofer, Lee, & Hernandez, 2007, p. 306). The
Kaplan-Meier method determined the median survival times, and the differences in the
cumulative survival curves of the PrCa cohorts. The Log-Rank, Tarone-Ware, and
Breslow’s statistics confirmed the differences in the survival distributions of the
Jamaican and White U.S. PrCa patients at varying periods of the observation
(Balakrishnan, & Rao, 2004, p. 283). The Breslow’s statistics weighted the observations
early in the follow-up, and the Tarone-Ware and Log-Rank statistics estimated the
variances at the later intervals of the study (Balakrishnan, & Rao, 2004, p. 283). The Cox
proportional hazard regression analyses estimated the differences in the hazard ratios of
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the Jamaican and White U.S.-born cohorts (Forthofer et al, 2007, p. 412). Hypotheses
tests of mediating effects in the association between brachytherapy and ERBT treatments
and survival of the White U.S.-born and Jamaican-born PrCa patients were completed
with interaction analyses (Szklo & Nieto, 2014, p.187). Finally, I determined whether the
relationship between the treatment cohorts and PrCa survival was a result of the
confounding effects of the covariates by stratifying these variables and evaluating the
percent changes in the crude and adjusted hazard ratios (Szklo & Nieto, 2014, p.187). A
description of the statistical analytical procedures for each research question follows.
Data Analyses Plan for Research Questions 1 and 2
Research Question1 and Research Question 2 focused on the estimation of the
differences in the survival distributions of the brachytherapy and ERBT treated Jamaican
and White U.S.-born cohorts. I conducted preliminary descriptive estimations of the
crude and cumulative hazard rates, censoring intervals, probability density estimates, and
the mean and median survival times of the PrCa patients for the 1992 to 2011 follow-up
with Life-Table estimates and Kaplan-Meier estimators. The Kaplan-Meier estimator
generated cumulative survival curves of the distributions of the brachytherapy and ERBT
treated Jamaican and the White U.S.-born cohorts. The survival intervals of the PrCa
patients were estimated on a month-by-month basis (SEER, 2015). Differences in the
distributions of the survival curves were confirmed using the Log-Rank (Mantel-Cox),
Breslow (Generalized Wilcoxon), and Tarone-Ware statistics. I conducted further
comparisons of the survival experiences of the brachytherapy and ERBT treated
Jamaican and White U.S.-born cohort with the multivariate Cox-proportional hazards
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regression model. The Cox-proportional hazards model estimated the differences in the
hazards ratios for the Jamaican and White U.S.-born PrCa patients based on the
assumption that the hazards among the Jamaican and the White U.S.-cohort were
constant throughout the follow-up (Forthofer et al., 2007, p. 412).
I performed interaction analysis to determine whether there were modification
effects in the association between brachytherapy and ERBT and survival among the
Jamaican and White U.S.-born PrCa cohorts (Szklo & Nieto, 2014, p.187). The
assumption for the hypothesis test was the relationship between brachytherapy and ERBT
and the risk of death among Jamaican, and the White U.S.-born PrCa patients were of
similar magnitude across subgroups of both cohorts. The alpha level for accepting a
significant interaction was p < .05. A significant interaction indicates modification effect
among the birthplace variable and PrCa treatment. A non-significant interaction effect
confirmed that there were no modification effects in the association identified.
Consequently, the first main effects of the differences in the hazard ratios were
interpreted as the outcome of the analysis (Green & Salkind, 2011, pp. 205-206). I did
further analysis of significant interaction effects with pairwise comparison of the second
main effect (Green & Salkind, 2011, pp. 205-206). Two Cox proportional hazard
regression models were created for the interaction analysis. The first model had the first
main effect (birthplace) and the second main effect (PrCa treatments). The second model
had the interaction terms (birthplace and PrCa treatments) with the interaction effect.
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Data Analysis Plan for Research Question 3
Research Question 3 focused on estimating the 5-year survival of PrCa patients
who received brachytherapy, ERBT, and other radiation treatments (radiation sequenced
with surgery). I developed cohort-treatment contingency tables for each 5-year interval
and estimated the hazard rates and median survival times of the PrCa cohorts according
to the treatments they received. I compared the differences in the survival distributions of
the Jamaican and White U.S.-born cohorts per treatments received using the Log-Rank
statistics. Further comparisons of the risk ratios of the Jamaican and White U.S.-born
PrCa patients according to treatments received for each 5-year interval were estimated
using the Cox-proportional hazards analysis.
I performed interaction analyses for each 5-year interval to determine whether
there were modification effects in the magnitude of the risk ratios of both cohorts (Szklo
& Nieto, 2014, p.187). The assumption for the hypothesis test was the association
between brachytherapy, ERBT, and other radiation treatments and the risk of death
among Jamaican and the White U.S.-born PrCa patients were of similar magnitude in
subpopulations of both cohorts. The alpha level for accepting a significant interaction
was p < 0.05. A significant interaction indicated that there was modification effect among
the birthplace variable and PrCa treatment. I conducted further analyses of all significant
interaction effects with pairwise comparisons of the second main effects of each
treatment group to determine where the differences were (Green & Salkind, 2011, pp.
205-206). A non-significant interaction effect confirmed that there no modification
effects in the association identified (Szklo & Nieto, 2014, p.187) and the first main
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effects of the differences in the hazard ratios among the treatment groups were
interpreted as the outcome of the analysis (Green & Salkind, 2011, pp. 205-206).
Data Analyses Plan for Research Questions 4 and 5
The data analysis for Research Question 4 and Research Question 5 focused on
determining whether the association identified between brachytherapy treatment and
ERBT were due to confounding effects of the covariates in the study. First, I estimated
baseline hazard ratios of the birthplace variable, PrCa treatment variables, and the
covariates with Cox regression analysis. Subsequently, I stratified the Jamaican and U.S.born White PrCa patients according to brachytherapy and ERBT treatment, marital status,
health insurance status, and age and estimated the adjusted hazard ratios. Finally, I
compared the crude hazard ratios of the brachytherapy and ERBT treated Jamaican, and
White U.S.-born PrCa patients with the adjusted hazard ratios to determine percent
changes in the magnitude of effects observed. I estimated the percent difference between
the crude and adjusted hazard ratios of the birthplace main effects to determine the degree
of confounding using the expression: Percent Excess Risk Explained = (Crude HRAdjusted HR)/Crude HR-1×100 (Szklo & Nieto 2014, p.161). Changes in the hazard
ratios of less than 10% were interpreted as minimal confounding and the crude or
adjusted hazard ratios accepted. The adjusted hazard ratios were interpreted where the
excess risk was greater than 10%. Changes in the crude and adjusted hazard ratios that
were close to one indicated that the confounder influenced the direction and magnitude of
the effect observed, and there was no association with the PrCa treatments and survival
(Szklo & Nieto 2014, p.171)
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In this dissertation, I examined the covariate effects of the sociodemographic
indicators age, marital status, and health insurance of the PrCa patients because studies
have shown that these variables impacted the survival of PrCa patients (Parris, 2013;
Xiao et al., 2009). Therefore, in examining the relationship between treatment outcomes
and PrCa survival, it was important to evaluate whether these variables confounded the
effects observed in this dissertation.
Data Presentation and Interpretation
The results of this study were presented using tables and graphs. I displayed
descriptive analysis of baseline characteristics of the prostate cancer cases, cumulative
hazard rates, censoring intervals, and probability density estimate in tables. I also used
tables to present hazard ratios with accompanying 95% confidence intervals and alpha
levels (p < 0.05). The cumulative incidence of prostate cancer-specific deaths was
demonstrated with Kaplan-Meier survival curves (Kenfield et al., 2011). Statistical
significance was interpreted using p-values (p < .05) and 95% confidence intervals (Rich,
2011). Counts fewer than 10 for specific SEER location were suppressed and not
presented in tables or graphs.
Threats to Validity
The internal validity of this dissertation may be influenced by the nonrandomization of the exposure group (Leighton, 2010c, p. 621). The Jamaican PrCa
patients were purposively selected for this dissertation because the study required a
cohort with specific characteristics for investigation, thus making it difficult to randomize
the selection of this group (Trochim et al. 2015, p. 87). The threat of maturation of the
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research participants was another consideration to the internal validity of the study
(Leighton, 2010c, p. 620). The study spanned 20 years, and the research participants may
experience developmental changes or comorbidities which influence their treatment
outcomes (Leighton, 2010c, p. 620). Therefore, to enhance the internal validity of the
study, I selected the participants based on similarities in their characteristics and the
criteria specified for inclusion in this dissertation (Leighton, 2010c, p. 622). Another
approach to improve the internal validity of the study was randomizing the comparison
group to ensure that the characteristics of the research participants had the probability of
being equally distributed among this group (Leighton, 2010c, p. 622).
A potential threat to the external validity of the study was the likelihood of history
and treatment interactions (Leighton, 2010b, p. 468). The observation spanned the 1992
to 2011 interval, and it was important to determine whether trends in PrCa treatments and
diagnosis impacted the treatment effects (Leighton, 2010b, p. 468). The data analysis
included interaction analysis to detect interaction effects, which would indicate that the
treatment effects varied with time (Leighton, 2010b, p. 468).
Ethical Procedures
The provisions of the Health Insurance Portability and Accountability Act
(HIPAA) privacy rule (45 CFR 164.514 [e]), which established the conditions for the use
of protected health of individuals using the limited data sets with a data use agreement,
guided this research (US Department of Human Services [USDHS], 2003). I obtained
approval for the conduct of this study from the Institutional Review Board (IRB) Walden
University on April 16, 2016. The IRB approval number is 04-11-16-0179761. Approval
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for access to the SEER program’s database was also granted prior to the conduct of the
research (see Appendices A and B). The inclusion and exclusion criteria for the selection
of the research participants were developed on the ethical principle that the harms and
benefits of the research were distributed equally among all PrCa patients who are selected
for the study (NIH, 2011).
The research participants’ identifiable data were not used for this study, and no
linkages were required to identify any of the research subjects during the investigation
(NIH, 2011). In presenting the data, rates fewer than ten for PrCa patients of any of the
SEER reporting locations were suppressed and not shown in figures and tables. This
approach was taken to protect the research subjects from social harms.
Confidentiality of the data was maintained by restricting its access to all
individuals, except the members of my dissertation research committee (NIH, 2011). The
data set was stored using a secured system (NIH, 2011) in zipped files on my personal
computer. The use my personal computer and its log on information were not shared
while accessing the SEER data set. The file name was disguised and file sharing options
disabled. The data was used only for the purposes indicated in the dissertation proposal.
I will share the research findings with the populations from which the sample was
taken using journal publications for scholars and professionals, conferences for
professional and special interest groups, the cancer societies for the cohorts, local
organizations, public forums, and newsletters.
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Summary and Transition
Chapter 3 described the research methods for examining the relationship between
the independent and dependent variables of this study. The research questions were
answered using the SEER research data, a retrospective cohort design, Kaplan-Meier
estimators, and the Cox proportional hazards regression model. The sample for this study
was the Jamaican and White U.S.-born PrCa patients of the 18 U.S. participating SEER
registries. A sample of N =10,572 research participants was selected from the SEER 18
registries database 2013 submission, and this sample included all PrCa patients with and
without a history of ERBT and brachytherapy treatment. The sample also comprised
PrCa patients who were diagnosed with Gleason scores 6 and 7 PrCa, TNM stages T1
and T2 PrCa, and SEER Historic Stage A classification. The variables were defined
primarily with the definitions provided in the variable listing of the SEER Research Data
Record 1973 to 2011 (SEER, 2013).
IRB approval from the Walden University was obtained before the start of this
study. I anticipated potential threats to the validity of this study according to the
limitations of using secondary data. The validity threats were addressed using appropriate
measures to reduce their effects in the findings of the research. The execution of the study
was guided by the provisions of the HIPAA privacy rule (45 CFR 164.514 [e]) (USDHS
2003), which established the conditions for the use of protected health of individuals
using the limited data sets with a data use agreement. Appropriate data security measures
were employed to protect the research participants.
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In Chapter 4, I reported the results of the data analysis for the research questions
and related hypotheses. I also provided descriptive statistics of the demographic
characteristics of the study’s participants, and tests of the statistical assumptions of the
Cox proportional hazard regression model. Additionally, in Chapter 4, I displayed the
findings of univariate and bivariate analyses with tables of the hazard ratios and related
95% confidence intervals and alpha levels for each variable. Furthermore, Chapter 4
highlighted the results of hypothesis tests of the relationships between the dependent and
independent variables and the tests for confounding effects.
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Chapter 4: Results
Introduction
My primary goal of this quantitative dissertation was to examine survival patterns
of brachytherapy, and ERBT treated Jamaican and White U.S.-born PrCa patients for the
period 1992 to 2011. I also aimed to ascertain whether there were survival differences
among brachytherapy and ERBT treated Jamaican and U.S.-born White PrCa patients
who had a diagnosis of early and intermediate stage disease. Additionally, I intended to
determine whether specific sociodemographic characteristics and a history of smoking in
the ERBT and brachytherapy treated Jamaican and U.S.-born White PrCa patients
affected their survival. I used a retrospective cohort study design, and analyses of
secondary data with survival models to answer the research question. This study’s five
research questions with their hypotheses are:
Research Question 1. Are there differences in the length of time Jamaican-born
PrCa patients compared with U.S.-born White PrCa patients who were treated with
brachytherapy for low and intermediate stages PrCa, live with the disease?
H01: There are no differences in the length of time Jamaican-born and U.S.-born
White PrCa patients treated with brachytherapy for low and intermediate stages PrCa live
with the disease.
Ha1: There are differences in the length of time Jamaican-born PrCa patients
versus U.S.-born White PrCa patients who were treated with brachytherapy for low and
intermediate stages PrCa, live with the disease.
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Research Question 2. Are there differences in the length of time Jamaican-born
PrCa patients compared with U.S.-born White PrCa patients who were treated with
ERBT for low and intermediate stages PrCa, live with the disease?
H02: There are no differences in the length of time Jamaican-born PrCa patients
and U.S.-born White PrCa patients treated with ERBT for low and intermediate stages
PrCa, live with the disease.
Ha2: There are differences in the length of time Jamaican-born PrCa patients
compared with U.S.-born White PrCa patients who were treated with ERBT for low and
intermediate stages PrCa, live with the disease.
Research Question 3. Are there differences in 5-year survival intervals of
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients per treatment
received for the period 1992 to 2011?
H03: There are no differences in the 5-year survival intervals of Jamaican-born
and U.S.-born White PrCa patients according to treatment received for the period 1992 to
2011.
Ha3: There are differences in the 5-year survival intervals of Jamaican-born PrCa
patients compared with U.S.-born White PrCa patients according to treatment received
for the period 1992 to 2011.
Research Question 4. Are there differences in the length of time brachytherapytreated Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and
intermediate stages PrCa live with the disease, after controlling for sociodemographic
characteristics?
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H04: There are no differences in the length of time brachytherapy-treated
Jamaican PrCa patients and U.S.-born White PrCa patients with low and intermediate
stages PrCa, live with the disease, after controlling for sociodemographic characteristics.
Ha4: There are differences in the length of time brachytherapy-treated Jamaican
PrCa patients and U.S.-born White PrCa patients with low and intermediate stages PrCa
live with the disease, after controlling for sociodemographic characteristics.
Research Question 5. Are there differences in the length of time ERBT treated
Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and
intermediate stages PrCa live with the disease, after controlling for sociodemographic
characteristics?
H05: There are no differences in the length of time ERBT-treated Jamaican PrCa
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live
with the disease, after controlling for sociodemographic characteristics and history of
smoking.
Ha5: There are differences in the length of time ERBT-treated Jamaican PrCa
patients and U.S.-born White PrCa patients with low and intermediate stages PrCa live
with the disease, after controlling for sociodemographic characteristics.
In Chapter 4, I provided descriptive statistics of the demographic characteristics
of the study’s participants, and tests of the statistical assumptions of the Cox proportional
hazard regression model. Subsequently, I presented a summary of the statistical analyses
for each research question. The findings of univariate and bivariate analyses with tables
of the hazard ratios and related 95% confidence intervals and p-values for each variable
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are also described. Additionally, I displayed the Kaplan-Meier survival curves of the
overall prostate cancer mortality for the Jamaican and White U.S.-born prostate cancer
cohorts, and associated statistical tests of equality of survival of the two groups. Finally,
the Chapter highlights the results of hypothesis tests of the relationships between the
dependent and independent variables and the tests for confounding effects.
Data Collection
The 18 participating SEER registries of the United States (November 2013
submission for the reporting years 1973 to 2011) was the secondary data used for data
analysis. I chose the 1973 to 2011 version of the SEER cancer registries for data analysis
because it had the Jamaican-born cohort for the study (SEER, 2013). I obtained the
dataset with an emailed request to the SEER Cancer Registry Data System for internet
access to the November 2013 submission of the 18 participating SEER registries
database. The application was completed with the SEER cancer registry signed data use
agreement form (see Appendix A). On receipt of the signed data use agreement, the
support team of the SEER cancer registry granted approval for internet access to the
SEER*Stat client-server system (see Appendix B). Subsequently, I prepared a smaller
dataset of the 18 participating SEER cancer registries database for the study using a case
listing of all the variables of the research. I exported the case listing into the IBM SPSS
statistical software version 23 for data analysis.
I modified the study’s protocol based on the limitations of the dataset. The cut-off
age of the research participants was extended to include PrCa patients older than 65
years. The proposed age-group for the data analysis was 30-64 years, and the cut-off age
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age-group was 60-64 years. However, the dataset had fewer PrCa patients aged 30 to 64
years when compared with the 65 and older age-group. The younger to older age-group
comparisons were 48.1% versus 51.9% for the Jamaicans and 31.7% versus 68.2% for
the U.S.-born Whites. Additionally, the highest proportion of Jamaican PrCa patients
(292 or 39%) and U.S.-born Whites (4021 or 40.1%) were 65 to 74 years old.
Consequently, the cut-off age was extended to include PrCa patients aged 65 years and
older.
The sample size of the research was expanded from N = 1,335 to N = 10,752 (8
times larger) due to the sampling procedures used for the selection of the PrCa patients.
The sample described in the research protocol included 267 Jamaicans and 1,068 White
U.S.-born PrCa patients. However, the dataset had 754 Jamaican PrCa patients and 719
met the criteria for selection; these PrCa patients were selected for the study using
purposive sampling. The sample of White U.S.-born PrCa patients was extended to
10,033, with the random sampling technique described in the research protocol. The
samples of Jamaicans and White U.S.-born PrCa patients were taken from 15 of the l8 the
SEER participating locations.
Additionally, I excluded three of the SEER reporting sites from the dataset, the
smoking variable was removed from the variable listing, and the SPSS version 23
software package was used instead of the Pohar Perme and Ederer 11 for data analysis.
The SEER reporting sites, Hawaii, Iowa, and Alaska Native were excluded from the data
to balance the selection of research participants for the Jamaicans and White U.S.-born
cohorts. The three excluded SEER locations had no Jamaican PrCa patients. The smoking
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variable was removed from the list of variables because the SEER cancer registry does
not report patient-level smoking data. The smoking data were available in the SEER
registry dataset as County-level attributes, which were not applicable to the research
questions. The Pohar-Perme and Ederer 11 statistical methods were not used for the data
analysis because the sample of the study was expanded to include PrCa patients who
were older than 65 years and these methods do not perform well in survival analyses
involving the older age groups (Seppa et al., 2015). Furthermore, it was indicated in the
SEER*Stat software, version 8.3.2 (SEER*Stat, 2016), that the Pohar-Perme survival
method is still in development. Therefore, the IBM SPSS statistical software package
(one of the alternative statistical software described in the research protocol) was used to
analyze the data.
The comparison group (U.S.-Born Whites) was selected with a simple random
sampling technique to attain representativeness of the sample. In choosing this sample,
the three SEER districts, Hawaii, Iowa, Alaska Native, which had no Jamaican PrCa
patients were excluded from the sample frame. Subsequently, the identification numbers
of the research participants for the remaining 15 reporting SEER locations were
reorganized in descending order. Finally, every 50th White U.S.-born PrCa patient who
met the selection criteria for inclusion in the study was selected from each of the 15
SEER reporting sites. I selected every Jamaican PrCa patient who met the selection
criteria for the sample. Figure 1, presents the flow chart of the sampling process.
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The sampling population was 274,201 PrCa patients
(273,447 White U.S.-born and 754 Jamaicans) from the
18 SEER Reporting locations.

Hawaii, Iowa, and Alaska
Native had no Jamaicans
and were excluded

15 SEER reporting sites with
Jamaican and White US-born
PrCa patients remained.
The White US-born PrCa
patients were selected using
a simple randomization
process.

The Jamaican-born
PrCa patients were
selected using
purposive sampling.

The identification numbers
of the White U.S.-born PrCa
patients were reorganized in
descending order.

Every Jamaican-born
PrCa patient was chosen
according to the
selection criteria.

Every 50th White U.S.-born
PrCa patients was selected
from each of the 15 SEER
reporting locations.

n =719 Jamaican-born
PrCa patients were
selected, 35 did not meet
the criteria for selection.

n =10,033 White U.S.-born
PrCa patients with the
selection criteria were
chosen for the sample.

Total sample N = 10,752 Jamaican
and White U.S.-Born PrCa patients
who met the selection criteria for the
study.

Figure 1. Flow-chart of the sampling process for the prostate cancer patients.
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Additionally, proportions of PrCa patients in the sample were compared with
proportions in the sampling population using the main variables of the study. The
findings of the comparative analysis showed that the proportions of PrCa patients in the
sample and sampling frame were similar (see Table 6). Furthermore, 95.4 % of the
Jamaican PrCa patients (the exposure group) were included in the sample; a small
percentage (4.6 %) of the Jamaican PrCa patients did not meet the criteria for inclusion.
Therefore, the samples of Jamaican and White US-born PrCa patients were representative
of their sampling populations.
Table 6
Comparison of the Proportions of the Sample and the Sampling Population of the
Prostate Cancer Patients
US-Born Whites
Sample Frame
n (%)
Treatment

Gleason
Grades

Vital
Status
*Age
Groups

SEER
Historic
Stage A

Jamaicans

Sample
n (%)

Sample Frame
n (%)

Sample
n (%)

Brachytherapy

28,149 (13.3)

1,323 (13.2)

112 (14.8)

112 (14.8)

ERBT

48,335 (22.9)

2,449 (24.4)

185 (24.5)

185 (24.5)

Moderately Differentiated

119,712 (56.7)

6,149 (61.3)

419 (55.6)

415 (57.7)

Well Differentiated

10,470 (5.0)

517 (5.2)

23 (3.1)

23 (3.1)

Poorly Differentiated

80,968 (38.3)

3,369 (33.6)

312 (41.4)

281 (39.1)

Alive

11,3358 (53.7)

5,393 (53.7)

531 (70.4)

524 (72.9)

Dead

97,792 (46.3)

4,642 (46.3)

223 (29.6)

195 (27.1)

35-39

59 (0.0)

3 (0.0)

2 (0.3)

2 (0.3)

40-44

676 (0.3)

31 (0.3)

5 (7%)

5 (7%)

65-69

41,319 (19.6)

2,037 (20.3)

173 (22.9)

165 (22.9)

70-74

41,657 (19.7)

1,984 (19.8)

123 (16.3)

116 (16.1)

Localized

173,342 (82.1)

8,397 (83.7)

637 (84.5)

637 (84.5)

Un-staged

5,574 (2.6)

251 (2.5)

11 (1.5)

11 (1.5)

Note: * The comparison included the age-groups with the lowest and highest proportion
of prostate cancer patients from the sample and sample frame.
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Descriptive Statistics that Characterize the Sample
The sample for this study comprised N = 10,752 PrCa patients selected from 15 of
the 18 SEER reporting sites. The exposure sample consisted of 677 (94.2 %) Jamaicanborn Black and 42 (5.8 %) Jamaican-born White PrCa patients. The comparison group
included 10,033 U.S.-born White PrCa patients. All PrCa cases were actively followed
during the study period, at the end of 2011, 72.9 % of the Jamaican PrCa patients were
censored, and 27.1 % died. Among the White U.S.-born PrCa patients in the study,
53.8% were censored, and 46.2 % were deceased. The diagnosis for all PrCa cases was
histologically confirmed. Table 7 presents the findings of the baseline characteristics of
the sample.
Table 7
Baseline Characteristics of the Prostate Cancer Patients From 15 SEER Reporting
Locations Reported for the Period 1992 to 2011
Baseline Characteristics of the Sample
Birthplace

PrCa
Patients

Actively
Followed

Censored

Deceased

Histologically
Confirmed

n

n

(%)

n

(%)

n

(%)

n

(%)

719

719

100%)

524

(72.9%)

195

(27.1%)

719

100%

United
States

10,033

10,033

(100%)

5,393

(53.8%)

4,640

(46.2%)

10,033

100%

Total

10,752

10,752

5,917

(55.0%)

4,835

(45.0%)

10,752

Jamaica

Note: N = 10,752
Among the 15 SEER reporting locations of the study, Greater California had the
highest proportion of PrCa patients (16.3%) followed by Connecticut (15%) and Los
Angeles (14.7%). The least number of PrCa patients were reported for the Greater and
rural Georgia (3.0%) and Kentucky (3.1%) areas. Table 8 shows the frequency of the
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Jamaican and White US-born PrCa patients of the 15 SEER reporting locations included
in the study.
Table 8
Frequency of Prostate Cancer Patients for Each of the 15 SEER Reporting Locations for
the Period 1992 to 2011
SEER Registry

Frequency (n)

%

535

5.0

California Excluding SF/SJ /LA

1,749

16.3

Connecticut

1,614

15.0

Detroit (Metropolitan)

557

5.2

*Georgia (Rural and Greater)

328

3.0

Kentucky

338

3.1

1,581

14.7

Louisiana

342

3.2

New Jersey

879

8.2

New Mexico

393

3.7

San Francisco-Oakland SMSA

600

5.6

San Jose-Monterey

365

3.4

1,031

9.6

Utah

440

4.0

Total

10,752

100

Atlanta (Metropolitan)

Los Angeles

Seattle (Puget Sound)

Note: N=10,752. *Georgia includes the research participants from rural and greater
Georgia.
The frequency of PrCa patients for the 20-year period of observation ranged from
367 (3.4 %) in 1994 to 822 (7.6%) cases in 2001. As shown in Table 9, higher numbers
of PrCa patients were reported between 2000 and 2002, and in 2004. In the 1990s, except
for 1992, the frequency of PrCa cases was lower than the number of PrCa cases reported
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between 2000 and 2004. However, the rate of PrCa patients declined gradually for the
reporting periods 2005 to 2011. In 2011, the number of PrCa patients was comparable
with the low prevalence period 1995 to 1999.
Table 9
Frequency of Jamaican and White U.S.-Born Prostate Cancer Patients of the SEER
Registry Database per Year for the Period 1992 to 2011
Year

Frequency (n)

Percent (%)

Cumulative (%)

1992

664

6.2

6.2

1993

425

4.0

10.1

1994

367

3.4

13.5

1995

402

3.7

17.3

1996

381

3.5

20.8

1997

410

3.8

24.6

1998

414

3.9

28.5

1999

398

3.7

32.2

2000

720

6.7

38.9

2001

822

7.6

46.5

2002

776

7.2

53.7

2003

575

5.3

59.1

2004

720

6.7

65.8

2005

583

5.4

71.2

2006

619

5.8

77.0

2007

577

5.4

82.3

2008

514

4.8

87.1

2009

496

4.6

91.7

2010

490

4.6

96.3

2011

399

3.7

100.0

Total

10,752

100.0

Note: N = 10752
PrCa patients aged 55 to 79 years were well represented in the study’s sample.
Fewer PrCa patients were 35 to 54 years, and the lowest number of PrCa patients (5%)
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was in the 35 to 39 age group. The highest proportion of PrCa patients for both Jamaican
and the White U.S.-born cohort was 65 to 69 years old; this included 165 (22.9%)
Jamaican and 2027 (20.3%) White U.S.-born PrCa patients. A higher proportion of
Jamaican PrCa patients were 55 to 69 years old when compared with the White U.S.-born
(57.2% versus 45.2%), and fewer were in the 70 years and older age groups (29% versus
47.9%) (see Table 10).
Table 10
Age Distribution of the Jamaican and White U.S.-Born Prostate Cancer Patients
Age Groups
3539

4044

4549

5054

5559

6064

6569

7074

7579

8084

85 +

n

2

5

27

65

119

127

165

116

63

19

11

%

0.3

0.7

3.8

9.0

16.6

17.7

22.9

16.1

8.8

2.6

1.5

n

3

31

162

490

981

1,519

2,037

1,984

1,579

845

402

%

0

0.3

1.6

4.9

9.8

15.1

20.3

19.8

15.7

8.4

4.0

Total (n)

5

36

189

555

1,100

1,646

2,202

2,100

1,642

864

413

Total %

0

0.3

1.9

5.2

10.2

15.3

20.5

19.5

15.3

8.0

3.8

Jamaica
BirthPlace
United
States

Note: N=10752.
Higher proportions of the PrCa patients were married (66.5% Jamaicans and
72.4% White U.S.-born). However, the marital status of 15.2% of the PrCa patients was
unknown. Lower proportions of PrCa patients were either widowed (11.2 %) or separated
(2.7%) (see Table 11).
Higher numbers of Jamaican PrCa patients (56.9%) and White U.S.-born (80.5%)
had health insurance. There were no specific details of the type of health insurance
coverage for 19% of the Jamaican and 15.9% of the U.S.-born cohorts. The health
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insurance status was unknown for 7.2% of the Jamaican PrCa patients and missing for
6% of both cohorts (see Table 11).
Table 11
Marital and Health Insurance Status of the Jamaican and White U.S.-Born Prostate
Cancer Patients
Jamaicans

n

White U.S.-Born

%

n

%

Marital Status
Married

478

66.5

7,267

72.4

Divorced

49

6.8

642

6.4

Separated

16

2.2

53

0.5

Unmarried

86

12.0

691

6.9

Widowed

32

4.5

671

6.7

Unknown

58

8.1

709

7.1

Total

719

100

10,033

100

Health Insurance Status
Insured

111

56.9

8,073

80.5

Insured/No Specifics

37

19.0

1,594

15.9

Any Medicaid

20

10.3

222

2.2

Uninsured

13

6.7

14

1.3

Unknown

14

7.2

0

0

*Total

195

100

9,903

100

Note: * Data on the health insurance status for 654 (6.0%) of the PrCa patients were not
available for the analysis.
Thirty-eight percent of the sample was treated with one or more types of
radiation; however, high numbers of PrCa patients (59.1%) received no radiation
treatment, and the treatment status of 3% of PrCa patients was unknown. Among the
White U.S.-born and Jamaican PrCa patients, ERBT was the most widely used PrCa
treatment, and its use was reported for 2630 (24.5%) of the PrCa cohorts. Brachytherapy
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was used among 1,435 (13.3%) of the PrCa patients. Table 12 describes the distribution
of radiation treatment types among the PrCa patients.
Table 12
Distribution of Prostate Cancer Treatments Among the Jamaican and White U.S.-Born
Prostate Cancer Patients
ERBT

Brachytherapy

Radiation

None

Unknown

Refused

Total

(NOS*)
Jamaica

n

181

112

0

400

16

10

719

%

25.2

15.5

0

55.6

2.3

1.4

100

n

2,449

1,323

20

5,951

201

89

10,033

%

24.4

13.2

0.2

59.3

2.0

0.9

100

2,630

1,435

20

6,351

217

99

10,752

Birthplace
USA
Total (n)

Note: N=10752. * The method of radiation is not specified. ERBT combined is
combination of beam radiation with implants or isotopes.
High numbers of PrCa patients in the study were classified with Gleason grades 1
and 11 PrCa, localized PrCa, and T1c and T2c PrCa. Higher proportions of the White
US-born PrCa patients when compared with Jamaicans were classified with Gleason
grade 1 PrCa (5.2% versus 3.2%) and Gleason grade 11 PrCa (61.3% versus 57.7%). On
the other hand, a higher percentage of Jamaican PrCa patients had Gleason grade 111
PrCa (39.1%) when compared with the White U.S.-born cohort (33.6%). The highest
proportions of Jamaican (45.6%) and U.S.-born (38.6%) PrCa patients were categorized
with T1c PrCa. There were no data for 23.7% of the PrCa patients of the SEER Historic
Stage A classification. Table 13 describes the Gleason grades, SEER Historic Stage A
classification, and TNM staging of the PrCa patients.
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Table 13
Distribution of Jamaican and White US-Born Prostate Cancer Cases According to
Gleason Grades, SEER Historic Stage A, and TNM Staging
Jamaicans

n

White U.S.-Born

%

n

%

Gleason Grades
Grade 1

23

3.2

517

5.2

Grade 11

415

57.7

6,148

61.3

Grade 111

281

39.1

3,368

33.6

Total

719

100

10,033

100

SEER Historic Stage A
Localized

637

88.6

8,397

83.7

Un-staged

11

1.5

251

2.5

Blanks

71

9.9

1,385

13.8

Total

719

100

10,033

100

SEER TNM Staging
T1a

3

1.5

225

2.2

T1b

1

0.5

121

1.2

T1c

89

45.6

3,871

38.6

T1 NOS

0

0

41

0.4

T2a

17

8.7

813

8.1

T2b

5

2.6

252

2.5

T2c

55

28.2

2,631

26.2

T2 NOS

25

12.8

2,069

20.6

*Total

195

100

10,023

100

Note: *The number of PrCa patients classified with the TNM Staging was reported for
the period 2004 to 2011.
An Evaluation of Statistical Assumptions Appropriate to the Study
The assumption of proportionality of the Cox Regression model was evaluated
with the graphical presentation of the Log Minus Log (LML) survival function versus the
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log of survival time; and statistical modelling with the time-dependent Cox model which
introduced time as a linear variable. The assumption of proportionality of the Cox
regression model was tested for each PrCa cohort per ERBT and brachytherapy prostate
cancer treatments. The White U.S.-born PrCa cohort was the referent category because
the research questions aimed at evaluating survival differences between the birthplace
covariate and PrCa treatment. The cumulative hazard functions for each treatment group
were plotted against time and the constancy of the ratios of the hazards determined
(Forthofer et al., 2007). The assumption of proportionality of baseline hazards was
accepted for each treatment cohort, on the basis that the cumulative survival curves for
the Jamaican and White U.S.-born cohorts remained parallel for the period of
observation. The results of the LML analysis demonstrated that the hazard of death for
the brachytherapy treated Jamaican PrCa patient was significantly lower than the risk of
death for the White U.S.-born brachytherapy treated PrCa patients, HR 0.63, 95% CI
[0.55, 0.73], p < .001 (see Table 14). The graph of the LML survival curves for the
Jamaican and White U.S.-born PrCa patients showed that both curves were parallel
throughout the period of observation, and indicated that hazards for both cohorts were
constant throughout the period of follow-up. The parallelism of the survival curves
signified that the assumption of proportionality of the survival distributions for the
Jamaican and White U.S.-born brachytherapy treated PrCa patients was met. Figure 2,
illustrates the survival curves of the LML survival analysis.
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Table 14
Log Minus Log Analysis of the Proportionality of the Hazards of the Prostate Cancer
Patients Treated With Brachytherapy
Variables in the Equation
95% CI for
Exp (B)
Birthplace

B

SE

Wald

df

Sig

Exp
(B)

LL

UL

Covariate
Mean

χ2

-2 Log
Likelihood

(Reference =
USA)
Jamaica

-0.46

0.07

39.39

1

.000

0.63

0.55

0.73

0.07

45.49

78,169.61

Note: LL is lower limits and UL is upper limits.

Figure 2. Plot of Log Minus Log survival function for brachytherapy.
The LML analysis of the hazard ratios for the ERBT Jamaican versus the ERBT
U.S.-born PrCa patients showed that Jamaicans had a significantly lower hazard of death,
HR 0.62, 95% CI [0.54, 0.72], p < .001 (see Table 15). The graph of the LML survival
curves for the ERBT treated Jamaican, and White U.S.-born PrCa patients revealed that
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both curves were divergent throughout the period of observation (see Figure 3). The
parallelism of the survival curves indicated that the assumption of proportionality of the
survival distributions for the ERBT treated Jamaican and White U.S.-born PrCa patients
was met.
Table 15
Log Minus Log Analysis of the Proportionality of the Hazards of the Prostate Cancer
Patients Treated With ERBT
Variables in the Equation
95% CI for
Exp (B)
Birthplace

B

SE

Wald

df

Sig

Exp
(B)

LL

UL

Covariate
Mean

χ2

-2 Log
Likelihood

(Reference
= United
States)
Jamaica

-0.46

0.07

40.28

1

.000

0.62

0.54

0.72

0.07

46.59

75,649.87

Note: LL is lower limits and UL is upper limits.

Figure 3. Plot of Log Minus Log survival function for ERBT.
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Cox regression analysis with time-dependent variable confirmed that the
assumption of proportionality of the hazards was met for both brachytherapy and ERBT
treated PrCa cohorts. At the inclusion of the time-dependent covariate with the country of
birth and brachytherapy variables in the Cox regression model, the hazard ratio differed
from the crude hazard ratio and was no longer statistically significant, HR 1.0,
95% CI [0.99, 1.01], p = 0.93. The lack of statistical significance in the analysis indicated
that time did not interact with covariates brachytherapy and country of birth. Hence the
hazard ratios for brachytherapy were proportional with time. Table 16 demonstrates the
interaction with time analysis for the brachytherapy treated PrCa patients
Table 16
Time-Dependent Analysis of the Proportionality of the Hazards of the Prostate Cancer
Patients Treated With Brachytherapy
Variables in the Equation
95% CI for
Exp (B)

Birthplace

B

SE

Wald

df

Sig

Exp
(B)

LL

UL

-0.76

0.14

31.06

1

.000

2.15

1.64

2.81

χ2

170.96
Brachytherapy

-0.91

0.09

93.66

1

.000

0.40

0.33

.48

Birthplace* T_Cov_

-0.00

0.00

7.81

1

.005

0.99

0.99

0.99

Brachytherapy*
T_Cov_

0.01

0.01

2.18

1

.139

1.01

0.99

1.02

Birthplace
*brachytherapy*
T_Cov_

0.00

0.00

0.00

1

0.927

1.00

0.99

1.01

-2 Log
Likelihood

81339.73

Note: * Indicates the interaction terms in the model. LL is lower limits UL is upper limits.
The hazard ratio for the ERBT treated PrCa patients also differed from the crude
hazard ratio and was no longer statistically significant with the introduction of the time-
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dependent covariate with the country of birth variable and ERBT to the model, HR 0.99,
95% CI [0.99, 1.00], p = 0.84. The lack of statistical significance of the time-dependent
covariate confirmed that time did not interact with covariates ERBT and country of birth.
Hence the hazard ratios for ERBT were proportional with time. Table 17 shows the
interaction with time analysis for the ERBT treated PrCa patients.
Table 17
Time-Dependent Analysis of the Proportionality of the Hazards of the Prostate Cancer
Patients Treated With ERBT
Variables in the Equation

Birthplace

B

SE

Wald

df

0.78

0.14

32.29

1

Sig
.000

Exp (B)
2.18

95% CI for
Exp (B)
LL
UL
1.67

χ2

-2 Log
Likelihood

2.85
148.15

ERBT

-0.33

0.06

29.86

1

.000

0.72

0.64

0.81

Birthplace*
T_Cov_

-0.00

0.00

7.45

1

.006

0.99

0.99

0.99

ERBT* T_Cov

0.01

0.00

2.39

1

.122

1.01

1.00

1.01

Birthplace*ERB
T* T_Cov_

0.00

0.00

0.04

1

0.839

1.00

0.99

1.00

81339.73

Note: * Indicates the interaction terms in the model. LL is lower limits, UL is upper
limits.
The LML estimate of the cumulative survival function versus the log of survival
times of both brachytherapy and ERBT Jamaican and White U.S.-born PrCa patients
confirmed that the survival curves were parallel. The time-dependent analyses verified
that the hazards of both ERBT and brachytherapy treated Jamaican and White U.S.-born
cohorts were constant throughout the period of observation. Therefore, the assumption of
proportionality of the Cox proportional hazard regression model was met, and this model
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was appropriate to examine survival differences of the brachytherapy and ERBT treated
Jamaican and U.S.-born PrCa patients.
Statistical Analyses for the Research Questions
Research Question 1 Analysis
Research Question 1: Are there differences in the length of time Jamaican-born
PrCa patients compared with U.S.-born White PrCa patients who were treated with
brachytherapy for low and intermediate stages PrCa, live with the disease? Ho1: There are
no differences in the length of time Jamaican-born and U.S.-born White PrCa patients
treated with brachytherapy for low and intermediate stages PrCa; live with the disease.
Ha1: There are differences in the length of time Jamaican-born PrCa patients versus U.S.born White PrCa patients who were treated with brachytherapy for low and intermediate
stages PrCa, live with the disease.
Univariate analyses using the Life-Table estimates and Kaplan-Meier estimators
provided preliminary descriptive statistics of the cumulative survival probability for the
brachytherapy treated White U.S.-born and Jamaican PrCa patients. The Kaplan-Meier
survival curves and the Log-Rank (Mantel-Cox), Breslow (Generalized Wilcoxon), and
Tarone-Ware statistics were used to determine whether there were differences in the
survival distributions of the brachytherapy treated Jamaican and the White U.S.-born
cohorts. The Cox proportional hazards regression model was used to estimate the
differences in the hazards ratios for the Jamaican and White U.S.-born PrCa patients
based on the assumption that the hazards between both cohorts were constant throughout
the follow-up. Hypothesis testing with interaction analysis was carried out to determine
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modification effects in the magnitude of the risk ratios of the brachytherapy treated
Jamaican and White U.S.-born cohorts. Tables 18 through 20, and Figure 4 present the
statistical analyses for Research Question 1.
Table 18, demonstrates the Life-Table estimates of the cumulative survival for the
Jamaican and U.S.-born PrCa patients of the study. The death rates were stable for most
of the period of observation but the number of Jamaican PrCa patients in the study
declined markedly at 150 months and the White U.S.-born PrCa patients at 160 months.
All Jamaican PrCa patients experienced the event at 190 months and the U.S.-Cohort at
230 months of follow-up.
Table 19 depicts the Kaplan-Meier comparison of the survival periods of the
Jamaican and White U.S.-born PrCa patients and the overall comparisons of the survival
distributions. The survival times for the Jamaican PrCa patients were similar (195
months) for the first and second percentiles of the follow-up period. The median survival
for the Jamaicans was undefined because more than 50 % of these PrCa patients survived
beyond half the observation period. The median survival interval for the U.S.-born cohort
was 142 months, SE 3, 95% CI [134.8, 147.1]. The Log-Rank, Breslow’s, and TaroneWare comparisons of the survival distributions confirmed that the survival experiences
for both cohorts were significantly different (p < .001).
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Table 18
Life-Table Estimates of Survival Times for the Jamaican and White U.S.-Born Prostate
Cancer Patients Treated With Brachytherapy for the Period 1992 to 2011
Life Table
Birth
Place

Start
Time

Started

At
Risk

Censored

Died

SE *

0
1
0
1
0
2
2
1
0
1
0
3
4
2
1
1
0
0
0
1

Cum
Survival
%
100
99
99
98
98
95
93
91
91
89
89
83
72
64
58
50
50
50
50
0

Jamaica

0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190

112
107
100
94
88
84
73
63
58
54
49
45
35
22
12
9
5
2
2
1

110
104
97
92
86
80
69
61
56
52
47
42
31
18
11
8
4
2
2
1

5
6
6
5
4
9
8
4
4
4
4
7
9
8
2
3
3
0
1
0

United
States

0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
220
230

1,323
1,300
1,251
1,181
1,105
1,017
921
811
718
616
509
429
328
232
157
113
86
55
33
24
17
11
8
4

1,314
1,285
1,234
1,156
1,081
988
885
782
686
580
484
394
292
205
144
103
74
47
30
21
15
11
7
2

19
30
34
50
47
58
72
58
65
73
51
70
72
55
26
20
24
17
7
7
5
1
2
4

PD

HR %

SE**

.00
.01
.01
.01
.01
.02
.03
.03
.03
.04
.04
.05
.07
.08
.09
.11
.11
.11
.11
0

.000
.001
.000
.001
.000
.002
.002
.002
.000
.002
.000
.004
.005
.005
.006
.007
.000
.000
.000
.011

0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
0
0
0
2

.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.01
.01
.01
.01
.00
.00
.00
.00

4
19
36
26
41
38
38
35
37
34
29
31
24
20
18
7
7
5
2
0
1
2
2
0

100
98
95
93
90
86
83
79
75
70
66
61
56
50
44
41
37
33
31
31
29
23
17
17

.00
.00
.01
.01
.01
.01
.01
.01
.01
.01
.02
.02
.02
.02
.02
.02
.03
.03
.03
.03
.04
.05
.05
.05

.000
.001
.003
.002
.004
.003
.004
.004
.004
.004
.004
.005
.005
.005
.006
.003
.004
.004
.002
.000
.002
.005
.007
.000

0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
0
1
2
3
0

.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.01
.00
.00
.01
.01
.02
.00

Note: N = 10,752= SE* is the standard error for the cumulative survival and SE**is the
standard error for the hazard rate. PD is probability density of survival estimate; HR is the
hazard rates.
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Table 19
Kaplan-Meier Comparison of the Survival Times for the Jamaican and White U.S.-Born
Prostate Cancer Patients Treated With Brachytherapy
Overall Comparisons
Percentiles
25%

50%

95% CI for
the Median

75%

Est

SE

Est

SE

Est

SE

LL

UL

Jamaica

195

-

195

-

128

6

-

-

United
States

219

15

142

3

89

3

134.8

147.1

Overall

219

12

142

3

92

3

135.8

148.1

Log-Rank

Breslow

χ2

Sig

χ2

Sig

40.3

.000

36.6

.000

TaroneWare
χ2
Sig

40.7

.000

Note: N = 10752. * No precision estimates were calculated for the median survival time
for the Jamaicans because more than 50% of the patients survived beyond the 50th
percentile of the observation period. Percentiles are the quartiles of the follow-up period
in months. LL is lower limits, UL is upper limits. Est is estimate. Sig is the p-value.
Figure 4 illustrates the Kaplan-Meier survival curves for the brachytherapy treated
cohorts. The cumulative survival curves showed visible differences in the survival
distributions of the Jamaican and White U.S.-born PrCa patients. The Kaplan-Meier
survival curve for the brachytherapy treated Jamaican PrCa patients had higher survival
probability overall when compared with the White U.S.-born PrCa patients. Both PrCa
cohorts had similar survival probability at baseline, but at approximately 30 months of
follow-up the survival curve for the Jamaican PrCa patients diverged from the U.S.
cohort and assumed a parallel form throughout the rest of the study. Brachytherapy
treatment demonstrated more favorable survival outcome for the Jamaican PrCa patients
for the first 150 months of follow-up and the curve declined sharply at 190 months. The
step-like appearance of the curve at 190 months of observation, indicated that fewer
participants were in the study at that period. This shift in the survival curve correlated
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with the descriptive statistics in Table 18. The small p-values (p < .001) of the
comparative analysis shown in Table 19 confirmed that the cumulative survival curves
were significantly different.

Figure 4. Kaplan-Meier survival curves for the brachytherapy treated patients.
I examined for differences in the hazards of the brachytherapy treated Jamaicans
and White U.S.-born PrCa patients with Cox regression hazards analysis (see Table 20). I
followed up with interaction analysis to determine whether the magnitude of the risk
ratios of the Cox regression model were similar across subgroups of the Jamaican and
White U.S.-born brachytherapy treated cohorts. The result of the interaction analysis is
presented in Table 20. I created two Cox regression models to examine the independent
and interaction effects of brachytherapy and birthplace in the survival outcomes of the
PrCa patients. An interaction term was modelled with the birthplace variable and
brachytherapy; the White U.S.-born cohort was the referent category. The hypothesis that
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the association identified was of similar magnitude across subgroups of the
brachytherapy treated Jamaican and White U.S.-born cohorts was accepted where there
were no significant interaction effects and rejected where there were significant
interaction effects in the model (Szklo & Nieto, 2014, p. 187). Alpha level (p < .05) was
the basis for accepting or rejecting the null hypothesis. I accepted the main effect for the
model with a non-significant interaction effect and a significant or non-significant
birthplace main effect. Table 20 presents the two models with the hazard ratios of the
main and interaction effects of brachytherapy and the birthplace variable. Model one
depicts the analysis of the independent effects of the predictor variable brachytherapy on
the outcome PrCa survival without interaction, and model two presents the analysis of the
main and interaction effects.
The result of the Cox regression analysis in model one showed a statistically
significant difference with the birthplace variable, HR 0.63, 95% CI [0.55, 0.73], p < .001
and brachytherapy, HR 0.69, 95% CI [0.63, 0.76], p < .001. At the introduction of the
interaction covariate in model two, the main effects for birthplace, HR 0.65, 95% CI
[0.56, 0.76], p < .001 and brachytherapy, HR 0.69, 95% CI [0.63, 0.77], p < .001 were
statistically significant. However, the interaction effect of brachytherapy and the
birthplace variable was not significant, HR 0.81, 95% CI [0.50, 1.23], p = .38. The main
effect of the birthplace variable was accepted because of the non-significant interaction
effect. The findings of the birthplace main effect indicate that brachytherapy reduced the
risk of death by 37% for the Jamaican cohort when compared with the White U.S.-born
PrCa patients, HR 0.63, 95% CI [0.55, 0.73], p < .001.
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The focus of the study was to determine differences in the survival of the
Jamaican versus the White U.S.-born PrCa patients who were treated with brachytherapy.
The statistically significant main effect for the birthplace variable and non-significant
interaction effect suggest that the coefficients were not modified by the interaction of
brachytherapy and country of birth. The non-significant statistical interaction also
indicates that brachytherapy treatment effects did not vary across subpopulations of the
brachytherapy treated cohorts of the study (Leighton, 2010b, p. 468; Szklo & Nieto,
2014). Hence, there is a significant difference in the survival times of the brachytherapy
treated Jamaicans and White U.S.-born PrCa patients.
Table 20
Main and Interaction Effects of the Differences in the Hazard Ratios for Jamaican and
White U.S.-Born Prostate Cancer Patients Treated With Brachytherapy
Variables in the Equation

Covariates

B

SE

Wald

df

p-value

Exp B

95% CI for
Exp (B)
LL
UL

Main Effects of Brachytherapy and Birthplace
Model 1

Birthplace
Reference =
United States

-0.45

0.07

38.97

1

.000

0.63

0.55

0.73

Brachytherapy

-0.37

0.04

59.39

1

.000

0.69

0.63

0.76

Main and Interaction Effects of Brachytherapy and Birthplace
Model 2

Birthplace
(Reference =
United States)

0.43

0.07

31.44

1

.000

0.65

0.56

0.76

Brachytherapy

-0.36

0.04

54.03

1

.000

0.69

0.63

0.77

Birthplace
*brachytherapy

-0.21

0.02

0.77

1

.378

0.81

0.50

1.29

Note: N = 10,752. * is the interaction covariate of brachytherapy and country of birth. LL
is lower limits, UL is upper limits.
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The Life-Table estimates and Kaplan-Meier estimators of Research Question 1
demonstrated that the Jamaican PrCa patients had a longer initial event-free period (100
months) when compared with the White U.S.-born PrCa patients (60 months), but
experienced the event earlier (190 months versus 230 months) (see Table 18 and Figure
4). The median survival time for the U.S.-born PrCa patients was 142 months, SE 3,
95% CI [134.8, 147.1], p < .001, while more than 50% of the Jamaicans survived beyond
half the period of follow-up (see Table 19). The Log-Rank, Breslow, and Tarone-Ware
tests of equality of the survival distributions for the brachytherapy treated the White U.S.born, and Jamaican PrCa patients confirmed that the survival curves for both cohorts
were significantly different (p < .001) (see Table 19).
Cox regression analysis of the differences in the hazard ratios of the
brachytherapy treated Jamaicans and White U.S.-born PrCa patients confirmed that there
were significant differences in their survival times (see Table 20). The hypothesis of a
modification effect in the magnitude of the risk ratios across subpopulations of the
brachytherapy treated Jamaican and White U.S.-born cohorts showed a non-significant
interaction effect. The brachytherapy treated Jamaicans were 0.63 times less likely to die
from PrCa at any given time during the 1992 to 2011 period of observation when
compared with the White U.S.-born PrCa patients, 95% CI [0.55, 0.73], p < .001.
Therefore, the alternative hypothesis that there are differences in the length of time
Jamaican-born PrCa patients versus U.S.-born White PrCa patients who were treated with
brachytherapy for low and intermediate stages PrCa, live with the disease was accepted.
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Research Question 2 Analysis
Research Question 2: Are there differences in the length of time Jamaican-born
PrCa patients compared with U.S.-born White PrCa patients who were treated with
ERBT for low and intermediate stages PrCa, live with the disease? H02: There are no
differences in the length of time Jamaican-born PrCa patients and U.S.-born White PrCa
patients treated with ERBT for low and intermediate stages PrCa, live with the disease.
Ha2: There are differences in the length of time Jamaican-born PrCa patients compared
with U.S.-born White PrCa patients who were treated with ERBT for low and
intermediate stages PrCa, live with the disease.
I obtained preliminary descriptive statistics, and crude and cumulative estimates
of the survival probability of the ERBT treated cohorts, using Life-Table estimates and
Kaplan-Meier estimators. The Log-Rank, Tarone-Ware, and Breslow’s statistics were
used to determine the equality of the survival distributions for the ERBT treated cohorts.
The Cox proportional hazards model was used to estimate the differences in the hazards
ratios for the ERBT treated Jamaican and White U.S.-born PrCa patients based on the
assumption that the hazards of both cohorts were constant throughout the follow-up.
Hypothesis testing with interaction analysis was carried out to determine modification
effects in the association identified between ERBT treatment and survival of the PrCa
patients. The findings of the statistical analyses for research question two are shown in
Table 21 through Table 23, and Figure 5.
Table 21 presents the Life-Table estimates of the ERBT treated PrCa cohorts. The
cumulative hazard rates were stable at one percent for the first 180 months of follow-up
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for the Jamaicans and 160 months for the White U.S.-born PrCa patients but increased to
2% at 190 and 170 months respectively. At 190 months, the number of ERBT treated
PrCa patients in the study declined significantly. All Jamaicans experienced the event at
210 months of follow-up and the White cohort at 230 months.
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Table 21
Life-Table Estimates of Survival Times for the Jamaican and White U.S.-Born Prostate
Cancer Patients Treated With ERBT for the Period 1992 to 2011
Life Table
Birth
Place

Start
Time

Started

At Risk

Censored

Died

Cum
Survival %

SE*

PD

HR %

SE**

Jamaica

0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210

181
163
151
139
129
114
101
91
80
67
57
51
41
31
23
19
17
12
8
8
4
2

173
159
146
135
124
110
98
88
77
64
54
49
37
29
21
19
16
11
8
7
4
2

16
8
10
8
11
9
6
6
7
6
5
5
9
5
4
1
3
3
0
3
1
0

2
4
2
2
4
4
4
5
6
4
1
5
1
3
0
1
2
1
0
1
1
2

99
96
95
94
91
87
84
79
73
68
67
60
58
52
52
49
43
39
39
33
24
00

.01
.01
.02
.02
.02
.03
.03
.04
.04
.04
.05
.05
.05
.06
.06
.06
.07
.07
.07
.08
.10
.00.

.001
.002
.001
.001
.003
.003
.004
.005
.006
.005
.001
.007
.002
.006
.000
.003
.006
.004
.000
.006
.009
.024

0
0
0
0
0
0
0
1
1
1
0
1
0
1
0
1
1
1
0
2
3
0

.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.01
.00
.01
.01
.01
.00
.02
.03
.00

United
States

0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
220
230

2,449
2,356
2,213
2,036
1,889
1,726
1,567
1,425
1,252
1,072
931
784
623
494
382
297
235
182
130
94
62
53
33
16

2,413
2,323
2,167
2,008
1,857
1,692
1,533
1,389
1,214
1,039
900
743
589
465
360
283
224
169
122
85
60
47
27
9

72
67
92
57
64
68
69
72
77
69
62
83
69
58
45
29
22
26
17
18
4
12
12
14

21
76
85
90
99
91
73
101
103
72
85
78
60
54
40
33
31
26
19
14
5
8
5
2

99
96
92
88
83
79
75
70
64
59
54
48
43
38
34
30
26
22
18
15
14
12
10
7

.00
.00
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.01
.02

.001
.003
.004
.004
.005
.004
.004
.005
.006
.004
.006
.006
.005
.005
.004
.004
.004
.004
.003
.003
.001
.002
.002
.002

0
0
0
0
1
1
0
1
1
1
1
1
1
1
1
1
1
2
2
2
1
2
2
3

.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.00
.01
.01
.02

Note: N = 10,752. SE* is the standard error for the cumulative survival and SE** is the
standard error for the hazard rate. PD is probability density of survival estimate; HR is the
hazard rates.
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Table 22 shows the Kaplan-Meier comparison of the survival periods of the
Jamaican and White U.S. cohorts. At the first percentile, Jamaicans survived the greater
portion of the observation period (209 months). The median survival was 154 months for
the Jamaicans, SE 14.6, 95% CI [125.2, 182.8] and 116 months for the White U.S.-born
PrCa patients, SE 2.2, 95% CI [111.6, 120.4]. The Log-Rank, Breslow’s, and TaroneWare tests of equality of the survival distributions confirmed that the survival
experiences of the Jamaican and White U.S.-born PrCa patients were significantly
different (p < .001).
Table 22
Kaplan-Meier Comparison of Survival Times for the Jamaican and White U.S.-Born
Prostate Cancer Patients Treated With ERBT
Overall Comparisons
Percentiles
25%

50%

95% CI for
the Median

75%

Est

SE

Est

SE

Est

SE

LL

UL

Jamaica

209

8

154

15

89

7

125.2

182.8

United
States

173

3

116

2

70

2

111.6

120.4

Overall

175

3

117

2

71

2

112.5

121.5

Log-Rank

Breslow

χ2

Sig

χ2

Sig

41.2

.000

42.5

.000

TaroneWare
χ2
Sig

45.5

.000

Note: N = 10,752. LL is lower limits, UL is upper limits. Est is estimate. Percentiles are
the quartiles of the follow-up period in months. Est is estimate. Sig is the p-value.
Figure 5 illustrates the cumulative survival probability for the ERBT treated
Jamaican and White U.S.-born PrCa. The Kaplan-Meier curves demonstrated perceptible
differences in the survival experiences of both cohorts. The curves shifted after 30
months of follow-up and remained parallel throughout the observation. The cumulative
survival curves showed that ERBT was more beneficial to the Jamaican PrCa patients
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throughout the observation when compared with the White U.S.-born cohort. Fewer
Jamaican and White U.S. PrCa patients were in the study between 160 and 200 months of
follow-up. All Jamaican PrCa patients experienced the event earlier than the White U.S.born patients. The frequency of the ERBT treated Jamaicans presented Table 21
corresponded with the shifts in the survival curves and confirmed that the number of
PrCa patients declined at the latter months of the follow-up. The cumulative survival
curve for the White U.S.-born cohort terminated at a later period (230 months) of followup. The comparison analysis of the survival distributions demonstrated in Table 22
verified that the survival curves for the Jamaicans and the White U.S. PrCa patients were
significantly different.

Figure 5. Kaplan-Meier survival curves for the ERBT treated patients.
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The differences in the hazards of Jamaicans and White U.S.-born PrCa patients
were examined further in Cox regression hazards analysis (see Table 23). The Coxproportional hazards model was used to estimate the differences in the hazards ratios for
the ERBT treated Jamaican and White U.S.-born PrCa patients based on the assumption
that the hazards among both cohorts were constant throughout the follow-up. I conducted
hypothesis test with interaction analysis to determine modification effects in the
magnitude of the association identified in the Cox regression analysis for the Jamaican
and White U.S.-born ERBT treated cohorts. The differences in the hazard ratios of the
main and interaction effects of ERBT and the birthplace variable were examined in two
separate Cox regression models. An interaction term was modelled with the birthplace
variable and ERBT; the White U.S.-born cohort was the referent category. The
hypothesis that the association identified was of similar magnitude across subgroups of
the ERBT treated Jamaican and White U.S.-born cohorts was accepted where there were
no significant interaction effects and rejected where there were interaction effects in the
model (Szklo & Nieto, 2014, p. 187). Alpha level (p < .05) was the basis for accepting or
rejecting the null hypothesis. I accepted the main effect for the model with a nonsignificant interaction effect and a significant or non-significant birthplace main effect. In
Table 23, model one depicts the analysis of the independent effects of the predictor
variable ERBT on PrCa survival without the interaction term, and model two presents the
analysis of the main and interaction effects.
The result of the Cox regression analysis in model one showed a statistically
significant difference with the birthplace variable, HR 1.6, 95% CI [1.38, 1.84],
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p < .001 and ERBT, HR 0.89, 95% CI [0.84, 0.95], p = .001. In model two, the Cox
regression analysis showed a significant main effect for birthplace, HR 1.50, 95% CI
[1.27, 1.78], p < .001 but ERBT did not, HR 1.14, 95% CI [0.61, 2.13], p = 0.69. The
interaction effect of ERBT and the birthplace variable was also not significant
HR 1.03, 95% CI [0.75, 1.41], p = 0.88. The birthplace main effect was accepted because
of the non-significant interaction effect. The ERBT treated Jamaican PrCa patients were
1.6 times more likely to die of PrCa when compared with the ERBT treated U.S.-born
White PrCa patients, HR 1.6, 95% CI [1.38, 1.84], p < .001.
The intent of the study was to determine differences in the survival of the
Jamaican versus the White U.S.-born PrCa patients who were treated with ERBT. The
birthplace main effect was statistically significant, and the interaction effect was not
significant. The statistically significant main effect for the birthplace variable and nonsignificant interaction effect confirmed that the coefficients were not modified by the
interaction of ERBT and country of birth. The non-significant statistical interaction also
indicates that ERBT treatment effects were similar in magnitude across subpopulations of
the cohorts studied (Leighton, 2010b, p. 468; Szklo & Nieto, 2014, p. 187). Hence there
is a significant difference in the survival of the ERBT treated Jamaicans and White U.S.born PrCa patients
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Table 23
Main and Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and
White U.S.-Born Prostate Cancer Patients Treated With ERBT
Variables in the Equation
95% CI for Exp (B)
Covariates

B

SE

Wald

df

p-value

Exp (B)

LL

UL

Main Effects of ERBT and Birthplace
Model 1

Birthplace
(Reference =
United States)

0.46

0.07

40.62

1

.000

1.59

1.38

1.84

ERBT

0.11

0.03

11.73

1

.001

0.89

0.84

0.95

Main and Interaction Effects of ERBT and Birthplace
Model 2

Birthplace
(Reference
=United States)

0.40

0.08

22.04

1

.000

1.50

1.27

1.78

ERBT

0.13

0.32

0.16

1

.685

1.14

0.61

2.13

ERBT*
Country of
Birth

0.02

0.16

0.02

1

.881

1.03

0.75

1.41

Note: N = 10,752. * is the interaction covariate of ERBT and Country of Birth. LL is
lower limits and UL is upper limits.
The analyses for Research Question 2 demonstrate that the Jamaican PrCa
patients had a longer event-free period at the start of the follow-up when compared with
the White U.S.-born PrCa patients (60 months versus 30 months). Both ERBT treated
groups survived more than 200 months of follow-up (see Table 21). Kaplan-Meier
statistics showed that the Jamaican ERBT treated PrCa patients had higher median
survival time when compared with the White U.S.-born PrCa patients (154 months), SE
15, 95% CI [125.2, 182.8], versus (116 months), SE 2, 95% CI [111.6, 120.4] The
Kaplan-Meier cumulative survival curve showed that the ERBT treated Jamaican PrCa
patients had higher survival probability when compared with the White U.S.-born cohort
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(see Figure 5). The Log-Rank, Breslow’s, and Tarone-Ware tests of equality of the
survival distributions for the ERBT treated White U.S.-born, and Jamaican PrCa patients
confirmed that the survival curves were significantly different (p < .001) (see Table 22).
Cox regression analysis of the differences in the hazard ratios of the Jamaican and
White U.S.-born ERBT treated PrCa patients confirmed that the hazard ratios of both
cohorts were significantly different (see Table 23). The hypothesis of a difference in the
magnitude of the risk ratios across subgroups of the ERBT treated Jamaican and White
U.S.-born cohorts demonstrated no interaction or modification effects. Hence, at any
given time during the during the 1992 to 2011 period of observation the ERBT treated
Jamaican PrCa patients were 1.6 times more likely to die of PrCa when compared with
the White U.S.-born PrCa patients, 95% CI [1.38, 1.84], p < .000. Thus, the alternative
hypothesis that there are differences in the length of time Jamaican-born PrCa patients
versus U.S.-born White PrCa patients who were treated with ERBT for low and
intermediate stages PrCa live with the disease was accepted.
Research Question 3 Analysis
Research Question 3: Are there differences in the 5-year survival intervals of
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients per treatment
received for the period 1992 to 2011? H03: There are no differences in the 5-year survival
intervals of Jamaican-born and U.S.-born White PrCa patients per treatment received for
the period 1992 to 2011. Ha.3: There are differences in the 5-year survival intervals of
Jamaican-born PrCa patients compared with U.S.-born White PrCa patients according to
treatment received for the period 1992 to 2011.
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In analyzing Research Question 3, I developed cohort-treatment contingency
tables for each 5-year interval and estimated the hazard rates and median survival times
of the PrCa cohorts according to the treatments they received. I compared the differences
in the survival distributions of the Jamaican and White U.S.-born cohorts per treatments
received using the Log-Rank statistics. The findings of the Kaplan-Meier statistical
analyses are presented in Tables, 24, 28, 32, and 36. I computed further analyses with the
Cox proportional hazards regression model to test the differences in the survival
experiences of the PrCa patients for each 5-year interval. Hypothesis testing with
interaction analysis was conducted to determine interaction or modification in the
magnitude of the risk ratios of the treatment cohorts. Each PrCa treatment
(brachytherapy, ERBT, and radiation sequenced with surgery) was modelled separately
with the birthplace variable and an interaction term which included birthplace and
treatment type. The hypothesis that the magnitude of the risk ratios of the Cox regression
model was comparable in subpopulations of the Jamaican and White U.S.-born cohorts
was accepted for each model with a non-significant interaction outcome and a significant
or non-significant birthplace main effect. In contrast, the hypothesis that the magnitude of
the risk ratios was similar among subgroups of the cohorts was rejected for each model
with a significant interaction effect. Alpha level (p < .05) was the basis for accepting or
rejecting the null hypothesis. Follow-up tests using pairwise comparisons of the second
main effects (the treatment groups and their corresponding non-treated groups) were
completed for each model with a significant interaction effect. The main outcomes of the
treatment and birthplace variables for each 5-year interval are presented in three separate
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models in Tables 25, 29, 33, and 37. The interaction effects of the birthplace covariate
and the PrCa treatments were modelled in Tables 26, 30, 34, 38. Tables 27, 31, 35, and
39 present the results of the pairwise comparisons for the significant interaction effects.
Survival interval 1992 to 1996. One thousand seven hundred and sixty-nine
Jamaican and U.S.-born PrCa patients received brachytherapy, ERBT, and other radiation
treatment for the 1992 to 1996 period of observation. Among the treatment groups, the
brachytherapy treated Jamaican PrCa patients had the highest number of censored cases
(55.2%) and higher median survival time (three years) when compared with the other
treatments. Fifty percent of the Jamaican cohort survived two years of follow-up, and
fewer received other types of radiation. Half of the U.S.-born PrCa patients who received
all three treatments were alive at two years of follow-up. Table 24 demonstrates that the
results of the Kaplan-Meier estimates of the 1992 to 1996 sample.
Table 24
Summary of Kaplan-Meier Estimates for the Sample of 1,769 Jamaican and U.S.-Born
Prostate Cancer Patients per Treatment Received Between 1992 and 1996
Birthplace

Jamaica

United
States

Treatment

Number
at Risk
(n)

Died

Censored (%)

Median
Survival

95% CI
for Median
LL

UL

χ2

p-value

Brachytherapy

29

13

16

(55.2)

3

2.43

3.58

8.04

.005

ERBT

66

44

22

(33.3)

2

1.67

2.33

8.58

.003

Other

19

10

9

(47.4)

2

1.01

2.98

8.68

.003

Brachytherapy

355

206

149

(42.0)

2

1.86

2.14

8.04

.005

ERBT

1,080

837

243

(22.5)

2

1.91

2.08

8.58

.003

Other

220

159

61

(27.7)

2

1.80

2.19

8.68

.003

Note: Median survival was estimated in years. LL is lower limits, UL is upper limits.
Other is radiation sequenced with surgery. χ2 is the Log-Rank comparison.
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Table 25 describes the main effects of the birthplace covariate and brachytherapy,
ERBT, and other radiation treatments for the period 1992 to 1996 period. The birthplace
main effects were statistically significant for all treatments types. Model one focused on
the difference between PrCa patients who were treated with brachytherapy, model two
demonstrates the differences among the ERBT treated cohorts, and model three presented
the differences among the PrCa patients who received other types of radiation. The
Jamaican PrCa patients were 1.2 times more likely to die of PrCa when compared with
the White U.S.-born (p < .001). Further analyses for the interaction or modification
effects in the association of the treatments and PrCa survival were completed.
Table 25
Main Effects of the Differences in the Hazard Ratios for the Jamaicans and White U.S.Born Prostate Cancer Patients per Treatment Received Between 1992 and 1996
Variables in the Equation
95% CI for Exp (B)
Variables

B

SE

Wald

df

Sig

Exp (B)

LL

UL

Brachytherapy Main Effects
Model 1

Birthplace (Reference
= United States

0.18

0.08

4.40

1

.036

1.20

1.01

1.42

Brachytherapy

-0.18

0.07

7.20

1

.007

0.82

0.72

0.95

1

.031

1.20

1.02

1.43

.000

1.16

1.08

1.26

ERBT Main Effects
Model 2

Birthplace
(Reference = United
States)

0.18

0.08

4.64

ERBT

0.15

0.04

15.1

1

Other Radiation Treatment Main Effects
Model 3

Birthplace
(Reference = United
States)

0.19

0.08

4.85

1

.028

1.21

1.02

1.44

Other

-0.07

0.07

0.86

1

.354

0.92

0.79

1.09

Note: N = 1,769. LL is lower limits, UL is upper limits. Other is radiation sequenced with
surgery.
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Table 26 shows the results of the interaction analyses for the PrCa patients who
were treated with brachytherapy, ERBT, and other radiation for the period 1992 to 1996.
In model one, which examined the effects of brachytherapy, the birthplace main effect,
HR 1.19, 95% CI [0.99, 1.42], p = .063, brachytherapy main effect, HR 0.64, 95% CI
[0.20, 2.03], p = 0.452 and the birthplace and brachytherapy interaction effect, HR 1.14,
95% CI [0.63, 2.05], p = 0.664 were not statistically significant.
In model two, which focused on treatment effects of ERBT, the birthplace main
effect, HR 1.14, 95% CI [0.99, 1.40], p = .058 and the main effect for ERBT were not
significant, HR 0.98, 95% CI [0.54, 1.78], p = 0.941. However, the interaction effect for
ERBT and birthplace, HR 1.08, 95% CI [1.04, 1.13], p < .001 was statistically significant.
In model three, which estimated the effects of other radiation treatment, the
birthplace main effect, HR 1.31, 95% CI [1.04, 1.66], p = .021 and other radiation
treatment main effect, HR 0.78, 95% CI [0.62, 0.98], p = .036 were significant. The
interaction effect of birthplace and other radiation treatment was not statistically
significant, HR 0.96, 95% CI [0.89, 1.04], p = .296.
The non-significant interaction effects for brachytherapy and other radiation
treatment indicate that the third variable (the interaction term) did not modify the main
effects observed. The brachytherapy treated Jamaicans and the Jamaican PrCa patients
who were treated with other radiation had 1.2 times higher risk of dying of PrCa when
compared with the White U.S.-born patients (p < .001). The main effect for ERBT was
not interpreted for this analysis because of the significant interaction effects.
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A follow-up, pairwise comparison of the hazard ratios of Jamaican and White
U.S.-born PrCa patients who received and did not receive ERBT for 1992 to 1996
interval was completed. The referent group was the PrCa patients who received no ERBT
(see Table 27). The findings indicate that the hazard ratios were significant for the White
U.S.-born PrCa patients but not for the Jamaicans. The risk of death for the ERBT treated
Jamaican PrCa patient was 1.5 times greater than the risk for the non-ERBT treated
patients, 95% CI [0.99, 2.20], p = .057. The risk of death for the White ERBT treated
PrCa patients was 1.14 times higher than the non-ERBT treated White cohort, 95% CI
[1.05, 1.25], p < .003. Hence, there was a significant difference among the ERBT treated
versus the non-ERBT treated White U.S.-born PrCa patients. There were no significant
treatment differences among the Jamaicans.
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Table 26
Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and White
U.S.-Born Prostate Cancer Patients per Treatment Received Between 1992 and 1996
Variables in the Equation
95% CI for Exp (B)
Variables

B

SE

Wald

df

Sig

Exp (B)

LL

UL

Brachytherapy with Interaction Variable
Model 1

Birthplace
(Reference = United
States)

0.17

0.09

3.45

1

.063

1.19

0.99

1.42

Brachytherapy

-0.44

0.58

0.56

1

.452

0.64

0.20

2.03

Brachytherapy
*Birthplace

0.13

0.30

0.18

1

.664

1.14

0.63

2.05

ERBT with Interaction Variable
Model 2

Birthplace
(Reference = United
States)

0.16

0.08

3.60

1

.058

1.14

0.99

1.40

ERBT

-0.02

0.30

0.01

1

.941

0.98

0.54

1.78

ERBT*Birthplace

0.08

0.02

14.34

1

.000

1.08

1.04

1.13

Other Radiation Treatment with Interaction Variable
Model 3

Birthplace
(Reference = United
States)

0.27

0.11

5.32

1

.021

1.31

1.04

1.66

Other

-0.25

0.11

4.38

1

.036

0.78

0.62

0.98

Other*Birthplace

-0.04

0.04

1.09

1

.296

0.96

0.89

1.04

Note: N = 1,769. LL is lower limits, UL is upper limits. Other is radiation sequenced with
surgery, * is the interaction term.
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Table 27
Pairwise Comparison of the Hazard Ratios for the Jamaican and White U.S.-Born
Prostate Cancer Patients Treated With ERBT for the 1992 to 1996 Period
Variables in the Equation
95% CI for Exp
(B)
Treatment

B

SE

Wald

df

Jamaicans

ERBT

0.39

0.20

3.63

1

White U.S.-Born

ERBT

0.13

0.04

8.86

1

Sig

Exp (B)

LL

UL

.057

1.48.

0.99

2.20

.003

1.14

1.05

1.25

Reference = (No ERBT)

Note: N = 1,769. LL is lower limits, UL is upper limits.
Survival interval 1997 to 2001. Kaplan-Meier estimates of the cumulative
survival of 1,271 Jamaican and U.S. PrCa treated cohort who were followed between
1997 and 2001 demonstrated that the median survival was undefined for the
brachytherapy and ERBT treated Jamaicans. However, an estimated 50% of the Jamaican
and White U.S.-born PrCa patients who received other radiation were alive at three years
of follow-up, 95% CI [2.18, 3.81] and [2.45, 3.54] respectively. Half of the U.S.-born
PrCa patients who received brachytherapy also survived beyond three years of treatment,
95% CI [2.79, 3.21], p = .010. On the other hand, 50% of the ERBT treated U.S.-born
PrCa patients were alive at two years of treatment (p = .004). Table 28 demonstrates that
the results of the Kaplan-Meier estimates of the 1997 to 2001 treatment groups.
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Table 28
Summary of Kaplan-Meier Estimates for the Sample of 1,271 Jamaican and White U.S.Born Cancer Patients per Treatment Received for the Period 1997 to 2001
Birthplace

Jamaica

United
States

Treatment

Number
at Risk
(n)

Died

Censored (%)

Median
Survival

95% CI for
Median
LL

UL

χ2

p-value

Brachytherapy

39

14

25

(64.1)

-

-

-

ERBT

42

17

25

(60.0)

-

-

-

Other

10

3

7

(70.0)

3

2.18

3.81

1.79

.005

Brachytherapy

409

200

209

(51.1)

3

2.79

3.21

6.61

.010

ERBT

667

418

249

(37.3)

2

1.85

2.14

8.23

.004

Other

104

48

56

(53.8)

3

2.45

3.54

1.79

.005

Note: Median survival was estimated in years. No median survival was estimated for
Brachytherapy and ERBT treated Jamaicans because; more than 50% of the Jamaicans
survived beyond the 50th percentile of the observation period. LL is lower limits, UL is
upper limits. Other is radiation sequenced with surgery. χ2 is the Log-Rank comparison.
Table 29 describes the main effects of the birthplace covariate and brachytherapy,
ERBT, and other radiation treatments for the period 1997 to 2001 period. The birthplace
main effects were statistically significant for all treatments types. Model one which
focused on the difference between PrCa patients who were treated with brachytherapy
confirmed that the Jamaican PrCa patients were 1.29 times more likely to die of PrCa
when compared with the White U.S.-born, 95% CI [1.02, 1.66], p = .036. Model two
which demonstrated the survival experience differences among the ERBT treated cohorts
demonstrated that the hazard among the Jamaican PrCa patients was 1.33 times greater
than the White U.S.-born, 95% CI [1.05, 1.71], p = .018. In model three which presented
the differences among the PrCa patients who received other radiation treatments, the
Jamaican PrCa patients had 1.32 times higher risk of dying of PrCa when compared with
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the White U.S.-born, 95% CI [1.04, 1.70], p = .022. Further hypothesis testing was
conducted with interaction analysis to determine modification effects in the survival
outcomes observed in the 1997 to 2001 cohort (see Table 30).
Table 29
Main Effects of the Differences in the Hazard Ratios for the Jamaican and White U.S.Born Prostate Cancer Patients per Treatment Received Between 1997 and 2001
Variables in the Equation
95% CI for Exp
(B)
Variables

B

SE

Wald

df

Sig

Exp (B)

LL

UL

Brachytherapy
Model 1

Birthplace
(Reference =
United States)

0.26

0.12

4.39

1

.036

1.29

1.02

1.66

Brachytherapy

-0.31

0.07

17.40

1

.000

0.73

0.64

0.85

ERBT
Model 2

Birthplace
(Reference =
United States)

0.29

0.12

5.55

1

.018

1.33

1.05

1.71

ERBT

0.14

0.05

6.30

1

.012

1.15

1.03

1.29

Other Radiation Treatment
Model 3

Birthplace
(Reference =
United States)

0.28

0.12

5.25

1

.022

1.32

1.04

1.70

Other

0.28

0.14

4.07

1

.043

1.33

1.01

1.76

Note: N = 1,271. LL is lower limits, UL is upper limits. Other is other types of radiation
treatments.
Table 30 demonstrates the results of the interaction analysis for the PrCa patients
who were treated with brachytherapy, ERBT, and other radiation for the period 1997 to
2001. In model one, which shows the effects of brachytherapy, the birthplace main effect,
HR 1.35, 95% CI [1.06, 1.72], p = .017 and interaction effect, HR 0.86, 95% CI [0.80,
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0.92], p < .001 were significant. The main effect for brachytherapy was not statistically
significant, HR 0.38, 95% CI [0.13, 1.08], p = .072.
In model two, which focused on the effects of ERBT, the birthplace main effect
HR 1.31, 95% CI [1.03, 1.67], p = .029 and interaction effect HR 1.08, 95% CI [1.02,
1.14], p = .010 were statistically significant. However, the main effect for ERBT was not
statistically significant, HR 0.50, 95% CI [0.19, 1.29], p = .149.
In model three, which explains the effects of other radiation treatment the
birthplace main effect, HR 1.00, 95% CI [0.69, 1.46], p = 0.982, other radiation treatment
main effect, HR 0.93, 95% CI [0.66, 1.32], p = 0.687, and interaction effects, HR 1.16,
95% CI [1.00, 1.33], p = .049 were not statistically significant.
The main effect for other radiation treatment was accepted, HR 1.32, 95% CI
[1.04,1.70], p =.022. The main effects of the birthplace covariate for brachytherapy and
ERBT were not interpreted for this analysis because of the significant interaction effects
in the two models. Further evaluations were conducted for brachytherapy, ERBT and
their correspondent control groups to determine whether there were differences in the
second main effects. The referent groups were PrCa patients who received no
brachytherapy and no ERBT.
Table 31 presents the pairwise comparisons of the hazard ratios of the different
treatment groups. The findings demonstrated that the treatment effects were significant
for the White U.S.-born PrCa patients but not for the Jamaicans. Among the White
cohort, brachytherapy treated PrCa patients had 33% lower risk of death when compared
with patients who did not receive brachytherapy, 95% CI [0.66, 0.90). The ERBT treated

131
patients were 1.14 times more likely to die of PrCa when compared with their control
groups 95% CI [1.01, 1.28). The results showed that the White U.S.-born PrCa patients
who were treated with brachytherapy, and ERBT between 1997 and 2001 had significant
differences in their hazard ratios when compared with the groups that did not receive
these treatments.
Table 30
Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and White
U.S.-Born Prostate Cancer Patients per Treatment Received Between 1997 and 2001
Variables in the Equation

Variables

B

SE

Wald

df

Sig

Exp (B)

95% CI for Exp
(B)
LL
UL

Brachytherapy with Interaction Variable
Model 1

Birthplace
(Reference =
United States)

0.29

0.12

5.72

1

.017

1.35

1.06

1.72

Brachytherapy

-0.97

0.54

3.24

1

.072

0.38

0.13

1.08

Brachytherapy
*Birthplace

-0.16

0.03

16.08

1

.000

0.86

0.80

0.92

ERBT with Interaction Variable
Model 2

Birthplace
(Reference =
United States)

0.27

0.12

4.77

1

.029

1.31

1.03

1.67

ERBT

-0.70

0.48

2.07

1

.150

0.49

0.19

1.29

ERBT*Birthplace

0.07

0.02

6.60

1

.010

1.08

1.02

1.14

Other Radiation Treatment with Interaction Variable
Model 3

Birthplace
(Reference =
United States)

0.00

0.19

0.00

1

.982

1.00

0.69

1.46

Other

-0.07

0.18

0.16

1

.687

0.93

0.66

1.32

Other*Birthplace

0.14

0.07

3.88

1

.049

1.16

1.00

1.33

Note: N = 1,271. LL is lower limits, UL is upper limits. Other is radiation sequenced with
surgery, * is the interaction term.
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Table 31
Pairwise Comparison of the Hazard Ratios for the Jamaican and White U.S.-Born
Prostate Cancer Patients Treated With Brachytherapy, and ERBT, for the Period 1997 to
2001
Variables in the Equation
95% CI for Exp (B)
Treatment

B

SE

Wald

df

Sig

Exp (B)

LL

UL

Reference = (No brachytherapy, No ERBT,)
Jamaicans

White
U.S.-Born

Brachytherapy

-0.41

0.32

1.69

1

.193

0.66

0.36

1.23

ERBT

-0.10

0.31

0.10

1

.743

0.90

0.49

1.66

Brachytherapy

-0.26

0.08

10.65

1

.001

0.77

0.66

0.90

ERBT

0.13

0.06

4.50

1

.034

1.14

1.01

1.28

Note: N = 1,271. LL is lower limits, UL is upper limits. Other is other types of radiation
treatments.
Survival interval 2002 to 2007. At the third 5-year interval of the study (2002 to
2007), 1,461 Jamaican and U.S. PrCa patients were treated with ERBT, brachytherapy,
and other radiation. More than 50% of the PrCa treatment groups, except the White U.S.born ERBT treated cohort, survived beyond half of the 2002 to 2007 period of
observation (see Table 32). Cox regression analysis of the differences in the risk ratios
among the Jamaican and White U.S.-born cohort for 2002 to 2007 was completed (see
Table 33).
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Table 32
Summary of Kaplan-Meier Estimates for the Sample of 1,461 Jamaican and White U.S.Born Prostate Cancer Patients per Treatment Received for the Period 2002 to 2007
Birthplace
Jamaica

United
States

Treatment

At Risk
(n)

Died

Censored

(%)

Brachytherapy

34

2

32

(94.1)

ERBT

48

9

39

(81.3)

Other

4

0

4

(100)

Brachytherapy

562

169

393

(70.0)

ERBT

701

272

42

(61.2)

Other

112

41

71

(63.4)

Note: The median survival times were undefined for the PrCa patients because more than
50% survived beyond the 50th percentile of the observation period. Other is radiation
sequenced with surgery.
Table 33 demonstrates the main effects of the birthplace variables, brachytherapy,
ERBT, and other radiation treatments for the 2002 to 2007 interval in three models.
Model one focused on the difference between PrCa patients who were treated with
brachytherapy, model two demonstrates the differences among the ERBT treated cohorts,
and model three presented the differences among the PrCa patients who received
radiation sequenced with surgery. The birthplace main effects were statistically
significant for all treatments types. The Jamaican PrCa patients were treated with
brachytherapy, ERBT, and other radiation treatments were 2.4 times more likely to die of
PrCa when compared with the White U.S.-born (p < .001). Hypothesis testing with
interaction analysis was completed to determine modification effects in the association
between the three PrCa treatments and PrCa survival among the 2002 to 2007 cohort (see
Table 34).
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Table 33
Main Effects of the Differences in the Hazard Ratios for the Jamaican and White U.S.Born Prostate Cancer Patients per Treatment Received Between 2002 and 2007
Variables in the Equation
95% CI for
Exp (B)
Variables

B

SE

Wald

df

Sig

Exp (B)

LL

UL

Brachytherapy
Model 1

Birthplace
(Reference = United
States)

0.89

0.17

26.17

1

.000

2.43

1.73

3.43

Brachytherapy

-0.27

0.08

10.34

1

.001

0.76

0.65

0.90

ERBT
Model 2

Birthplace
(Reference = United
States)

0.88

0.17

25.73

1

.000

2.41

1.72

3.40

ERBT

0.08

0.06

1.51

1

.218

1.08

0.95

1.24

Other Radiation Treatment
Model 3

Birthplace
(Reference = United
States)

0.88

0.17

25.7

1

.000

2.42

1.72

3.40

Other

0.04

0.16

0.07

1

.791

1.04

0.76

1.42

Note: N = 1,461. LL is lower limits, UL is upper limits. Other is radiation sequenced with
surgery. CI is confidence interval.
Table 34 presents the results of the interaction analysis for the PrCa patients who
were treated with brachytherapy, ERBT, and other radiation for the period 2002 to 2007.
In model one, which examined the effects of brachytherapy and the birthplace main
effect, HR 2.48, 95% CI [1.76, 3.48], p < .001, the main effect for brachytherapy, HR
0.03, 95% CI [0.00, 0.52], p = .015, and the interaction effect of brachytherapy and
birthplace, HR 0.88, 95% CI [0.81, 0.95], p = .002 were significant.
In model two, which focused on the treatment effect of ERBT on PrCa survival,
the birthplace main effect, HR 2.39, 95% CI [1.70, 3.37], p < .001 and ERBT main effect,
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HR 0.23, 95% CI [0.06, 0.87], p = .030 were significant. The interaction effect of ERBT
and birthplace was not significant, HR 01.04, 95% CI [0.97, 1.12], p = .230.
Model three, which estimated other radiation treatment effects in PrCa survival,
showed that the birthplace main effect, HR 2.33, 95% CI [1.48, 3.67], p < .001 and other
radiation treatment main effect, HR 0.43, 95% CI [0.28, 0.68], p < .001 were statistically
significant. The interaction effect of birthplace and other radiation was not statistically
significant, HR 1.02, 95% CI [0.87, 1.19], p = 0.809.
The non-significant interaction effects of ERBT and other radiation treatment in
models two and three confirmed that the interaction terms did not mediate the birthplace
main effects. The findings indicate that the ERBT treated Jamaican PrCa patients and
those who received other radiation treatment had 2.41 and 2.42 times higher risk of death
when compared with the White U.S.-born patients. Further evaluation of the significant
interaction effects in model one was conducted using pairwise comparisons of the
brachytherapy treated and non-brachytherapy treated PrCa patients.
Table 35 presents the pairwise comparisons of the hazard ratios of brachytherapytreated and non-brachytherapy treated PrCa patients. The brachytherapy treated Jamaican
PrCa patients had a 63% lower risk of dying from PrCa when compared with PrCa
patients who did not receive brachytherapy, 95% CI [0.09, 1.55], p = .172. On the other
hand, the brachytherapy treated White U.S.-born PrCa patients experienced 21% reduced
risk when compared with the PrCa patients who did not receive brachytherapy, 95% CI
[0.66, 0.93], p = .005. Although the brachytherapy treated cohorts experienced better
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survival when compared with the non-brachytherapy treated group, the finding was not
significant for the Jamaicans.
Table 34
Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and White
U.S.-Born Prostate Cancer Patients per Treatment Received Between 2002 and 2007
Variables in the Equation
95% for Exp (B)
Variables
Model 1

B

SE

Wald

df

Sig

Exp (B)

LL

UL

Brachytherapy with Interaction Variable
Birthplace
(Reference = United
States)

0.91

0.17

27.11

1

.000

2.48

1.76

3.48

Brachytherapy

-3.44

1.41

5.89

1

.015

0.03

0.00

0.52

Brachytherapy
*Birthplace

-0.13

0.04

9.78

1

.002

0.88

0.81

0.95

ERBT with Interaction Variable
Model 2

Birthplace
(Reference = United
States)

0.87

0.17

25.10

1

.000

2.39

1.70

3.37

ERBT

-1.46

0.67

4.71

1

.030

0.23

0.06

0.87

ERBT*Birthplace

0.04

0.03

1.43

1

.230

1.04

0.97

1.12

Other Radiation Treatment with Interaction Variable
Model 3

Birthplace
(Reference = United
States)

0.85

0.23

13.22

1

.000

2.33

1.48

3.67

Other

-0.84

0.23

12.87

1

.000

0.43

0.28

0.68

Other*Birthplace

0.02

0.08

0.05

1

.809

1.02

0.87

1.19

Note: N = 1,461. LL is lower limits, UL is upper limits. Other is radiation sequenced with
surgery. CI is confidence interval, * is the interaction term.
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Table 35
Pairwise Comparison of the Hazard Ratios for the Jamaican and White U.S.-Born
Prostate Cancer Patients Treated With Brachytherapy for the Period 2002 to 2007
Variables in the Equation

Treatment

B

SE

Wald

df

Sig

Exp (B)

95% CI for Exp
(B)
LL
UL

Reference = (No brachytherapy)
Jamaicans

Brachytherapy

-1.01

0.73

1.86

1

.172

0.37

0.09

1.55

White U.S.-born

Brachytherapy

-0.24

0.08

7.98

1

.005

0.79

0.66

0.93

Note: N = 1,461. LL is lower limits, UL is upper limits.
Survival interval 2007 to 2011. Fewer White U.S.-born and Jamaican PrCa
patients (899) were observed for survival outcomes for the 2007 to 2011 treatment period
when compared with the other follow-up periods. All PrCa patients survived beyond 50%
of the interval for the 2007 to 2011 period of observation. More than 80% of the U.S.
cohort and all Jamaicans were censored. Table 36 demonstrates the results of the KaplanMeier cumulative survival estimates for the 2007 to 2011 period of observation. Cox
regression analysis confirmed the differences in the survival experiences for the 2002 to
2011 treatment cohorts (see Table 37).

138
Table 36
Summary of the Kaplan-Meier Estimates for the Sample of 899 Jamaican and White U.S.Born Prostate Cancer Patients per Treatment Received for the Period 2007 to 2011
Birthplace

Treatment

Number
at Risk
(n)

Died

Censored

(%)

Jamaica

Brachytherapy

34

0

34

(100)

ERBT

55

0

55

(100)

Other

7

0

7

(100)

Brachytherapy

258

17

241

(93.4)

ERBT

480

60

420

(87.5)

Other

65

7

58

(89.2)

United
States

Note: The median survival times were undefined for the PrCa patients because more than
50% survived beyond the 50th percentile of the observation period. Other is radiation
sequenced with surgery.
Table 37 describes the main effects of the birthplace covariate and brachytherapy,
ERBT, and other radiation treatments for the period 2007 to 2011 period. The birthplace
main effects were statistically significant for all treatments types. Model one focused on
the differences in treatment effects for the PrCa patients who were treated with
brachytherapy. The findings showed that the Jamaican PrCa patients were 3.72 times
more likely to die of PrCa when compared with the White U.S.-born, 95% CI [1.84,
7.51], p < .001. Model two which demonstrates the differences in treatment effects
among the ERBT treated cohorts indicated that the Jamaican PrCa patients were 3.78
times more likely to die of PrCa when compared with the White U.S.-born, 95% CI [1.88,
7.64], p < .001. Model three which presented the differences in treatment outcomes
among the PrCa patients who received other types of radiation showed that the Jamaican
PrCa patients were 3.79 times more likely to die of PrCa when compared with the White
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U.S.-born, 95% CI [1.88, 7.67], p < .001. Further analyses with hypothesis tests were
conducted to determine the interaction effects in the association between the three PrCa
treatments and PrCa survival among the 2007 to 2011 cohort (see Table 38).
Table 37
Main Effects of the Differences in the Hazard Ratios of the Jamaican and White U.S.Born Prostate Cancer Patients per Treatment Received Between 2007 and 2011
Variables in the Equation
95% CI for Exp (B)

Model 1

Variables

B

Birthplace
(Reference =
United States)
Brachytherapy

SE

Wald

df

Sig

Exp (B)

LL

UL

1.31

Brachytherapy
0.35
13.45
1

.000

3.72

1.84

7.51

-0.74

0.25

1

.003

0.47

0.29

0.77

8.9
ERBT

Model 2

Birthplace
(Reference =
United States)

1.33

0.35

13.80

1

.000

3.78

1.88

7.64

ERBT

-0.12

0.14

0.79

1

.374.

0.88

0.66

1.17

Other Radiation Treatment
Model 3

Birthplace
(Reference =
United States)

1.33

0.35

13.87

1

.000

3.79

1.88

7.67

Other

0.27

0.38

0.51

1

.473

1.31

0.62

2.78

Note: N = 899. LL is lower limits, UL is upper limits. Other is other types of radiation
treatments. CI is confidence interval.
Table 38 showed the findings of the interaction analysis for the PrCa patients who
were treated with brachytherapy, ERBT, and other radiation for the period 2007 to 2011.
Model one, which examined the treatment effects of brachytherapy, demonstrated that the
birthplace main effect, HR 3.85, 95% CI [1.91, 7.76], p < .001, and interaction effect, HR
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0.69, 95% CI [0.54, 0.89], p = .003 were statistically significant. Brachytherapy main
effect, HR 0.00, 95% CI [0.00, 4.32], p = .776 was not significant.
In model two, which estimated the treatment effect of ERBT, the birthplace main
effect, HR 3.84, 95% CI [1.89, 7.74], p < .001 was significant but the ERBT main effect
was not, HR 0.87, 95% CI [0.66, 1.16], p = .341. The interaction effect of birthplace and
ERBT was also not significant, HR 0.95, 95% CI [0.82, 1.09], p = .445.
In model three, which presented the treatment outcomes for other radiation
treatment the birthplace main effect, HR 2.93, 95% CI [1.05, 8.15], p = .040 was
statistically significant. Other radiation treatment main effect, HR 0.36, 95% CI [0.13,
0.99], p = .049 and interaction effect were not statistically significant, HR 1.14, 95% CI
[0.78, 1.66], p = .493.
The non-significant interaction effects for ERBT and other radiation treatment in
models two and three confirmed that the interaction terms did not modify the main effects
observed and demonstrated that there was a difference in the survival outcomes of the
PrCa patients who received ERBT and other radiation treatments for the 2007 to 2011
period. The risk of death was 3.8 times higher for the Jamaicans who received ERBT and
other forms of radiation when compared with the White U.S.-born patients (p < .001).
The main effect of brachytherapy and the birthplace covariate were not interpreted in this
analysis because of the significant interaction effect. Further evaluation of the significant
interaction effects for brachytherapy was conducted using pairwise comparisons of the
brachytherapy treated and non-treated groups. Table 39 presents the pairwise
comparisons of the hazard ratios of brachytherapy-treated PrCa patients. The results of
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the comparison showed that brachytherapy reduced the risk of death for the Jamaicans
and the White U.S.-born PrCa patients, but the findings were not significant for the
Jamaicans. The brachytherapy treated Jamaican PrCa patient was 0.02 times less likely to
die of PrCa patients when compared with patients who did not receive brachytherapy,
95% CI [0.00, 285.5], p = .429. The White U.S.-born PrCa brachytherapy treated patients
had 53% reduced risk of death when compared with the White cohort that did not receive
brachytherapy, 95% CI [0.29, 0.78], p = .003. Therefore, the U.S.-born brachytherapy
treated PrCa patients demonstrated more favorable survival benefits when compared with
the Jamaicans.
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Table 38
Interaction Effects of the Differences in the Hazard Ratios of the Jamaican and White
U.S.-Born Prostate Cancer Patients per Treatment Received Between 2007 and 2011
Variables in the Equation
95% CI for
Exp (B)
Variables

B

SE

Wald

df

Sig

Exp (B)

LL

UL

Brachytherapy with Interaction Variable
Model 1

Birthplace
(Reference =
United States)

1.35

0.35

14.13

1

.000

3.85

1.91

7.76

Brachytherapy

-15.51

54.48

0.08

1

.776

0.00

0.00

4.32

Brachytherapy
*Birthplace

-0.37

0.12

8.50

1

.003

0.69

0.54

0.89

ERBT with Interaction Variable
Model 2

Birthplace
(Reference =
United States)

1.34

0.35

14.05

1

.000

3.84

1.89

7.74

ERBT

-0.14

0.14

0.90

1

.341

0.87

0.66

1.16

ERBT*Birthplace

-0.06

0.07

0.58

1

.445

0.95

0.82

1.09

Other Radiation Treatment with Interaction Variable
Model 3

Birthplace
(Reference =
United States)

1.08

0.52

4.23

1

.040

2.93

1.05

8.15

Other

-1.04

0.52

3.89

1

.049

0.36

0.13

0.99

Other*Birthplace

0.13

0.19

0.47

1

.493

1.14

0.78

1.66

Note: N = 899. LL is lower limits, UL is upper limits. Other is radiation sequenced with
surgery. CI is confidence interval, * is the interaction term.
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Table 39
Pairwise Comparison of the Hazard Ratios for the Jamaican and White U.S.-Born
Prostate Cancer Patients Treated With Brachytherapy for the Period 2007 to 2011
Variables in the Equation
95% CI for Exp (B)
Treatment

B

SE

Wald

df

Sig

Exp (B)

LL

UL

Reference = (No brachytherapy)
Jamaicans

Brachytherapy

-3.820

4.83

0.62

1

.429

0.022

0.000

285.5

White U.S.-born

Brachytherapy

-0.742

0.25

8.66

1

.003

0.476

0.291

0.781

Note: N = 899. LL is lower limits, UL is upper limits.
The analyses for research question three revealed statistically significant
differences in the median survival for the Jamaican and U.S. PrCa patients who received
brachytherapy, ERBT, and other radiation treatments for the 5-year periods 1992 to 1996
and 1997 to 2001. At the first 5-year interval, the Jamaicans who were treated with
brachytherapy had a median survival of three years, 95% CI, [2.43, 3.58], p = .005 and
two years for ERBT and other treatments (p = .003). The median survival for the White
U.S.-born cohort was two years for all treatment types (p < .001) (see Table 24).
At the second 5-year period (1997 to 2001), 50% of the Jamaican brachytherapy
and ERBT treated PrCa patients survived beyond half of the period of follow-up, and
those who received other treatments were alive at three years of follow-up. The U.S.
cohort had a median survival of three years (p = .010) after receiving brachytherapy and
other radiation treatment and two years post ERBT treatment (p = .004) (see Table 28).
At last two 5-year intervals, the survival time for 50% of all PrCa patients exceeded half
of the observation periods (see Table 32 and Table 36).
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The hypothesis tests of a modification effect in the differences in the hazard ratios
of the Jamaican-born and White U.S.-born PrCa patients demonstrated interaction effects
for ERBT (1992 to 1996), brachytherapy and ERBT (1997 to 2001), and brachytherapy
(2002 to 2011). There were significant differences among the birthplaces for the 1992 to
1996 brachytherapy and radiation sequenced with surgery cohorts. Between 2002 and
2011, the birthplace cohorts differed significantly in treatment outcomes for ERBT and
radiation sequenced with surgery, but not brachytherapy. Pairwise comparisons of the
brachytherapy treated patients revealed significant differences among the White PrCa
patients but not among the Jamaicans (see Tables 31, 35 and 39). Similarly, pairwise
comparisons of the ERBT treated groups (see Tables 27 and 31) demonstrated significant
differences among the White U.S.-born patients but not among the Jamaicans. There
were no significant interaction effects for the cohorts that received other radiation
treatment. Therefore, the hypothesis that there are differences in the 5-year survival
intervals of Jamaican-born and U.S.-White PrCa patients according to treatment received
for the period 1992 to 2011 was accepted.
Research Question 4 Analysis
Research Question 4: Are there differences in the length of time brachytherapy
treated Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and
intermediate stages PrCa live with the disease, after controlling for sociodemographic
characteristics?
In determining the confounding effects of age, marital status, and health insurance
status in the outcome of brachytherapy and PrCa survival, the baseline hazard ratios of
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the birthplace variable, brachytherapy, and the covariates were first estimated with Cox
regression analysis. Subsequently, the brachytherapy and ERBT treated Jamaican, and
White U.S.-born White PrCa patients were stratified with the covariates marital status,
health insurance status, and age, and the adjusted hazard ratios estimated. The results
demonstrated that the crude hazard ratio for the birthplace variable was, HR .34, 95% CI
[0.14, 0.82]. When the covariates were examined in separate models, the estimates for the
adjusted hazard ratios for the birthplace variable for marital status, HR 0.26, 95% CI
[0.11, 0.63] and health insurance status, HR 0.28, 95% CI [0.12, 0.68] reflected a
decrease from the baseline. The adjusted hazard ratio for age increased minimally, HR
0.37, 95% CI [0.15, 0.88]. Table 40, shows the Cox regression analysis of the birthplace
covariate and brachytherapy treatment with all covariates; then separately with each
covariate.
In defining the degree of confounding effects of the covariates marital and health
insurance status, I estimated the excess risk in the crude and adjusted hazard ratios of the
birthplace main effects with the expression: Percent Excess Risk Explained = (Crude HRAdjusted HR)/Crude HR-1×100 (Szklo & Nieto 2014, p.161). Less than 10% change in
the hazard ratios were interpreted as minimal confounding, and the crude or adjusted
hazard ratio was accepted as the outcome. A change in the hazard ratio of the birthplace
main effect that was greater than 10% was a confounding effect and the adjusted hazard
ratios for the birthplace variable were interpreted in the results. Besides, a shift in the
magnitude of the hazard ratios, which was close to one was interpreted as no association
with the outcome of interest (Szklo & Nieto 2014, p.161).
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The results of the analysis for confounding revealed that the excess risk for
marital status was 12.8%, ([0.344-0.260]/ [0.344-1]), health insurance status was -9.6%,
([0.344-0.260]/ [0.344-1]), and age was 3.3 % ([0.344-0.366]/ [0.344-1]). Furthermore,
the magnitude and direction of the adjusted hazard ratios did not change greatly from the
baseline estimates. Therefore, based on the percent change in the adjusted and crude
hazard ratios, the association between brachytherapy treatment and PrCa survival was not
explained by the patients’ marital status, health insurance status, and age. Thus, the
alternate hypothesis that there are differences in the length of time brachytherapy treated
Jamaican-born PrCa patients and U.S.-born White PrCa patients with low and
intermediate stages PrCa live with the disease, after controlling for sociodemographic
characteristics was accepted.

147
Table 40
Cox Regression Analysis Adjusting for the Covariate Effects of Marital, Health
Insurances Status, and Age of the Jamaican and White U.S.-Born Patients Treated With
Brachytherapy
Model 1
Covariates

HR

95% CI
LL

Birthplace
(Reference =
United States)
Brachytherapy
Marital Status
Health Insurance
Status
Age Groups

Model 2
HR

UL

0.34

0.14, 0.82

1.43
1.09
0.88

1.19, 1.73
1.04, 1.16
0.79, 0.99

1.49

1.44, 1.54

Birthplace
(Reference =
United States)
Brachytherapy
Marital Status
Birthplace
(Reference =
United States)
Brachytherapy
Health Insurance
Status

Model 3

95% CI
LL

HR

UL

0.26

0.11, 0.63

1.51
1.30

1.25, 1.82
1.23, 1.38

Model 4

95% CI
LL

0.28

0.12, 0.68

1.53
0.95

1.27, 1.84
0.85, 1.07

Birthplace
(Reference =
United States)
Brachytherapy
Age at Diagnosis
(Age Groups)

HR

UL

95% CI
LL

UL

0.37

0.15, 0.88

1.45
1.50

1.20, 1.75
1.45, 1.55

Note: N =10,752. HR is hazard ratio. CI is confidence interval.
Research Question 5 Analysis
Research Question 5: Are there differences in the length of time ERBT treated
Jamaican-born PrCa patients and US-born White PrCa patients with low and intermediate
stages PrCa live with the disease, after controlling for sociodemographic characteristics?
In estimating the effects of age, marital status, and health insurance status in the
association of ERBT and PrCa survival, the baseline hazard ratios of the birthplace
variable, ERBT, and the covariates were first estimated with Cox regression analysis. The

148
ERBT treated Jamaican and U.S.-born White PrCa patients were then stratified with the
covariates marital status, health insurance status, and age and the hazard ratios estimated.
The findings revealed that crude hazard ratio for the birthplace variable was HR 0.34,
95% CI [0.14, 0.82]. Estimation of the stratified covariates demonstrated a reduction in
the adjusted hazard ratios of the birthplace covariates for the marital status, HR 0.26, 95%
CI [0.11, 0.61], and health insurance status, HR 0.27, 95% CI [0.11, 0.66] of the PrCa
cohorts. The adjusted hazard ratio for age showed a slight increase from the crude
estimate, HR 0.36, 95% CI [0.15, 0.88]. Table 41, presents the Cox regression analysis of
the birthplace covariate and ERBT treatment with all covariates; then separately with
each covariate.
Further analysis of the percent change in the crude and adjusted hazard ratios
were carried out to determine the degree of confounding using the expression: Percent
Excess Risk Explained = (Crude HR-Adjusted HR)/Crude HR-1×100 (Szklo & Nieto
2014, p.161). An excess risk of greater than 10% in the hazard ratios was interpreted as
confounding, and the adjusted hazard ratios were accepted. Less than 10% change in the
birthplace variable was minimal confounding, and the crude or adjusted hazard ratios for
the birthplace variable were interpreted in the results. Furthermore, changes in the
magnitude of the hazard ratios which was close to one were measured as no association
with the outcome of interest (Szklo & Nieto 2014, p.161).
The findings showed that the percent change for marital status was 13.2%,
([0.342-0.255]/ [0.342-1]), health insurance status was 10.3%, ([0.342-0.274]/ [0.342-1]),
and age was 3.1 % ([0.342-0.366]/ [0.363-1]). Additionally, the magnitude and direction
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of the adjusted hazard ratios did not change greatly from the crude estimates. The percent
change in the adjusted and crude hazard ratios suggested that the covariates marital,
health insurance status and age did not explain the association between brachytherapy
treatment. Thus, the alternate hypothesis that there are differences in the length of time
ERBT treated Jamaican-born PrCa patients and White U.S.-born PrCa patients with low
and intermediate stages PrCa lived with the disease, after controlling for
sociodemographic characteristics was accepted.
Table 41
Cox Regression Analysis Adjusting for the Covariate Effects of Marital, Health Insurance
Status, and Age of the Jamaican and White U.S-Born Patients Treated With ERBT
Model 1
Covariates

HR

LL
Birthplace
(Reference =
United States)
ERBT
Marital Status
Health Insurance
Status
Age at Diagnosis
(Age Groups)
Birthplace
(Reference =
United States)
ERBT
Marital Status
Birthplace
(Reference =
United States)
ERBT
Health Insurance
Status

Model 2

95% CI

HR

UL

0.34

0.14, 0.82

1.19
1.10
0.88

1.03, 1.38
1.04, 1.17
0.78, 0.98

1.49

1.45, 1.55

Model 3

95% CI
LL

HR

UL

0.26

0.11, 0.61

0.96
1.31

0.83, 1.11
1.23, 1.39

Model 4

95% CI
LL

UL

0.27

0.11, 0.66

0.93
0.95

0.80, 1.07
0.85, 1.07

Birthplace
(Reference =
United States)
ERBT
Age at Diagnosis
(Age Groups)

Note: N = 10752. HR is hazard ratio. CI is confidence interval.

HR

95% CI
LL

UL

0.36

0.15, 0.88

1.19
1.51

1.03, 1.38
1.46, 1.57
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Summary and Transition
Chapter 4 presents the results of the statistical analyses related to the research
questions and hypotheses. The Kaplan-Meier statistical methods and Cox regression
hazard model estimated the survival differences of the Jamaican and White U.S.-born
brachytherapy and ERBT treated PrCa patients.
A sample of 10752 (719 Jamaicans and 10,033 White U.S.-born) PrCa patients
was used to complete the data analysis. Preliminary descriptive statistics showed that
higher proportions of the PrCa patients were reported from the SEER reporting locations
of Connecticut (22%) and Seattle (15.1%), but there were no outliers for the Jamaican
population. PrCa patients were more likely to be in the 55 to 79 age-group, married, and
had health insurance. Higher numbers of the PrCa patients 415 (57.7%) were diagnosed
with Gleason grade 11 PrCa. A greater proportion of the Jamaicans had Gleason grade
111 PrCa (Jamaicans 39% versus U.S. Whites 34%). ERBT was the most widely used
PrCa treatment among the Jamaicans and White U.S.-born PrCa patients.
Univariate analyses revealed that brachytherapy and ERBT treated Jamaican PrCa
patients had higher median survival when compared with the U.S. cohort. More than 50%
of the brachytherapy treated Jamaican PrCa patients survived beyond the 50th percentile
of the observation period. The median survival for the brachytherapy treated White U.S.born PrCa patients was 142 months, SE 3, 95% CI [134.8, 147.1], p < .001. The median
survival for the ERBT treated Jamaican and White U.S.-born PrCa patient was 154
months and 116 months respectively (p < .001).
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Hypothesis test for interaction effects in the association of brachytherapy and
ERBT in the survival of the PrCa patients showed no modification effects. Cox
proportional hazards analyses confirmed that the Jamaican brachytherapy treated PrCa
patients experienced lower hazard of death when compared with the brachytherapy
treated White U.S.-born PrCa patients, HR 0.63, 95% CI [0. 55, 0.73], p < .001. On the
other hand, the ERBT treated Jamaicans had a higher risk of death when compared with
the ERBT treated White U.S.-born PrCa patients, HR 1.6, 95% CI [1.38, 1.84], p < .001.
The Kaplan-Meier analyses for the 5-year survival intervals for brachytherapy,
ERBT, and radiation sequenced with surgery showed significant differences in the
survival times for the brachytherapy treated White U.S.-born and Jamaican PrCa patients.
At the initiation of the observation period (1992 to 1996), brachytherapy treatment
demonstrated higher survival probability for the Jamaicans (median survival three years)
when compared the White U.S.-born and PrCa patients who received ERBT and radiation
sequenced with surgery (median survival two years) (p < .001). As the follow up
progressed into the second 5-year interval (1997 to 2001) the median survival for the
brachytherapy treated White U.S.-born PrCa and all males who received other types of
radiation increased to three years, (p < .001). The White U.S.-born PrCa patients
experienced no change in their median survival for ERBT treatment (median survival two
years) (p < .001).
Cox regression analysis of the differences in 5-year survival of the Jamaican and
White U.S. PrCa cohorts confirmed that brachytherapy, when compared with ERBT, was
more beneficial to the survival of the Jamaican PrCa patients for the first 5-year interval
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(1992 to 1996) and other types of radiation treatments at ten years of follow up. The risk
was 1.2 times higher (p < .001) for the brachytherapy treated Jamaicans versus the White
U.S.-born and those who received other types of radiation for the 1992 to 1996 interval.
The hazard doubled for the Jamaicans for all treatments at ten years of follow-up and
continued to increase for the subsequent 5-year intervals, HR 2.4 to HR 3.8, p < .001. The
risk was 2.4 times greater for the Jamaicans who received ERBT and other radiation
treatments between 2002 and 2007 and increased to HR 3.7 and HR 3.8 (p < .001) for
2007 to 2011 follow-up. The White U.S.-born PrCa patients benefited from
brachytherapy treatment for the 1997 to 2001 follow-up, HR 0.77, 95% CI [0.66, 0.90],
p < .001. The White U.S.-born PrCa patients also had improved survival from
brachytherapy during the last decade of therapy, HR 0.78, 95% CI [0.66, 0.93], p = .005
and HR 0.48, 95% CI [0.29, 0.78], p = .003. Overall, the treatment effects waned with
each 5-year interval.
Cox regression analysis for confounding effects of the covariates demonstrated
minimal confounding for marital status (brachytherapy 12% and ERBT 13%) and no
confounding effects for age and health insurance status. The percent change in the crude
and adjusted hazard ratios for age and health insurance status was less than 10%. The
adjusted hazard ratios for the covariate main effect remained less than one, did not vary
greatly from the crude estimates, and remained statistically significant (p < .001). The
percent change in the crude and adjusted hazard ratios signified that there were no real
deviations in the magnitude and direction of the effects identified.
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The findings of all research questions satisfied the alternative hypotheses of the
research questions that there are differences in survival outcomes of Jamaican and White
U.S.-born PrCa patients. Hence, the alternative hypotheses were accepted for the five
research questions. In Chapter 5, I corroborated the findings of Chapter 4 with the peer
reviewed literature and discussed the results in the context of the theoretical framework
of the study. Additionally, in Chapter 5, I provided the limitations of the dissertation, the
implications of the findings, recommendations for further research, and the conclusion of
the research
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
This dissertation was designed to examine the survival patterns of brachytherapy,
and ERBT treated Jamaican PrCa patients in the SEER 18 registries database for the
period 1992 to 2011. I also aimed to ascertain whether there were survival differences
among brachytherapy and ERBT treated Jamaican and U.S.-born White PrCa patients
who had a diagnosis of early and intermediate stages PrCa. Additionally, I intended to
determine whether specific sociodemographic characteristics affected the survival
outcomes of the ERBT and brachytherapy treated Jamaican and White U.S.-born PrCa
patients. The research utilized quantitative methods, a retrospective cohort study design,
and analyses of secondary data with survival models.
The study was conducted to generalize findings on the outcomes of brachytherapy
and ERBT to the Jamaican communities. Studies on the effectiveness of brachytherapy in
other populations may not extrapolate to the Jamaican population because researchers
documented that this cohort has a higher risk for PrCa due to genetic influences (Kidd et
al., 2012). Additionally, Jamaicans are usually diagnosed with higher PSA levels,
Gleason scores, and tumor stages when compared with other widely studied populations
(Fedewa & Jemal, 2013; Rich et al., 2013). Furthermore, brachytherapy treatment has
been acclaimed as an appropriate option for earlier stage PrCa among the White
populations in the United States (Schreiber et al., 2013). However, brachytherapy is not
well utilized among Jamaican PrCa patients (Morrison et al., 2014). There is also a lack
of information on the efficacy of brachytherapy in PrCa patients who received the
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treatment in Jamaica (Morrison et al., 2014). Additionally, ERBT is more widely used to
treat PrCa patients in Jamaica when compared with brachytherapy (Morrison et al.,
2014). However, the treatment effect of brachytherapy and ERBT in the survival of the
Jamaican PrCa patient is understudied. Hence, it was necessary to conduct this research.
The study’s findings demonstrated that the Jamaican PrCa patients who received
brachytherapy treatment and ERBT had a significantly higher cumulative survival
probability when compared with the White U.S.-born PrCa patients (p < .001). Cox
proportional hazards regression analyses confirmed that brachytherapy reduced the risk
of death by 37% for the Jamaicans, HR 0.63, 95% CI [0. 55, 0.73], p < .001. On the other
hand, the ERBT treated Jamaicans were 1.6 times more likely to die of PrCa when
compared with the White PrCa patients 95% CI [1.38, 1.84], p < .001. Hypothesis testing
for interaction effects in the survival outcomes of brachytherapy and ERBT among the
Jamaican and White U.S.-born PrCa patients confirmed that there were no modification
effects in the association identified.
Significant differences in the hazard ratios of the Jamaican-born and White U.S.born PrCa patients at 5-year survival intervals were confirmed. For the period 1992 to
1996, there were significant differences among the birthplace cohorts for brachytherapy
and radiation sequenced with surgery. Between 1997 and 2011, brachytherapy treatment
was effective for the White U.S. PrCa patients but not for the Jamaicans. Pairwise
comparisons of the ERBT treated groups showed significant differences among the White
U.S.-born patients but the effects were not significant for the Jamaicans.
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Analyses for confounding effects of marital status, age, and health insurance
status confirmed that age and health insurance status did not explain the effects observed
(percent change less than 10%), and there was minimal confounding for marital status.
The adjusted hazard ratios of the covariates did not vary significantly, indicating that
there was no change in the direction of the association identified. Hence the alternative
hypotheses that there are survival differences among the brachytherapy and ERBT treated
Jamaican, and White U.S.-born PrCa patients were accepted for the five research
questions.
Interpretation of the Findings
Descriptive Findings
The study utilized a sample of 719 Jamaican and 10,033 White U.S.-born PrCa
patients from a population of 274, 201 PrCa patients of the 18 SEER registries database
2013 submission. The PrCa cohorts had positive microscopic confirmation of the disease,
and they were actively followed for the 1992 to 2011 period of observation. The sample
size was eight times larger than the proposed sample of the research due to the sampling
technique used to select the research participants. The large sample size of this study was
one of the strengths of the data analysis; it enabled the detection of the survival
differences observed among the cohorts. The sampling technique also provided a sample
in which the important characteristics of the White PrCa patients were represented
proportionately and this facilitated ease of comparison with the Jamaican cohort.
The sample of Jamaicans used in this study will be beneficial to infer findings of
the analysis to the Jamaicans in their homeland because of its size and characteristics.
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Anderson et al. (2012), Fedewa and Jemal (2013), and Kampel et al. (2011) asserted that
despite their place of residence, Jamaicans in the SEER database demonstrated
characteristics of PrCa that were homogeneous with PrCa patients in Jamaica. Fedewa
and Jemal documented that Jamaicans were the largest non-U.S.-born Black population
in the SEER databases. Fedewa and Jemal also cited that the Jamaican PrCa patients in
the SEER databases had Gleason scores that were comparable with native Jamaicans.
Anderson et al. and Kampel et al. established that a high proportion of Jamaicans in the
SEER database (87.6%) had localized disease, and this is a current trend among
Jamaicans in their country of birth and the United States. Additionally, the proportion of
Jamaican PrCa patients in this study (719) was almost ten times larger than the number of
Jamaican PrCa patients (75 PrCa patients) who were treated in Jamaica with
brachytherapy since 2004 (Morrison et al. 2014). Morrison et al. (2014) documented their
inability to make inferences about the effectiveness of brachytherapy treatment among
native Jamaicans who received this treatment due to lack of information on treatment
outcomes. Thus, the sample of Jamaicans in this study is a useful proxy for PrCa patients
living in their native country to provide data on PrCa treatment outcomes.
In this dissertation, I intended to measure both cause-specific and all-cause
mortality according to the conclusions of Lin et al. (2009) and Thompson et al. (2013).
However, the SEER cause-specific mortality was estimated as the appropriate endpoint in
this study because of its comprehensive definition. The SEER cause-specific mortality
was fitting for the analysis because the PrCa patients in this dissertation were selected
using the SEER cause-specific definition of the ICD-O version10 site-specific code for
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prostate cancer (C60) (NCI, 2017). The SEER program defined the PrCa patients who
died of the disease as having the event, the PrCa patients who died of other causes were
censored (NCI, 2017a). The SEER program also accounted for causes of death according
to the tumor sequence, site, and other diseases associated with the site-specific disease,
and used the ICD classification codes for specific cancer sites (NCI, 2017b). In this
dissertation, the PrCa patients who died of the disease had the event of interest, and the
censored cases were PrCa patients who died of other causes. The outcomes of this
research demonstrated that higher proportions of Jamaican PrCa patients were censored
when compared with the White U.S.-born PrCa patients (72% versus 53.8%). The
Jamaican PrCa patients also had a lower death rate when compared with the White U.S.born PrCa patients (27.1%) versus (46.2%). Based on the definition of PrCa used in this
study, the results established that higher numbers of Jamaican PrCa patients when
compared with the White U.S.-born cohort died of causes other than PrCa.
The differences in the death rates among the Jamaicans and U.S.-born White PrCa
patients in this study contrasted with findings of studies in the Black population of the
United States (Hernandez et al., 2010; Ragin et al., 2011; Tyson & Castle, 2014).
Hernandez et al. (2010) documented that the incidence of PrCa among the U.S. Black and
White male populations was higher for the Blacks (38.8% versus 26.4%). Ragin et al.
(2011), and Tyson and Castle (2014) confirmed that among the different races in the
United States, the White U.S. population had better survival rates for PrCa. The
differences in the death rates of the Jamaicans and White U.S.-born PrCa patients in this
study inferred that although Jamaicans are a subgroup of the African American
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population in the United States the death rates for the general Black U.S. population of
may not apply to them.
Three of 18 SEER reporting sites (Hawaii, Iowa and Alaska Native) were
excluded from the study because no Jamaican PrCa patients were identified in the SEER
database for these locations. Iowa and Hawaii were two of eight SEER sites, which
reported cancer cases to the SEER program since the inception of its data collection on
cancer cases in January 1973 (NCI 2017c). Subsequently, the SEER program extended its
coverage of Blacks and other minority groups between 1978 and 1992 and added ten
predominantly Black rural counties (NCI 2017c). Thus, the lack of information on
Jamaicans for Hawaii, Iowa, and Alaska suggests that these three geographic areas may
not report data on these PrCa patients for the period of observation. Therefore, the three
reporting sites, which had no Jamaican PrCa patients were removed from the study to
balance the selection of PrCa patients for the comparison group.
Higher proportions of PrCa patients were reported from the SEER locations of
Greater California (16.3%), Connecticut (15%), and Los Angeles (14.7%). The Greater
California and Los Angeles areas had the highest total populations reported by the U.S.
Bureau of Census (2010) and accounted for 20,585,610 and 9,818,605 residents
respectively (NCI 2017d). Hence, the rate of the disease in Greater California and Los
Angeles may be a result of the populace of these two areas. The frequency of PrCa cases
reported for Connecticut could be attributed to its duration in the SEER program because
its total population 3,574,097 (NCI 2017d) was lower than many of the SEER reporting
locations. The State of Connecticut participated in the SEER program since the initiation
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of its data collection for cancer patients in 1973 and remained in the program throughout
the years (NCI 2017c). However, none of the SEER locations, which reported higher
numbers of PrCa patients were outliers for the Jamaican population.
Higher numbers of PrCa patients were reported for the 2001 and 2002, reporting
periods but the incidence of PrCa declined in 2011. The increase in the occurrence of
PrCa patients between 2001 and 2002 was concurrent with the expansion of the SEER
program at that period. In 2001, the SEER program added four reporting sites including
Greater California, which had a high number of PrCa patients (NCI 2017c). Thus, the
extended coverage in 2001 may have contributed to the increase in the frequency of PrCa
cases reported between 2001 and 2002. In 2011, the reduction in the rate of the PrCa
patients coexisted with a decrease in the use of radical prostatectomy combined with
ERBT to treat PrCa in the United States (Hager et al., 2014), and an increase in the
utilization of active surveillance (Cooperberg & Carroll, 2015). Additionally, in 2011 and
2012 brachytherapy utilization declined significantly and the usage of ERBT increased
(Safdieh et al., 2016). Thus, the population size of the SEER reporting locations,
changing trends in the SEER program and PrCa treatments, were interrelated with the
shifts in the PrCa reporting patterns of the SEER registries for the observation period.
The results of this research indicated that the Jamaican PrCa patients were more
likely to be diagnosed with earlier stage PrCa. Sixty percent of Jamaican PrCa patients
were diagnosed with Gleason grade 11 PrCa, and 88.6% had localized PrCa. The results
of this study supported the conclusions of Anderson et al. (2012) and Kampel et al.
(2011) which, purported that increasing numbers of Jamaicans are currently diagnosed
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with earlier stages PrCa. Although a high proportion of Jamaicans had localized PrCa and
Gleason grades 1 and 11 in this research, the proportion of Jamaican PrCa patients with
Gleason grade 111, T1c and T2c PrCa was higher than the percentage of the White USborn cohort. Fifty-two-point one percent of the Jamaican PrCa patients had T1c PrCa,
and 39.2% was diagnosed with T2c. On the other hand, 41.4% of the White US PrCa had
T1c PrCa, and 36.8% had the T2c stage of the disease. The proportions of Jamaican and
White U.S.-born PrCa patients with Gleason grade 111 were 39.1% and 33.6%
respectively. The results indicate that while Jamaicans were diagnosed with earlier stage
PrCa, they had higher Gleason scores and TNM stage when compared with the White
U.S.-born patients. Fedewa and Jemal (2013) and Rich et al. (2013) documented similar
findings in their studies. According to Fedewa and Jemal and Rich et al., the frequency of
Gleason grades and tumor stage among the Jamaicans and the White population was
higher for the Jamaicans
The Research Questions
Research Questions 1 and 2 compared the differences in the survival of the
brachytherapy treated Jamaicans and the White U.S.-born PrCa patients. The alternate
hypotheses that there are differences in the survival of the brachytherapy treated and
ERBT treated Jamaicans versus the U.S.-born White PrCa patients were accepted. A
higher proportion of the Jamaican PrCa patients (15.5%), when compared with the White
U.S.-born PrCa patients (13.2%) utilized brachytherapy treatment. The Jamaican PrCa
patients also had higher survival probability. The median survival time for the White
U.S.-born brachytherapy treated PrCa patients was 142 months, SE 3, 95% CI [134.8,
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147.1], p < .001; while more than 50% of the Jamaicans survived beyond half the period
of follow-up (p < .001). The socioeconomic indicators age, marital status, and health
insurance status, of the Jamaicans in this dissertation, may explain the higher uptake of
brachytherapy treatment in this cohort. In this study, among the Jamaicans and White
U.S.-born PrCa patients, a higher proportion of the Jamaicans was younger than 69 years
old (71% versus 52%). Additionally, the highest proportions of Jamaican PrCa patients in
this research were married (66.5%) and had health insurance (80.5%). The results were
consistent with the findings of Williams et al. (2011), Schreiber et al. (2013), and
Morrison et al. (2014).
Williams et al. (2011) established that PrCa patients in the younger age group
were more likely to be treated with brachytherapy. Schreiber et al. (2013), cited that PrCa
patients of lower socioeconomic status in the United States had poorer utilization of
brachytherapy treatment. Morrison et al. (2014) indicated that in Jamaica, PrCa patients
who had health insurance had greater access to brachytherapy treatment. Despite the
limitations of small samples, misclassification, and the quality of the secondary data used
for their studies, the patterns of brachytherapy use among PrCa patients identified by
Morrison et al., Schreiber et al., and Williams et al. compared with the results of this
study.
The study’s findings also demonstrated that brachytherapy treated Jamaican PrCa
patients had a lower risk of death from PrCa when compared with the brachytherapy
treated White US-born PrCa patients, HR 0.63, 95% CI [0.55, 0.73], p < .001. The
treatment effects of brachytherapy in this study corroborated with the findings of Aluwini
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et al. (2015), Cendales et al. (2015), Rodrigues et al. (2014), Skowronek (2013), Williams
et al. (2011), and Zuber et al. (2015). Aluwini et al. (2015), Williams et al. (2011), and
Zuber et al. (2015) documented that brachytherapy treatment was beneficial for
maintaining biochemical control in PrCa patients with the earlier stage disease. Cendales
et al., Rodrigues et al., and Skowronek, established that brachytherapy was equally
effective at both high and low doses for treating localized PrCa. The effects of
brachytherapy treatment in this research, as well as other prospective and retrospective
studies, which used reliable SEER coding and high-quality Medicare data were similar
(Aluwini et al., 2015; Zuber et al., 2011).
ERBT was prevalent among the PrCa patients in this study when compared with
brachytherapy treatment (49.6% versus 28.7%). The difference in ERBT utilization
among the Jamaicans and White U.S. born PrCa was marginal (25.2% versus 24.4%).
The trend in ERBT uptake in this dissertation differed with recent findings of Valdivieso
et al. (2015) and Safdieh et al. (2016). In observational studies, Valdivieso et al. and
Safdieh et al. identified that ERBT as a monotherapy was less popularly used to treat
low-risk PrCa when compared with brachytherapy. Valdivieso et al. reported that 40% of
PrCa patients in a sample of 2701 PrCa patients in the 1992 to 2009 SEER MedicareLinked database used brachytherapy as monotherapy for low-risk disease; 33% used
ERBT in combination with other PrCa treatments. In a sample of 89413 PrCa patients
taken from the National Cancer Database, Safdieh et al. established that 58.4% of the
patients used brachytherapy and 41.6% received ERBT as monotherapy. On the other
hand, Mahmood et al. (2014) cited a 6.2% increase in ERBT usage and a similar decrease
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in brachytherapy between 2004 and 2009. Despite the decline in brachytherapy use
reported by Mahmood et al., Safdieh et al. indicated that the utilization of ERBT for
treating localized PrCa is less prevalent in recent years.
In this research, the ERBT treated Jamaican PrCa patients had a higher a median
survival time when compared with the White U.S.-born PrCa patients (154 months versus
116 months, p < .001). However, Cox regression analysis revealed that the risk of dying
from PrCa among the ERBT treated Jamaican and White U.S. cohort was 1.6 times
higher for the Jamaican PrCa patients, 95% CI [1.38, 1.84], p < .001. Current studies on
the outcomes of ERBT focused on the effects of ERBT with surgery and other types of
radiation in the survival of PrCa patients (Nepple et al., 2014; Hoffman et al., 2013).
There were limited recent peer-reviewed literature on the effects of ERBT as
monotherapy to validate findings with the results of this dissertation. Hence, I
corroborated the ERBT outcomes of this research with studies which compared the
effects of ERBT with surgery, and brachytherapy. Nepple et al. (2014) and Hoffman et al.
(2013) showed that ERBT was associated with increased risk of death from PrCa. Nepple
et al. compared the hazard of death among PrCa patients who were treated with ERBT,
surgery, and brachytherapy. The findings of Nepple et al. showed that the ERBT cohorts
versus patients who received surgery (radical prostatectomy) had a higher risk of death,
HR 1.66, 95% CI [1.05, 2.63]. However, the difference in the risk for the brachytherapy
and the surgery cohort was not significant, HR 1.83, 95% CI [0.88, 3.82]. In another
study which examined the survival differences of a surgery and ERBT treated cohort,
Hoffman et al. observed that higher numbers of ERBT treated PrCa patients died (ERBT
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464, surgery 104), HR 0.35, 95% CI [0.26, 0.49], p < .001. The conclusions of Nepple et
al. and Hoffman et al. confirmed that ERBT might be associated with higher risk of death
when compared with the hazard associated with surgery and brachytherapy. The findings
also demonstrated that ERBT may not be as effective as other forms of PrCa treatments.
The Jamaican PrCa patients also demonstrated greater survival benefits from
brachytherapy treatment versus ERBT. Brachytherapy reduced the risk of death for the
Jamaicans by 37% (p < .001). On the other hand, the hazard for ERBT treated Jamaicans
was 1.6 times higher when compared with the White U.S. ERBT treated patients
(p < .001). The brachytherapy treatment outcomes for the Jamaican and White U.S. PrCa
patients were not consistent with the effects observed in a Canadian cohort (Smith et al.
2015), the Cleveland Clinic PrCa cohort (Nepple et al., 2013), and a Dutch cohort
(Goldner et al., 2012). Smith et al. (2015), Nepple et al. (2013), and Goldner et al. (2012)
identified no significant differences in the treatment effects of brachytherapy versus
ERBT treatments among the United States, Canadian, and Dutch PrCa patients with
localized disease (p > .05). However, the findings of Smith et al., Nepple et al., and
Goldner et al. may not apply to Jamaicans because of the small samples of African
American PrCa patients in their studies.
The differences in treatment outcomes of brachytherapy and ERBT identified
among the Jamaican PrCa patients in this study varied with finding in other populations
(Goldner et al., 2012; Smith et al., 2015; Nepple et al., 2013), and suggest that the results
may be unique to the Jamaicans. However, the findings on the treatment outcomes
require further explorations among Jamaicans in their homeland because differences in
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the delivery of treatments to PrCa patients in the United States and the Caribbean may
create survival advantages for Jamaicans residing in the United States. Example, in the
United States, radiotherapy is widely utilized to treat PrCa, and there are advancements in
other treatment methods for PrCa (Hager et al., 2015). Furthermore, integrated prostate
cancer centers are being implemented in the United States, and the expansion of deferred
and defensive treatment strategies for PrCa patients in this country is well documented
(Hager et al., 2015).
On the other hand, while Jamaicans residing in the United States are in an
environment where the management of PrCa is constantly evolving, they may be less
likely to receive appropriate treatments. Moses, Orom, Brasel, Gaddy, and Underwood
(2017) alluded to disparities in access to PrCa treatments for African Americans and
other minority groups. Jamaicans comprise the African American and minority
populations of the United States and may experience similar disparities in treatment
access. Although the findings of the study may not extrapolate to Jamaicans in their
homeland because of differences in the settings in which the study was conducted,
considerations should be given to similarities in the characteristics of Jamaicans living in
Jamaica and the United States. Furthermore, data on the Jamaican population were
collected from a wide cross section of SEER reporting locations (15 SEER sites)
improving the representativeness of the sample. Thus, the findings of this study indicate
that there are treatment effects of brachytherapy and ERBT, which require follow-up
studies among Jamaicans in their homeland.
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Research Question 3 focused on the 5-year survival probability of the Jamaican
versus the White U.S.-born PrCa patients who were treated with brachytherapy, ERBT,
and radiation sequenced with surgery (other radiation). The study’s outcome
demonstrated that brachytherapy was more active in the survival of the Jamaican PrCa
patients at five years of follow-up when compared with ERBT and radiation sequenced
with surgery (median survival three years versus two years, p < .001). At ten years of
observation, radiation sequenced with surgery demonstrated greater survival probability
for the Jamaicans and the White U.S. PrCa cohorts (median survival three years,
p < .001). Additionally, at the 10-year follow-up brachytherapy improved the median
survival time for the White U.S.-born patients. ERBT provided no tangible changes in the
median survival times for the White U.S.-born cohorts for both 5-year and 10-year
intervals.
Cox regression analysis confirmed that brachytherapy was more beneficial to the
Jamaicans for the first 5-year interval (1992 to 1996) and radiation sequenced with
surgery at ten years of follow-up. The White U.S.-born brachytherapy treated PrCa
patients had enhanced survival for the 1997 to 2001 follow-up and at the last decade of
the study. The hazard doubled for all treatment groups at ten years of follow-up and
continued to increase for the subsequent 5-year intervals, HR 2.4 to HR 3.8, p < .001.
The survival outcomes for brachytherapy identified among the PrCa patients in
this study contrasted with the findings of Valdivieso et al. (2015). In a sample of 2701
low-risk U.S. PrCa patients of the SEER-Medicare-linked database, Valdivieso et al.
reported that fewer than 50% of the brachytherapy-treated PrCa patients survived ten
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years of follow-up. The conclusions of this dissertation may differ with Valdivieso et al
who used the SEER Medicare data exclusively for their study. In this study, the sample
included PrCa patients from varying health insurance providers in the United States. On
the other hand, in a 5-year prospective study (2002 and 2007) Dickinson et al. (2014)
cited favorable survival outcomes among three U.K. PrCa cohorts with localized PrCa
who were treated with brachytherapy. Dickinson et al. identified 94.2% biochemical
relapse-free survival (p = .033) for the 5-year observation period. Similarly, in a followup study on low-risk PrCa patients, Parekh et al. (2016) confirmed that brachytherapy as
a monotherapy provided good 5-year and 8-year survival advantage for PrCa patients
with localized disease (96.6% PSA failure-free survival). Although the endpoints for
PrCa survival were different in the studies conducted by Dickinson et al., Parekh et al.,
and this dissertation, the findings established that brachytherapy is advantageous for
treating localized PrCa at 5-year and 10-year intervals. Hence, the 5-year and 10-year
survival advantage among the brachytherapy treated Jamaicans in this study may infer to
Jamaicans.
The 5-year survival outcomes of the ERBT treated patients in this dissertation
were lower than the effects observed for those who received brachytherapy, and men who
were treated with radiation sequenced with surgery. The findings differed with Kibel et
al. (2017) but related with the results of Vassil (2010). Vassil compared the 5-year
survival rates for PrCa patients who received ERBT, permanent seed implants, and
surgery and identified lower survival rates for patients who received ERBT (85.7%)
versus permanent seed implant (89.5%). Conversely, Kibel et al. demonstrated no

169
significant differences in the survival rates of the ERBT versus brachytherapy treated
PrCa patients (82.6% versus 81.7%) at 10 years of follow-up. The survival rates of ERBT
identified by Kibel et al. did not differ markedly and suggested that ERBT may not be
more efficient at five years and ten years of treatment. Kibel et al reported limitations of
small samples in their study. In this study, the pairwise comparisons showed survival
differences among the ERBT treated and non-ERBT treated White patients for ten years
of follow-up, but not the Jamaicans. The treatment effects identified among the White
cohort may be due to their consistently larger sample sizes for each 5-year interval.
Hence, the survival differences reported in the interaction effects of the 5-year and 10year survival outcomes among the ERBT treated cohorts in this dissertation require
follow-up with larger samples of Jamaicans in future studies on 5-year treatment effects
among Jamaicans.
Research Question 4 and Research Question 5 evaluated for confounding effects
of the sociodemographic indicators of the Jamaican and White U.S.-born PrCa patients.
The findings showed minimal percent changes in the crude and adjusted hazard ratios for
health insurance status (brachytherapy -9.6%, ERBT 10.3%) and age of the PrCa patients
(brachytherapy 3.3%, ERBT 3.1%). The excess risk for marital status was greater than
10% (brachytherapy 12.8%, ERBT 13.2%). However, the hazard ratios for the main
effects of all covariates remained less than one and did not vary considerably after
adjustment (p < .001), indicating that there was an effect and there were no changes in the
direction of the effects observed (Szklo & Nieto, 2014, p.171).
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The covariate effects of age in this investigation contrasted with the relationship
of age and PrCa survival in studies conducted by researchers Antwi et al. (2013), Fufaa
(2011), and Lin et al. (2009). In a predominantly White U.S. community, Antwi et al.
reported higher mortality from PrCa among a cohort of young African American PrCa
patients. Antwi et al. also documented that African American PrCa patients were more
likely to be diagnosed at younger ages. Fufaa demonstrated that older PrCa
(age > 81years) and PrCa patients aged 31 to 40 years had shorter survival intervals when
compared with patients in other age groups. Lin et al. reported that younger PrCa patients
with advanced disease had higher probability of dying of PrCa. However, the study
conducted by Fufaa was limited by underreporting and the use of death certificates to
provide data on patient’s characteristics. Additionally, the investigation carried out by
Antwi et al. applied to the population of a predominantly White U.S. PrCa cohort.
Besides, Lin et al. cited misclassification of tumor grade and stage. Furthermore, Antwi
et al. and Lin et al. documented that their inability to measure comorbid conditions
affected the findings of their studies. The differing conclusion of this research with the
studies conducted by Antwi et al., Fufaa, and Lin et al. could be attributed to the large
sample size of this study. Moreover, in the design of this dissertation, all age-groups of
the participants were included.
The covariate effects of marital status and health insurance status in this study
also demonstrated minimal confounding and may not explain the association between
brachytherapy, ERBT, and PrCa survival among the Jamaicans and White U.S-born
cohorts. The results also contrasted with the relationships documented in studies
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conducted by Abdelsattar et al. (2017), Mahal et al. (2014), Mahmood et al. (2014),
Parris (2013), Rand et al. (2014), and Xiao et al. (2011). Paris identified that the health
insurance of a cohort of the Florida Cancer Data System was a determining factor in the
choice of PrCa treatments, which improved survival from the disease Likewise,
Abdelsattar et al. revealed that having health insurance reduced survival disparities of
PrCa patients living in communities with differing socioeconomic conditions. Similarly,
Mahal et al. alluded to the advantages of health insurance in improving access to
favorable PrCa treatments among African American PrCa patients. Furthermore, Xiao et
al. documented that White U.S. PrCa patients who had no health insurance progressed to
the later stages of PrCa (p < .001). Mahmood et al. confirmed that age and marital status
were significant predictors of PrCa survival in a U.S. cohort with localized disease
(p < .001). Additionally, Paris and Rand et al. documented a statistically significant
relationship between the marital status of the PrCa patient and their likelihood of
surviving the disease.
Although peer-reviewed literature established that the health insurance and
marital status are linked to survival outcomes of PrCa patients, the investigators alluded
to limitations, which may explain the results of their studies (Abdelsattar et al. 2017;
Mahal et al. 2014; Parris, 2013). According to Mahal et al. (2014), data were missing on
important characteristics such as the grade and stage of the PrCa patients and their health
insurance status. Abdelsattar et al. (2017) utilized the SEER registry dataset and
documented that data on health insurance of the PrCa patients were classified broadly and
increased the likelihood of misclassification in their study. Paris (2013) used data on all-
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cause mortality to determine differences in PrCa survival and marital and health
insurance status because cancer-specific data were not available in the dataset used for
that study. The findings of this dissertation may contrast with Abdelsattar et al., Mahal et
al., and Parris, because missing information was minimal (six percent for health
insurance). However, the health insurance variable did not explain the association
identified in this dissertation. Furthermore, the definition of PrCa in this research
included both cause-specific and all-cause mortality. Additionally, the characteristics of
the PrCa patients were distributed among the study’s participants reducing the risk of
misclassification.
Theoretical Framework
The oxidative stress theory was chosen for this dissertation because of its
assumptions that oxidative stress contributes to age-related cancers such as PrCa and
promotes radiation-induced programmed cell death in the prostate gland (Khandrika et
al., 2009; Nakajima, 2008). The treatment effects of this study relate to the assumptions
of this theory because the alternative hypotheses of the research questions were accepted
and in this dissertation, and the incidence of PrCa increased as men aged. The mechanism
of radiation-induced cell death of the oxidative theory explains the effects of
brachytherapy, ERBT, and radiation sequenced with surgery in the survival outcomes of
the Jamaican and White U.S.-born PrCa patients. Khandrika et al. (2009), posited that
radiation induces oxidative stress in the prostate gland and causes an increase in ROS
production in the gland. Continuous increases in ROS production damage the cell’s DNA
of the prostate and inhibit duplication and cell division (Khandrika et al., 2009).
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Subsequently, programmed cell death occurs and stops the progression of carcinogenesis
(Khandrika et al., 2009; Nakajima, 2008).
The results of this study demonstrated that brachytherapy reduced the risk of
death for the Jamaican PrCa patients and ERBT improved the survival outcomes of the
White U.S. cohort. The radiation treatments were also effective at varying 5-year
intervals for the 20-year observation. Brachytherapy was effective in the survival of
Jamaicans and the White PrCa patients. ERBT and radiation sequenced with surgery
were effective for the first ten years of follow-up. Additionally, the treatment differences
in treatment effects observed among the Jamaicans and White U.S.-born PrCa patients
remained significant after controlling for the sociodemographic characteristics of the
PrCa patients. Hence, the alternative hypotheses for the research questions were accepted.
The relationship among the variables of this study confirmed the mechanism of
radiation-induced PrCa cell death in halting carcinogenesis and subsequently improving
the survival times of the PrCa patients. The treatment effects observed among the PrCa
patients of this study correlated with findings in experimental studies conducted by Fang
et al. (2012), You et al. (2015) and Khandrika et al. (2009) on the functions of the
oxidative stress pathway in interrupting PrCa carcinogenesis. Fang et al., You et al., and
Khandrika et al. established that radiation is an extracellular environmental factor, which
induces increased oxidative stress in the prostate gland and damage the cell’s DNA
structure. Fang et al. and You et al. confirmed that radiation promotes apoptosis, and
decreases cell proliferation in localized PrCa. Thus, the assumption of the oxidative
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theory that radiation-induced programmed cell death halts carcinogenesis in the prostate
gland was accepted for this study.
The oxidative stress theory also links the role of ageing in the development of
PrCa. The oxidative stress theory proposed that oxidative stress contributes to significant
age-related chronic diseases, including cancers (Sowell et al., 2010, p. 341). Ageing
causes cellular dysfunction of the prostate gland, which results in abnormal signaling,
genotoxic alterations, and subsequently cancer of the prostate gland (Khandrika et al.,
2009). In this dissertation, fewer PrCa patients were in the younger age-group (30 to 64
years) when compared with the 65 and older age-group. The highest proportion of
Jamaican PrCa patients (73.3%) and the White U.S.-born PrCa patients (60.7 %) were
older than 55 years. The frequency of PrCa patients who were in the older age-group in
this dissertation indicates that age may have contributed to the disease. Thus, the
assumption of the oxidative theory that increasing age plays a role in PrCa development
is a consideration for the PrCa patients in this dissertation.
Limitations and Strengths of the Study
This dissertation utilized secondary data, which had its limitations. Due to the
data limitations, the smoking variable was not measured in this study because the SEER
registry reports the smoking data at the County level. I recommended that follow-up
studies in the Jamaican population should examine the covariate effects of smoking.
Additionally, the definition for the covariate age was expanded to include men who were
30 years and older. Fewer PrCa patients in the data set were in the age group (30 to 64
years) which was proposed for data analysis. Hence, I changed the focus of the study
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from the younger cohort. Due to the expansion of the age group of the PrCa patients, the
Pohar-Perme and Ederer 11 statistical methods were not used for the data analysis
because these methods do not perform well in survival analyses involving the older age
groups (Seppa, et al., 2015). However, the alternative statistical software, SPSS version
23, that was indicated in the research protocol was used for data analysis.
Another limitation of the dataset was the broad classification of the PrCa patients
in the SEER dataset according to their health insurance status. PrCa patients who were
classified as uninsured, having private insurance or had unknown health insurance status
were also Medicare eligible; the PrCa patients who were diagnosed before 65 years old
were not. Therefore, the likelihood of misclassifying the PrCa patients who were older
than 65 years according to their health insurance status at the time of diagnosis was a
consideration for this study. However, I stratified the PrCa patients in age groups greater
and younger than 65 years and conducted statistical adjustments to examine for
intervening effects of age. Age was not a confounder in this study.
The research was also limited by unavailable patient-level data on the PrCa
patient’s primary means of payment for health care and the health insurance coverage
plan at the time of diagnosis (SEER, 2013). Similarly, if the PrCa patient’s health
insurance plan was different between the time of diagnosis and treatment initiation,
information on the health insurance coverage at the time that the PrCa patient started
treatment was not available (SEER, 2013). Additionally, the SEER program began
reporting data on the health insurance status of the PrCa patients in 2007 (Abdelsattar et
al., 2017; Mahal et al., 2014); hence, data for prior years in this study were not available
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for the analysis. These limitations were reported by other researchers as well (Abdelsattar
et al., 2017; Mahal et al., 2014) and should be considered in the interpretation of the
findings and included in follow-up investigations.
It was difficult to determine the patients who had the lowest grade disease from
the SEER Historic Stage A classification. The PrCa patients with the lower grade PrCa
were categorized with localized or regionalized PrCa, and this classification was not
disaggregated. Thus, the Gleason grades 1, 11, and 111 categorizations for PrCa were
used in combination with the SEER Historic Stage A, and the AJCC’s 6th edition of the
TNM staging to make conclusions about the effects of stage and grade of the disease.
The study used the 1973 to 2011 version of the SEER 18 SEER registries to
examine the relationship between the variables. The SEER program released its most
recent version of the 18 SEER registries database in 2016. However, the later version of
the SEER 18 registries research data did not include the Jamaican cohort which was
needed for this study. Subsequently, the SEER 18 registries Research data, November
2013 submission was used for the data analysis instead of the current version of the
SEER dataset. Hence, I could not make deductions on the current trends of PrCa
treatments.
There were limited current peer-reviewed sources on the relationship between
radiation treatment sequenced with surgery and the use of ERBT as a monotherapy in
PrCa survival in the Jamaican cohort. Consequently, it was difficult to corroborate the
findings of other studies with the results of the relationships identified for this variable in
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this dissertation. Hence, I used current studies that compared treatment effects of ERBT,
with brachytherapy and surgery for validation where data were lacking.
I was unable to measure comorbidities in this research. In this study, PrCa
patients may change their vital status with time, irrespective of the treatment they receive,
because of comorbidities. The SEER research data did not include comorbidities; hence
this could not be measured in the data analysis. However, this may not impact the results
greatly because the SEER program includes other diseases that are associated with the
site-specific disease in their definition of PrCa.
The findings of this dissertation may be limited for extrapolation to the Jamaicans
living in their homeland due to differences in the delivery of PrCa treatments among
Jamaicans residing in the United States and the Caribbean. Ragin et al. (2011)
documented that there are differences in access to and utilization of PrCa treatments
among Caribbean-born males residing in their country when compared with PrCa patients
living in the United States. The differences in access to treatments influence the survival
outcomes of the Caribbean-born males residing in their homeland (Ragin, 2011).
Mutetwa et al. (2012) also reported differences in PrCa survival among the Caribbeanborn males in the United States and asserted that the disparities may be due to differences
in screening interventions between countries. Although the findings of the study may be
limited to generalize to Jamaicans in their homeland because of differences in the setting
in which the study was conducted, there are some important inferences of the results. The
Jamaican population of this study has similar characteristics as Jamaicans living in
Jamaica and the United States. Additionally, the data on the Jamaican population of this
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study were collected from a wide cross section of SEER reporting locations (15 SEER
sites) improving the representativeness of the sample of Jamaicans. Thus, the findings of
this study have clinical and practical significance for treatment decisions for Jamaican
PrCa patients and may function as a baseline for follow-up investigations in that cohort.
One of the strengths of this research was the representativeness of the sample
used. The study used the SEER registries database, which is a comprehensive national
database that covered approximately 27.8% of the U.S. population (NCI, 2017e). The
SEER 18 registries database comprised different ethnicities and expanded its inclusion of
many minority groups over the years (NCI, 2017c). Thus, the SEER 18 registries
coverage of PrCa cases in the United States may be representative of the general United
States population. Additionally, the characteristics of the sample and the sampling frame
were similar (see Table 6). The proportions of the PrCa patients in the sample
corresponded with the sampling frame. The proportionality of the sample enhanced its
representativeness and facilitated comparisons of both cohorts. Additionally, although I
selected the Jamaicans using purposive sampling, a large percentage (93. 4%) of these
patients met the criteria for inclusion. Thus, the sample of the study was appropriate for
generalization to Jamaican and White US-born communities.
Another high point of this study was the statistical methods applied to determine
whether the association identified was explained by mediating and confounding factors.
First, I tested the differences in the survival experiences among the Jamaican and White
U.S.-born PrCa patients that were observed in the Kaplan-Meier analysis with the Cox
Proportional hazard regression analysis. The Cox regression model satisfied the
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proportional hazards assumption that the hazards were constant for the period of
observation. Subsequently, I conducted hypothesis testing with interaction analysis to
identify interaction or mediating effects in the association of brachytherapy and ERBT
treatments in the survival outcomes of the PrCa patients. There were fewer significant
interactions in the analysis when compared with non-significant interactions. The nonsignificant interactions were important for generalizing the findings among subgroups of
the cohorts studied and over the period of observation. Finally, I adjusted for
confounding effects of covariates of this dissertation which were defined a priori
and determined the excess risk between the crude and adjusted hazard ratios. The
statistical analyses revealed that the association identified in this investigation was not
influenced by mediating or confounding factors.
Recommendations
Findings of this dissertation provide the foundation for additional studies in PrCa
treatments for the Jamaican males. Future research should be conducted on the effects of
radiation treatment among Jamaicans using prospective designs and covering a current
period. This research spanned the 1992 to 2011 reporting periods of the SEER 18
research registries due to the limitations of the dataset used for the study. PrCa treatment
trends, incidence patterns, and diagnostic approaches are changing (Cooperberg &
Carroll, 2015; Hager et al., 2014; Safdieh, et al. 2016) and current data are needed for
further investigations on the treatment effects of brachytherapy and ERBT in PrCa
survival.
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Further research on the effects of ERBT and brachytherapy treatments among the
Jamaican males should include PrCa patients who are managed with active surveillance.
Klotz et al. (2010) recommended future studies on the effects of active surveillance on
PrCa patients with the aggressive forms of the disease. Additionally, Nepple et al. (2013)
suggested that active surveillance should be included in studies that examine the effects
of ERBT and brachytherapy. Active surveillance was not measured in this dissertation
because the variables that comprise the specific criteria for this variable were not
available in the data set. Comparison of active surveillance, brachytherapy, and ERBT
treatment effects among the Jamaicans could provide substantial evidence to generalize
findings to this population, because Jamaicans demonstrate similar characteristics of
PrCa staging irrespective of their geographic locations.
Future studies on the effects of ERBT and brachytherapy in PrCa survival should
include the smoking variable. The smoking variable was not measured in this dissertation
because smoking data were reported at the County level in the SEER registries databases.
Studies have shown that smoking may be associated with high death rates among PrCa
patients particularly among the African American population (Antwi et al., 2013; Wong
et al., 2009). Smoking is a prevalent lifestyle factor among Jamaicans in their homeland
and contributed to chronic diseases in the country (Wilks et al., 2008). Thus, it is
important to determine its influence on PrCa treatment outcomes.
Additional research on the effects of ERBT and brachytherapy in PrCa survival
should compare the treatment effects in PrCa patients who are younger and older than 65
years. Fufaa (2011) and Lin et al. (2009) documented that the age of the PrCa patient may
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affect survival outcomes. In this dissertation, all PrCa patients older than 30 years were
included in the analysis due to limitations of the data set.
Implications
Positive Social Change
This dissertation has important social change implications for the Jamaican
population. Studies have shown that the Jamaicans have a high rate of PrCa, and
experience disparities in access to PrCa treatment and preventive care (Aiken &
Eldemire-Shearer, 2012; Gibson et al., 2013; Morrison et al., 2014; Rich et al., 2012). In
Jamaica, the population without health insurance experiences challenges in utilizing
brachytherapy and there is a need for improving access to ERBT (Morrison et al., 2014).
This study may create social change by revealing opportunities for expanding PrCa
treatments and reducing mortality from prostate cancer among Jamaicans. Currently, the
Jamaican Government is seeking to advance the services offered to cancer patients in
Jamaica and is promoting research activities in prostate cancer in the country (Ministry of
Health, 2013; Reynolds-Baker, 2013). Therefore, this investigation is timely, and its
objectives align with the government’s goals to address cancer epidemiology among
Jamaicans.
Clinicians in Jamaica are also challenged with providing PrCa treatments which
are accessible and affordable to Jamaicans, and they need data on treatment outcomes to
make informed decisions (Morrison et al., 2014). The results of this study will enlighten
health care providers in Jamaica about the effectiveness of brachytherapy and ERBT in
treating a Jamaican PrCa cohort. Additionally, health care planners may use the data for
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cost-benefit analysis for policy decisions aimed at increasing access to brachytherapy and
ERBT treatments to Jamaicans. Improving access to affordable PrCa treatments is likely
to reduce morbidity and deaths from the disease, reduce the years of potential life lost
(YPLL) from PrCa, and enhance the life expectancy (LE) of the country.
I anticipate that this dissertation will provide important contributions to public
health practice and policies through patient education, advocacy, and policy
development. Based on the results of this research, I recommend that there should be a
greater focus on educating Jamaican PrCa patients with localized disease and their
families about the benefits of brachytherapy as an option for managing localized disease.
I also propose that greater prominence should be given to collaborative efforts of the
privately funded health care facilities, government-funded hospitals, the Radiation
Oncology Center of Jamaica and the Jamaica Cancer Society to increase access to
brachytherapy and ERBT use among the Jamaican PrCa patients. Additionally, I suggest
that cost-benefit evaluations on brachytherapy and ERBT use among the Jamaican PrCa
patients should be conducted to inform policy making decisions in the redirection of
resources to improve access to these PrCa treatments. I anticipate that the findings of this
study will be useful for cost-benefit determinations aimed at increasing access to
brachytherapy and ERBT for the Jamaican cohort.
The findings of this dissertation will add new information to the existing body of
knowledge on the treatment outcomes of ERBT and brachytherapy treatment in PrCa
survival specifically in the Jamaican population. Extensive studies of PrCa treatment
effects were carried out among the White populations and in the general population of
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African Americans (Alumini et al., 2015; Cendales et al., 2015; Marshall et al. 2014;
Nepple et al., 2013; Rodrigues et al., 2014; Williams et al., 2011). Currently, I have not
identified publications which examined the effects of brachytherapy and ERBT in the
survival of a subgroup of the African American population or the Jamaican PrCa patients.
Hence, I anticipate that the findings of this study will be vital to the scholar practitioners
who are engaged in PrCa studies on PrCa treatment effects, particularly in the Jamaican
population.
Conclusion
The management of PrCa is a prime challenge for Jamaican clinicians, and the
disease pattern among Jamaicans is a public health concern in the country. The efforts of
clinicians to provide effective treatment interventions for PrCa patients in Jamaica are
constrained by a lack of the physical infrastructure that will enable access to PrCa
treatment. Clinicians are also limited in accessing current empirical data on treatment
effectiveness in the Jamaican society and are consequently challenged to make informed
decisions for treatment. This study confirms that brachytherapy is efficacious for
managing PrCa in the Jamaican communities and this treatment option should be given
priority by health care planners and treatment facilities that deliver treatments to
Jamaican males.
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Appendix B: The SEER Data Request Approval
Information in this e-mail may be confidential. It is intended only for the addressee(s) identified above. If you are
not the addressee(s), or an employee or agent of the addressee(s), please note that any dissemination,
distribution, or copying of this communication is strictly prohibited. If you have received this e-mail in error,
please notify the sender of the error.

From: Seertrack <seertrack@imsweb.com>
Date: Wed, 12 Aug 2015 12:04:16 +0000
Subject: SEER Data Request Approved
Thank you for your interest in the SEER Research Data. Your signed Research Data Agreement
is on file at SEER. Your username and password have been generated for Internet access.
These will allow you to utilize the SEER*Stat client-server system and/or download the files
which make up the SEER Research Data DVD. These options are described at the following
URL:
http://seer.cancer.gov/data/options.html
You can change your password once you log into SEER*Stat from the "Client Server User
Information" option located under the Profile menu.
A recent preliminary evaluation of SEER data uncovered problems with the quality of the PSA
value and PSA interpretation variables. As data quality is our primary concern, PSA values
have not been included in the current data file (November 2014 submission) on the SEER
website and in the SEER*Stat software while a more complete evaluation of these data is
underway to explore the full magnitude of the problem. While this problem also exists in prior
submissions of the SEER data, we have not removed the fields from earlier submissions at this
time and will reevaluate this decision when we have a better understanding of the magnitude of
the problem. However, we do not recommend using these fields for analyses. For more
information, see http://seer.cancer.gov/data/psa-values.html.
Send questions or comments to:
- seertrack@imsweb.com -- regarding access to SEER Research Data
- seerstat@imsweb.com -- for SEER*Stat technical support
- seerweb@imsweb.com -- general questions regarding SEER or SEER data
Thank you,
SEER*Stat Technical Support
IMS, Inc.

